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first step in the transplantation procedure, the cells of the immune system in the patient are 
often depleted by chemotherapy, which is called conditioning, and then the patient will receive 
donor-derived HSC that can engraft and develop a new healthy immune system. HSCs can be 
isolated from different sources; BM, mobilized peripheral blood and umbilical cord blood, all of 
which are used in the clinic for transplantation.
HSCs are rare cells that are difficult to characterize precisely by marker expression alone. The 
most robust criterion to determine true stem cell potential is the ability to provide long-term 
repopulation of an entire host with all hematopoietic lineages. In mice, this is often assessed 
by performing transplantations in secondary recipients to determine self-renewal capacity. For 
human HSCs this is, of course, not feasible in a clinical setting.
When an HSC is transplanted it can migrate to the BM of the recipient, which in most but 
not all patients had been depleted of autologous cells before transplantation by irradiation 
or chemotherapeutics. The BM niche contains many different stromal cells providing a 
favorable milieu for the HSC, which in turn will undergo the process of both self-renewal 
and differentiation6. Long-term repopulating (LT)-HSCs give rise to short-term repopulating 
(ST)-HSCs giving rise to multi-potent progenitors (MPPs), each being more restricted in 
their potential to self-renew and their multi-lineage differentiation potential7. A lot of 
studies have been performed to determine the phenotype of the LT-HSC, most of which 
have been performed in mice. The field of human HSC knowledge lags behind compared to 
that of mice due to absence of appropriate models to study both self-renewal and multi- 
lineage differentiation.
In a clinical setting, the CD34+ fraction is used for transplantation as these cells can be isolated 
in a good laboratory practice (GLP) setting. However, already in 1997 it was described that 
the phenotype of HSCs could be further refined to CD34+CD38- containing a frequency 
of 1 in 617 cells with true HSC potential, defined by the capacity to repopulate a NOD/Scid 
mouse8. Thereafter, it was shown that this cell fraction can be divided in 3 groups based on 
the expression of both CD90 and CD45RA. The Lin-CD34+CD38-CD90+CD45RA- cell population 
isolated from umbilical cord blood was demonstrated to have multi-lineage BM engraftment 
potential when 10 cells were transplanted9. This cell population could be further subdivided by 
CD49f discrimination of which the CD49f+ population contained a frequency of LT-HSC of 1 in 
10.5 cells10. This illustrates that currently we are not yet able to identify the one cell phenotype 
that is most primitive and contains the highest long term repopulating capacity. Currently, the 
human HSC is described to be most enriched within the Lin-CD34+CD38-CD45RA-CD90+CD49f+ 
population followed by the MPP that has lost expression of both CD90 and CD49f11 (Fig. 1). 
From the MPP two cell types branch off; the CD34+CD38-CD45RA+CD90- MLP (multi-lymphoid 
progenitor) that can give rise to NK-, B- and T cells, and the Lin-CD34+CD38+CD45RA-CD135+ CMP 
(common myeloid progenitor) that can give rise to the megakaryocytic-erythroid progenitor 
(MEP) and granulocyte-monocyte progenitor (GMP)12. The MLP has also been named common 
lymphoid progenitor (CLP), which comes from many studies on hematopoiesis in the mouse. 
In humans this has been studied less extensively. Cells from the myeloid lineage, erythrocytes 
and granulocytes are progeny from the last two progenitor types. Also on the gene expression 
“As part of a normal day, most people will flush a toilet, open a door, or drink from a water 
fountain without even thinking about it – or about the lurking pathogens poised to infect us. We 
are afforded this luxury, because of our immune system, which responds rapidly and specifically to 
just about anything thrown at it.” (from: Editor’s Summary of Gaspar et al. 2011, Sci Transl Med)1
As illustrated by the quote above, our immune system protects us every day from pathogens 
that are present in the environment. When the immune system is compromised, infections 
cannot be cleared which can lead to severe illness. Development of the different cells from the 
immune system is tightly regulated by expression of many genes. Deficiencies or deregulation of 
these genes can have severe consequences that heavily impact on normal life. In this thesis, the 
effect of lower or absent expression of genes and overexpression of genes on the development 
of the human immune system is described using severe combined immunodeficiency (SCID) 
and T-cell acute lymphoblastic leukemia (T-ALL) as examples. Therefore, the development of 
lymphoid cells from hematopoietic stem cells (HSCs) is discussed in this introduction together 
with the consequences of genetic aberrancies affecting these processes.
Hematopoiesis
The blood in our body consists of many different cell types. HSCs, which reside in the bone 
marrow (BM), are able to produce all the different cells present in our blood system, including 
platelets, red blood cells and white blood cells. This involves a highly controlled process of 
both self-renewal, to maintain the pool of HSCs, and differentiation. The process of both self-
renewal and differentiation is coordinated by many signaling pathways, such as Notch2, Wnt3, 
4, BMP5 and several others. Aberrancies in genes and their expression, either congenital or 
acquired, can influence these processes, eventually leading to arrests in development or to the 
development of hematological malignancies.
Under normal circumstances, HSCs give rise to all white blood cells, including both innate and 
adaptive immune cells. The innate immune system is already present at birth and is a non-
specific defense against pathogens and therefore is able to respond quickly. It is comprised 
of different cells types, including mast cells, macrophages, neutrophils, eosinophils, dendritic 
cells and natural killer (NK) cells. The cells of the adaptive immune system, comprised of B cells 
and T cells, are also present at birth as the cells from the innate immune system. However, cells 
from the adaptive immune system respond in an antigen-specific manner. These cells express 
receptors specific for antigens and upon antigen encounter they will proliferate but also form 
memory cells. These memory cells are able to respond quicker upon a second encounter with 
the same antigen; a regimen that is made use of by vaccination, thereby providing protection 
against the pathogen. The adaptive immune system is only found in vertebrates.
The regenerative capacity of HSC is of great use in the clinic for the treatment of many 
diseases affecting the blood system; leukemia, lymphoma, SCID and hemoglobinopathies, 
encompassing thalassemia and sickle cell disease. Either autologous or allogeneic stem cells 
are used for transplantation, often depending on the availability of the donor material. As a 
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receptors cannot bind and therefore the NK cell will be activated. Activating receptors are able 
to recognize infected cells and often activation needs to occur via recognition with more than 
one activating receptors except for CD16.
Rearrangement of antigen specific receptors
Unlike NK cells that express both activating and inhibitory receptors for recognition of 
pathogens or allogeneic cells, B cells and T cells have antigen-specific receptors. A high degree 
of diversity is created by V(D)J recombination of the receptor loci. Both the T-cell receptor 
(TCR) and immunoglobulin (Ig) loci contain variable (V) and joining (J) segments, some also 
contain diversity (D) segments, and through recombination of these segments a high diversity 
is generated to be able to recognize many different antigens. The Ig heavy chain contains V, 
D and J segments, while the Ig kappa and Ig lambda chain only contain V and J segments. An 
Ig molecule, also known as B-cell receptor (BCR) contains 2 heavy chains together with 2 light 
chains, either kappa or lambda. For the TCR, the loci encoding the delta (TRD) and beta (TRB) 
chain contain V, D and J segments and the alpha (TRA) and gamma (TRG) loci contain only V 
and J segments. A TCR is either composed of a TCRγ chain paired with TCRδ or of a TCRα chain 
paired with TCRβ.
Rearrangements of Ig and TCR loci take place in a highly ordered fashion. First, a D segment 
rearranges to a J segment which is then followed by rearrangement of a V segment to DJ. 
When D segments are not present within the locus, V rearranges directly to a J segment. 
Recombination activating gene (RAG) proteins (RAG1 and RAG2) make double strand breaks 
(DSB) at the recombination signal sequences (RSSs) between the V (D) and J segments. 
These DSBs are recognized by a complex of DNA-dependent protein kinase catalytic subunit 
(DNAPKcs) together with KU70 and KU80, which can phosphorylate Artemis which then opens 
the coding joints that are left after RAG mediated enzymatic DNA cleavage18. Another complex 
involving X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV (LIG4) and XRCC4-
like factor (XLF) is needed for ligation in order to complete recombination. 
B cells
As NK cells, B cells develop in the BM up to an immature stage after which they migrate to 
peripheral lymphoid organs, such as spleen and lymph nodes, to further mature. In BM 
aspirates the different stages of development can be characterized using flow cytometry19. 
Using this approach, patients suffering from B-cell deficiencies, for instance SCID, can be 
identified by determining arrests in B-cell development. During development the Ig heavy chain 
and the kappa and lambda light chain loci are rearranged to generate a functional and diverse 
repertoire. Rearrangement of IGH starts in the pro-B cell stage and in the small pre-B-II stage 
the IGK and IGL loci are rearranged20 (Fig. 2). In Pax5 deficient mice, it was demonstrated that 
expression of Pax5 is needed for rearrangement of the IGH locus and is considered as a B-cell 
level there is a separation between lymphoid fate and a myeloid fate at the MLP stage13. Many 
of the transcription factors that are important in HSCs are known to be causative of leukemia 
when deregulated, for example RUNX1, MLL, SCL/TAL1 and LMO27, 14. From the progenitors 
onwards, most of the lineages develop within the BM, except for the T cells that need the 
specialized environment provided by the thymus. Hereafter, the focus will be on lymphocytes 
that have developed from the MLP.
Figure 1: Overview of hematopoiesis. Schematic depiction of hematopoiesis starting from the long-
term reconstituting hematopoietic stem cell (LT-HSC) that gives rise to the multi-potent progenitor 
(MPP). From the MPP onwards two branches diverge; the common myeloid progenitor (CMP) and the 
common lymphoid progenitor (CLP)/multi-lymphoid progenitor (MLP). The CMP gives rise to both the 
megakaryocytic-erythroid progenitor (MEP) and granulocyte-monocyte progenitor (GMP). Myeloid 
dendritic cells (mDC), monocytes and granulocytes develop from the GMP, while erythrocytes and 
megakaryocytes develop from the MEP. The MLP gives rise to natural killer (NK) cells, B cells, T cells and 
plasmacytoid dendritic cells (pDC). This is according to the classical model of hematopoiesis as studied 
extensively in the mouse, the alternative model suggests a less strict separation of lineages but more a 
loss of potential during development.
NK cells
NK cells are part of the innate immune system and develop in the BM but can further mature 
in other lymphoid organs. They need interleukin (IL)-15 for their survival and proliferation. In 
addition, NK cells can be found in the thymus15 and they share a common progenitor with the 
developing T cells16. Mature NK cells in humans are characterized by the expression of CD56 
and absence of the T cell marker CD3. NK cells are cytolytic cells that release granules or secrete 
cytokines upon activation to kill tumor cells or virus infected cells. It recognizes these cells 
with both activating and inhibitory molecules that are expressed on the surface of the NK cell 
(reviewed in 17). When, for instance a cell has downregulated MCH class I expression, inhibitory 
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as it has been postulated that developing T cells “prime” the thymic environment making it 
more receptive27. The first wave of thymus seeding cells, as described in mice, might have this 
same function allowing for better seeding and differentiation of the second wave comprised 
of more multipotent cells. Robust and rapid outgrowth of T cells after HSC transplantations 
can still be problematic28 and ways to improve this might benefit clinical outcome.
In humans, three phenotypes of TSPs have been proposed; a CD34hiCD45RAhiCD7+ phenotype29, 
30, Lin-CD34+CD10+CD24- 31 and cells characterized as Lin-CD34+CD10-CD45RA+CD62Lhi 32. Haddad 
et al. did show that the CD34hiCD45RAhiCD7+ cells they identified were able to migrate into 
thymic lobes in an ex vivo culture system. These cells could be differentiated from CD34+ 
cells isolated from cordblood using the in vitro OP9-DL1 coculture system and were able to 
engraft thymi of immunodeficient mice33. The TSP phenotype identified by Six et al., however, 
do not express CD7 and have capacity to develop into B cells, NK cells and T cells using in 
vitro coculture systems31. Furthermore, in the human thymus cells positive for the expression 
of CD34 but negative for the expression of CD7 can be found, and it was demonstrated that 
CD34+ cells upregulate CD7 only after 4 days of coculture on OP9-DL133. This argues against 
CD7+ cells as being the most immature cells in present in the thymus; however, it might be 
that the thymus can also be seeded by multiple populations. The cells identified by Kohn et al. 
are negative for the expression of CD7 but they did not succeed in transplanting these cells in 
immunodeficient mice to monitor for thymus seeding and engraftment. Therefore, the nature 
of the TSP in humans remains controversial.
The subsequent steps of T-cell development and commitment and the phenotypes associated 
with these processes have been extensively described in the mouse26, 34. There are many 
similarities between T-cell development in mice and men, as in both species it starts in de CD4-
CD8- double negative (DN) compartment and also the CD4+CD8+ double positive (DP) stage is 
comparable after which cells become either CD4+ single positive (SP) or CD8+ SP (Fig. 3). The 
SP cells have undergone positive selection, to select for thymocytes of which their TCR can 
bind major histocompatibility complex (MHC, in humans also called human leukocyte antigen 
- HLA), and negative selection, to eliminate cells that recognize self-antigens. These mature T 
cells are now ready to emigrate to the peripheral blood.
However, differences also exist between T-cell development in mice and men. Between 
the DN and DP stage lies the immature single positive (ISP) stage that is CD8+ in mice and 
CD4+ in humans, but in both species there is no expression of CD3 or a TCR35. In mice, the 
DN compartment can be further subdivided in DN1-4 based on the expression of CD44 and 
CD2536 and further subdivision of these DN compartments has been described too26, 34. The DN 
compartment of human developing T-cell progenitors can also be subdivided, but different 
markers have been described to do so; such as CD34 in combination with CD38 and CD1a37, 
CD1a and CD538 and CD733, 39. During T-cell development the TCR loci are rearranged, most cells 
will eventually become a TCRαβ+ T cell, and in mice the point of β-selection is at the DN3 stage. 
At this point the progenitor needs to have rearranged the TRB locus in a way that it produces 
a functional β-chain, otherwise the progenitor cannot progress in its development and will 
eventually die38. In humans, it has been debated where the point of β-selection exactly resides; 
commitment factor as it is required for B-cell development and suppresses the development 
of other lineages21. B cells that have in-frame rearrangement of the heavy chain and one of the 
light chains, either κ or λ, are able to express a BCR and will be positively selected. Naïve B cells 
in the periphery can be recognized by expression of both IgM and IgD. First the immature B 
cell expresses the IgM chain but by alternative splicing of the heavy chain transcript it will also 
express IgD when becoming a naïve B cell. Immunoglobulins can be either membrane bound 
to serve as BCR or can be secreted as antibodies. When a B cell recognizes antigen through 
the BCR it can either become a natural effector B cell or it will migrate to a germinal center. 
Here it can encounter a T cell recognizing the same antigen which will than provide the T cell 
help needed for class switch recombination of the heavy chain to change isotype to IgG, IgA 
or IgE22. Different isotypes confer different effector functions while still recognizing the same 
antigen. During this process the naïve B cell will become a memory B cell characterized by 
upregulation of CD2723, which in its turn can give rise to plasma cells that can produce large 
amounts of antibody.
Figure 2: Human B cell development. B cells develop in the bone marrow from the multi-lymphoid 
progenitor (MLP). Indicated are the different stages of B cell development, the markers that can be used 
to identify these stages and the stages at which recombination of immunoglobulin (Ig) loci is ongoing. 
Adapted from thesis of H. IJspeert and thesis of K. Pike-Overzet.
T cells
T cells develop within the thymus providing a specialized environment consisting of the 
appropriate cytokines and specialized stromal cells24. Thymus seeding progenitors (TSP) that 
have developed from the HSC in the BM, migrate via the peripheral blood to the thymus. 
Both the precise phenotype of this cell and the signals that drive its migration to the thymus 
are still controversial. It has been estimated that there are only 10-50 cells migrating to the 
thymus each day25, which makes it hard to detect and isolate these cells. In mice, studies 
have been performed to identify the early thymic progenitor (ETP) by careful flow cytometric 
analysis and isolation of murine thymi. It was found that the fetal thymus is seeded in two 
waves by distinct progenitors, first by a T-lineage restricted progenitor and later by a more 
multipotent progenitor26. Also in the setting of HSC transplantations it has been proposed that 
administration of T-cell progenitors might improve the outgrowth of T cells from the HSCs, 
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the TRB locus will start rearranging and the precursor will develop along the TCRαβ lineage. 
γδ T cells do not recognize MHC-restricted antigens but do recognize CD1, which can present 
lipids50 and are frequently found in gut and skin51.
Severe Combined Immunodeficiency
SCID is a subset of primary immunodeficiency (PID) that is characterized by a deficiency in 
(functional) T cells with an incidence ranging from 1-2 per 100,000 live births52-55. Patients 
often present within their first year of life with a failure to thrive and recurrent infections52, 
56. Different forms of SCID exist in which the deficiency in T cells can be accompanied by a 
deficiency in B cells or NK cells or both57, 58. As SCID patients lack an adaptive immune response 
they present with opportunistic infections and a failure to thrive, which is often diagnosed 
within their first year of life. The different phenotypes of SCID are caused by the differences in 
mutations and affected genes that are causative of SCID (Table 1). Currently, around 16 genes 
have been identified59 but there are still cases remaining of affected children without a known 
genetic cause. In a cohort studied by Gaspar et al.60 there were 20 out of 117 patients (17%) 
without a molecular diagnosis, this percentage might be different in other cohorts as presence 
of certain types of SCID can vary between geographic regions. The different types of SCID are 
categorized in two different groups based on the presence or absence of B cells: T-B- SCID and 
T-B+ SCID61. Both groups encompass patients with presence or absence of circulating NK cells, 
depending on the genetic aberrancy. 
Table 1: Overview of SCID-causing genes. 
T-B- ADA, AK2
RAG1, RAG2, Artemis (DCLRE1C), DNA-PKcs (PRKDC), LIG4, XLF
T-B+ IL2RG, JAK3
IL7RA, CD45 (PTPRC), CD3D, CD3E, CD3Z (CD247), CORO1A
Severe combined immunodeficiency (SCID) is characterized by a deficiency of (functional) T cells that 
can be accompanied by a deficiency in B cells or NK cells or both. Indicated are the different phenotypes 
of SCID and the genes, when mutated, can cause this type of deficiency. Included genes were based on 
criteria described by Bousfiha et al.59.
T-B- SCID
T-B-NK- SCID is caused by genes that are involved in cell metabolism, such as ADA62, PNP63, 64 or AK265, 
the latter leading to a disease also called reticular dysgenesis. As the phenotype caused by PNP 
deficiency is less profound these patients are often classified as combined immunodeficiency 
(CID) instead of SCID66. Deficiency in ADA, encoding adenosine deaminase, results in the 
accumulation of 2’-deoxyadenosine, which will be converted to deoxyadenosinetriphosphate 
(dATP). The dATP is the primary cause of lymphotoxicity as demonstrated in mice67. Using FTOC, 
it was demonstrated that inhibition of ADA in human thymocytes does results in accumulation 
of intracellular dATP which leads to apoptosis68. ADA-SCID patients can be treated by BM 
it has been ascribed to the DP stage40, the ISP stage41-43 and to the CD1a+ DN3 stage35. The 
current opinion is that, as in mice, it resides in the DN3 population35, 37. 
Figure 3: Human T cell development. T cells develop within the specialized environment provided by 
the thymus. The thymus seeding progenitor (TSP) seeds the thymus and develops into the immature 
thymocytes. Indicated are the stages of rearrangement of T cell receptor (TR) loci and markers to identify 
different stages. DN; double negative (CD4-CD8-), ISP; immature single positive, DP; double positive 
(CD4+CD8+), SP; single positive. Adapted from thesis of K. Pike-Overzet and Dik et al.37.
After successful development and selection of the progenitors in the thymus they emigrate as 
mature T cells to the peripheral lymphoid organs and help protect us against pathogens. These 
mature CD4+ and CD8+ T cells have a TCR comprised of an α and a β chain. CD8+ T cells are also 
called cytotoxic T cells and recognize antigens that are presented by MHC class-I to fight virus 
infected cells and it has been demonstrated that they can be reactive towards tumor cells44. 
CD4+ T cells recognize MHC class-II restricted antigens and are also called T helper cells. These 
cells help other white blood cells to fight pathogens, for example they are needed for class 
switching of B cells. The different subtypes of T helper cells secrete different cytokines after 
antigen recognition to aid in distinct immune responses. Another type of CD4+ T cells is the 
regulatory T cell that has a high expression of CD2545. Regulatory T cells, which can develop in 
the thymus during the DP stage46, help to dampen the immune response and play important 
roles in autoimmunity and cancer; with autoimmunity they do not respond adequate enough 
to dampen immune responses and T cells attack autologous cells, in the case of cancer the 
cancer cells induce regulatory T cells to dampen the T cell response against the tumor47.
There are also T cells that have a TCR comprised of a γ and a δ chain (γδ T cells). Less is known 
about the development and function of these cells especially when compared to TCRαβ+ T 
cells. During T-cell development γδ T cells split of before the point of β-selection, as the TRD 
and TRG loci are rearranged before the TRB locus and productive rearrangement of TRB cannot 
be detected in TCRγδ+ T cells37, 48, 49. When rearrangement of TRD and TRG is non-functional, 
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effects on B cells are difficult to study in knockout mice for Il2rg or Il7ra as these mice also 
suffer from a B-cell deficiency which is opposed to the phenotype observed in patients84, 85. 
Furthermore, this demonstrates differences in lymphoid development between mice and men.
Another type of SCID only involves deficiency specific for T cells resulting in a T-B+NK+ 
phenotype. Most often this is caused by a mutation in the IL-7 receptor α chain (IL7RA), 
which, together with IL-2Rγ, makes up the receptor for IL-7 that is needed early in T-cell 
development86, 87. Furthermore, mutations in CD45 (encoded by PTPRC)88, 89, the molecule that 
marks lymphocytes and in Coronin 1a (CORO1A), which is important in thymic egress90 have 
been found in SCID patients only deficient in T cells. Mutations in the kinase ZAP-70 lead to 
a deficiency in peripheral CD8+ T cells, while CD4+ T cells are present but fail to respond to 
TCR stimulation, do not produce IL-2 and have reduced tyrosine phosphorylation91. Of most 
SCID patients it is unknown at which stage the arrest in T-cell development resides as thymic 
biopsies are not routinely performed. For the ZAP-70 deficiency it has been demonstrated 
using immunohistochemistry of thymic biopsies that DP cells were present in the cortex but 
no CD8+ SP cells were present, showing a CD8 specific block at the DP stage91. For SCID caused 
by mutations in the CD3 δ chain (CD3D) the developmental arrest has been described and 
assigned to the ISP to DP transition92 although by a different group ascribed to the DN stage, 
but in that study the presence of ISP cells was not determined93. The CD3 complex, which 
associates with the TCR, exists of different subunits next to the δ chain; the γ chain (CD3G), 
ε chain (CD3E) and ζ chain (CD3Z). Mutations in all of these different CD3 chains have been 
described in T-B+NK+ SCID patients92, 94, 95. Patients with mutations in CD3G, CORO1A and ZAP70 
have also been classified as CID66.
For SCID caused by various mutations it is known where the arrest in B-cell development 
reside as this can be determined by flow cytometric analyses and repertoire analysis of the 
immunoglobulin loci in bone marrow aspirates 19, 74, 76. On the T cell side the arrests are only 
known for mutations in ZAP70 and CD3D91-93; for other mutations this remains unknown as 
thymus biopsies are not routinely taken. To further study the effects of mutations causing SCID 
different knockout mouse models have been made and studied84, 85, 96-100. As already mentioned, 
murine and human T-cell development show similarities but also many discrepancies. This is 
also illustrated in many of these mouse models, as for instance, Il7r-/- mice are deficient in both 
T cells and B cells85 while in humans only T cells are absent86 and in Il2rg-/- mice the arrest in 
T-cell development is less strict84. This underscores the need for better models to study T-cell 
arrests for human SCID.
Gene therapy for SCID
SCID is fatal if left untreated. For a long time, the only treatment for SCID was a BM transplant, 
although ADA-SCID patients can benefit from ERT using bovine PEG-ADA. However, ERT is very 
costly as it involves lifelong administration and requires appropriate monitoring69. Depending 
on the donor, the extent of human leukocyte antigen (HLA) matching and type of SCID can lead 
transplantation, enzyme replacement therapy (ERT) using bovine PEG-ADA or gene therapy69. 
Mutations in purine nucleoside phosphatase (PNP) that affect the enzymatic activity can cause 
the same phenotype as ADA-deficiency70. However, they can have variable B-cell function. 
PNP catalyzes the conversion of both inosine and deoxyinosine to hypoxanthine and of both 
guanosine and deoxyguanosine to guanine. The intracellular accumulation of deoxyguanosine 
triphosphate is believed to be toxic for lymphocytes and blocks cell division63. Patients suffering 
from reticular dysgenesis have one of the most severe forms of SCID as they, in addition to the 
absence of lymphocytes, also do not have granulocytes. AK2 (adenylate kinase 2) is involved 
in mitochondrial oxidative phosphorylation and its deficiency can be compensated for in many 
cells types by AK1. In the mononuclear cell fraction from the BM, no expression of AK1 was 
detected whereby this could not compensate the AK2 deficiency and the disease manifests so 
profound in the immune system65. Furthermore, it was demonstrated that restoration of AK2 
expression in bone marrow cells restores development towards neutrophils, thereby, showing 
the causative effect of AK2 deficiency71.
Mutations in genes involved in V(D)J recombination of TCR and immunoglobulins lead to SCID 
characterized as T-B-NK+. Genes that have been identified include: RAG1 or RAG272, Artemis 
(encoded by DCLRE1C)73, LIG474, XLF (also known as Cernunnos and Non-homologous end-joining 
factor 1, NHEJ1)75 and DNA-PKcs (encoded by PRKDC)76. As with PNP deficiency, mutations in LIG4 
and XLF can also be classified as CID instead of SCID66. As described, these genes are needed 
during V(D)J recombination of TCR and immunoglobulin loci. When one of all these genes 
is mutated this can lead to defective recombination, which leads to absence of expression 
of a functional TCR in T cells or immunoglobulins in B cells and because these receptors are 
needed to proceed during T-cell and B-cell development, defects in recombination will result 
in immunodeficiency.
T-B+ SCID
Mutations in the interleukin-2 receptor gamma chain (IL2RG)77 and Janus kinase 3 (JAK3)78, 79 
can be causative of T-B+NK- SCID, which is the most prevalent form of SCID80. IL2RG encodes 
the common gamma chain (γc), which is involved in IL-2, -4, -7, -9,-15 and -21 signaling
81. The 
gene is located on the X chromosome, thereby mainly affecting boys and also known as 
X-linked SCID or X-SCID. JAK3 is downstream of IL2RG on the cytoplasmic part of the receptor 
complex and thereby deficiencies in both these genes result in a comparable phenotype. As 
humans that only lack IL-2 had normal T-cell and NK-cell development82, it is thought that the 
absence of signaling through IL -7 and IL-15 are causative for the deficiency in both T cells and 
NK cells, respectively, as these cytokines are known to be important early in development of 
these lymphocytes. Furthermore, it has been observed that in T-B+NK- SCID patients also the 
B cells do not function completely normal; they are present in normal or sometimes elevated 
numbers but their production of immunoglobulins is often impaired. This can be caused by the 
lack of T cells of which the helper T cells are needed for class switching of immunoglobulins, 
but it has also been demonstrated that the lack of IL-21 signaling is partially causative83. The 




After the occurrence of severe adverse events in the gene therapy trials based on the γ-retroviral 
vector, new vectors have been studied that do not rely on the strong viral LTR for expression of 
the transgene. These new vectors were based on human immunodeficiency virus type 1 (HIV-
1), which is a lentivirus also belonging to the family of retroviridae. Effectiveness of this system, 
encompassing a split-genome packaging design using 3 plasmids, was shown by Naldini et 
al.117. Furthermore, they demonstrated that lentivirus is far more effective in transducing non-
dividing cells than the MLV-based counterpart. This is especially of use for transduction of 
HSCs, as the otherwise needed proliferation might affect their pluripotentency. Thereafter this 
system was modified to the so-called third generation lentivirus vector system. A split-genome 
packaging design of 4 plasmids was used to increase safety and viral genes that are important 
for virus replication were removed118. Furthermore, an additional modification was made that 
removes the U3 region from the 3’ LTR, thereby decreasing the transactivational activity it 
can have on nearby genes119. These self-inactivating (SIN) lentiviruses have been used widely 
for preclinical120-126 and clinical127-130 gene therapy studies. Besides being able to transduce non-
proliferating cells, lentiviruses also have a favorable integration pattern when compared to 
γ-retroviruses. Gamma retroviruses have a tendency to integrate more frequently around the 
transcription start site of a gene and thereby the risk of dysregulation is higher109, 131. The more 
random integration pattern, together with the removal of the U3 region from the LTR region, 
make these third generation SIN lentiviruses safer than the MLV-based γ-retroviral vectors. 
Indeed, no development of leukemia has been observed using the lentiviral vectors127, 128, 132, 
which have now been widely implemented. Only one clonal dominance with integration near 
HMG2A has been observed in a trial for β-thallasemia, but no leukemia development has been 
documented130. Furthermore, when integration sites of both vectors were compared it was 
observed that integrations detected for lentiviral vectors have a safer integration profile133, 134. 
So far, SIN lentiviral vectors have been proven safe in clinical trials.
SIN γ-retroviral vectors
Next to SIN lentiviruses, SIN γ-retroviral vectors have been created. These also have a deletion of 
the U3 region in the LTR and need an internal promoter to drive expression of the transgene135. 
The SIN design eliminates, as with the lentiviral vectors, the enhancer activities on neighboring 
genes. However, a concern might be that their integration pattern is comparable to the MLV-
based γ-retroviral vectors136. These vectors have been developed and tested in preclinical 
models for CGD, WAS and X-linked SCID, which demonstrated efficacy135, 137, 138. Trials using SIN 
γ-retroviral vectors for X-linked SCID using the elongation factor 1α short (EFS) promoter are 
currently ongoing139-141. Recently, it was reported that gene therapy using a SIN γ-retroviral 
vector in which IL2RG expression is driven by the EFS promoter was effective in 7 out of 9 
treated patients142. One patient died of an adenoviral infection before T-cell reconstitution. 
This study demonstrated initial safety of the SIN γ-retroviral vector, as no leukemias were 
observed, and the efficacy of gene therapy using a γ-retroviral vector expressing IL2RG. It 
to differences in outcome. Transplantation of HSC from a related genetically matched donor 
results in a 10-year survival of 84%101. For a related phenotypically identical and an unrelated 
donor the survival is 64% and 66% respectively, and for a related HLA-mismatched this is only 
54%101. For monogenic disease, such as SCID, gene therapy might be a successful treatment 
option, especially when an HLA-matched donor is not available. 
The advantage is that autologous HSCs are used and therefore the risk of graft rejection 
or graft-versus-host-disease is very low. Furthermore, gene corrected cells will, most likely, 
have a selective growth advantage over their non-transduced counterparts that suffer from a 
developmental arrest102. Several gene therapy trials have been conducted for different types 
of SCID, starting in the early 2000s103-105. In short, blood stem cells are harvested from the 
BM of the patient, in which a correct copy of the affected gene is introduced ex vivo using a 
crippled virus for gene delivery after which the cells are given back to the patient. These initial 
studies used a mouse leukemia virus (MLV)-based γ-retroviral vector to drive expression of the 
transgene by the long terminal repeat (LTR). A retrovirus reverse transcribes its RNA into DNA 
which then uses the enzyme integrase to integrate the DNA into the host genome. Due to this 
integration, the gene will be passed on to every daughter cell. Initially, there was restoration 
of functionality and patients demonstrated presence of cells from different lymphoid cell 
lineages in their peripheral blood together with improved immune functionality. Patients were 
able to go home and live in a normal environment and had normal growth and development. 
Unfortunately, thereafter it was reported that 4 patients in the X-linked SCID trial conducted in 
Paris and 1 patient in the London X-linked SCID trial out of the 20 total treated patients developed 
T-ALL106-108. In the trial for ADA-SCID, that had used a similar vector, no T-ALL development was 
observed109 and also not in another ADA-SCID gene therapy trial conducted in London110. The 
T-ALLs in the X-linked SCID trials did result from insertional mutagenesis leading to ectopic 
expression of oncogenes. Insertional mutagenesis was also detected in gene therapy trials 
for X-linked chronic granulatomous disease (CGD)111 and Wiskott-Aldrich Syndrome (WAS)112 
leading to development of myelodysplasia and leukemia, respectively. Below, the mechanisms 
of insertional mutagenesis and T-ALL development will be described in more detail. Due to the 
occurrence of these adverse side effects, new viral vectors were designed for delivery of the 
transgene (reviewed in 113, 114).
The 5 patients that developed a T-ALL due to insertional mutagenesis were treated with 
chemotherapy, which cured the leukemia in 4 patients. Unfortunately, one patient did not 
survive106. No insertional mutagenesis related T-ALL developed in both gene therapy trials for 
ADA-SCID although integrations near LMO2 were detected, which lead to T-ALL development 
in the X-linked SCID trials109. In 2010, it was reported that for gene therapy trials using a MLV-
based γ-retroviral vector 18 out of 20 X-linked SCID patients treated with gene therapy and all 
27 treated ADA-SCID patients are alive115. In addition, 17 X-linked SCID patients and 19 ADA-SCID 
patients have correction of their immunodeficiency and are now able to have a normal life, 
although some patients still need some immunoglobulin substitution, indicating incomplete B 
cell recovery or function1, 115, 116.
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Figure 4: Different mechanisms of insertional mutagenesis leading to aberrant expression of endogenous 
genes. It is needed to have integration of the vector in the DNA in order to have expression of the 
therapeutic gene in all offspring from a cell. This can, however, lead to overexpression of genes which 
might lead to the development of leukemia. Different mechanisms leading to aberrant expression are: 
A) integration of the vector in front of an oncogene leading to a long read-through transcript, B) enhancer 
effects of the viral long terminal repeat (LTR) on an oncogene, C) disruption of a negative regulatory 
element (NRE) thereby leading to aberrant expression of an oncogene and D) integration within a gene 
thereby generating a truncated constitutively active form. Adapted from Staal et al.114. 
It has been demonstrated that the expression of LMO2, TAL1 and LYL1 is high in human CD34+ 
cells and increases when stimulated with cytokines used in the X-linked SCID gene therapy 
trials144. This was confirmed by the data from Schwarzwaelder et al.131 that postulated that 
many of the integrations that they found in X-linked SCID patients were in genes that are active 
in CD34+ cells. Indeed LMO2, TAL1 and LYL1 were frequently hit by insertional mutagenesis in 
the patients that developed T-ALL as outlined above. However, it has been suggested that 
the constitutive expression of IL2RG might be causative of the observed T-ALLs, as it was 
observed that overexpression of IL2RG in a murine X-linked SCID model led to the development 
of thymomas145. In response to this, it was demonstrated that the overexpression of IL2RG in 
human CD34+ cells did not lead to aberrant T-cell development in vitro culture systems, while 
overexpression of LMO2 did144, 146. Furthermore, LMO2, TAL1 and LYL1 are known oncogenes 
associated with human T-ALL147, while IL2RG is not. Intriguingly, integrations near LMO2 
were also found in patients in the ADA-SCID gene therapy trial, but here it did not lead to 
development of T-ALL148.
needs to be noted that the follow-up time in this report was too short to conclusively say that 
the SIN retroviral vector was safer than the full LTR homolog.
Insertional mutagenesis
During the gene therapy trials performed for X-linked SCID using the MLV-based γ-retroviral 
vectors T-ALL was observed in 5 out of 20 patients106-108. The same phenomenon was observed 
in a gene therapy trial for CGD111 and in a WAS gene therapy trial112 using comparable vectors. 
In the CGD trial this led to the development of myelodysplasia in 2 out of 2 treated patients 
and in the WAS trial 1 patient developed AML, 4 patients developed T-ALL and 2 patients 
developed T-ALL with secondary AML. The development of these leukemias was caused by 
integration of the therapeutic vector in the DNA, resulting in dysregulation of surrounding 
genes, which is called insertional mutagenesis. The γ-retroviral vector preferentially integrates 
in transcription start sites (TSS) and transcriptionally active regions143. Indeed, in 5 patients 
that were treated with gene therapy for X-linked SCID in London, which did not have T-ALL, 
it was found that a high percentage of integrations was located around the TSS and a higher 
percentage than expected was located in common integrations sites (CIS)131. In addition, many 
integration sites were found near genes that are transcriptionally active in CD34+ cells, which 
is the cell type used for transduction in these trials. There are several mechanisms that can 
underlie insertional mutagenesis; a long read-through transcript could be generated from the 
viral gene including a nearby gene, the LTR could have enhancer effects on the promoter from 
nearby genes, integration of the vector could potentially disrupt a negative regulatory element 
and integration of the vector within a gene could generate a truncated constitutively active 
form of the gene (Fig. 4)114.
In the X-linked SCID trials in London an integration upstream of LIM-domain only 2 (LMO2) 
was found108, while in Paris two patients had integrations near the TSS of LMO2107, one patient 
near the TSS of cyclin D2 (CCND2) and one patient harbored integrations in both LMO2 and 
BMI1 polycomb ring finger oncogene (BMI1)106. Furthermore, it was demonstrated that these 
genes were highly expressed in the T-ALLs. In the CGD trial the two treated patients developed 
myelodysplasia due to insertional mutagenesis in the MDS1-EVI1 locus, which led to higher 
expression of ecotropic viral integration site 1 (EVI1)111. Insertions within or near LMO2 were 
found in all 6 T-ALL cases which in 2 patients was combined with an integration upstream of 
TAL1 (T-cell acute lymphocytic leukemia 1) and in another patient combined with an integration 
near the TSS of LYL1 (lymphoblastic leukemia derived sequence 1) in the WAS trial (Table 2)112. 
Four of the patients had overexpression of LMO2, TAL1 was found to be overexpressed in the 
2 patients but LYL1 was not found to be overexpressed. The secondary AMLs were caused 
by a meningioma (disrupted in balance) 1 (MN1) dominant clone and by a MDS1 clone, an 
integration in the MDS1 locus was also found in the patient that only developed AML in this 
trial. The developed leukemias all had a long latency, suggesting that additional mutations 
were needed besides the insertional mutagenesis. These were indeed found in leukemic cells 
from patients and were comprised of NOTCH1 mutations, a STIL-TAL1 fusion, CDKN2A deletion106, 
108 or monosomy 7 (Table 2)111.
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T-cell acute lymphoblastic leukemia (T-ALL)
Overexpression of oncogenes or deletions in tumor suppressor genes can lead to the 
development of cancer. Often more consecutive mutations are needed for a cell to become 
cancerous as described in the multiple-hit model149, 150 and as also has been observed for the 
T-ALLs that developed in the gene therapy trials. Overexpression of proto-oncogenes or loss 
of tumor-suppressor genes can lead to aberrant T-cell development and if more genetic lesions 
are acquired this can lead to T-ALL. The leukemic cells will then migrate to lymphoid organs 
such as peripheral blood, BM and spleen. The symptoms associated with T-ALL are a result of 
the increase in white blood cells in the blood of the patient, which decreases the number of red 
blood cells per mm3 and can lead to anemia, dizziness and fever. 
T-ALL can present with different phenotypes mirroring different stages of T-cell development, 
which is caused by the genes that are affected or aberrantly expressed. Different clusters 
have been described using these expression profiles and phenotypes, which demonstrated 
that T-ALLs from different clusters have different prognoses and sometimes need different 
treatment regimens. NOTCH1 has a prominent role in T-cell development and activating 
mutations in this gene have been found in more than 50% of T-ALL cases151. Activation of NOTCH1 
can also be caused by genomic rearrangements. Rearrangements are often detected in T-ALL 
cells and they mostly involve translocation of one of the TCR loci to an oncogene, which, in 
addition to NOTCH1, has been described for LYL1, LMO1, LMO2, TAL1 (SCL), TAL2, HOX11 (TLX1), 
HOX11L2 (TLX3), LCK, CCND2, and BHLHB1152. The promoter or enhancer sequences from the 
TCR loci will then drive the expression of the oncogenes. Most of these genes are expressed 
in HSC and in the early stages of T-cell development and are downregulated thereafter. The 
translocations keep these genes constitutively active whereby thymocytes retain a high 
proliferative potential and arrest in development until they acquire additional mutations that 
can lead to T-ALL.
Two types of mutations can be distinguished in T-ALL; type A, which are also called driver 
mutations, and type B mutations, which are also known as helper mutations. Type A mutations 
can be grouped in 7 different clusters; TAL/LMO, TLX1, TLX3, LYL1147, 153, HOXA42, NKX2.1/NKX2.2 
and MEF2C154. The TAL/LMO cluster is phenotypically characterized as late cortical by the 
expression of TCRαβ and CD3147. NKX2.1/NKX2.2 is biologically related with TLX1 T-ALL, both 
having an arrest at the cortical stage characterized by CD1 expression147, 154 while the TLX3 
cluster is more mature compared to TLX142. The T-ALLs characterized by high MEF2C expression 
have a very immature phenotype with expression of CD34 and the myeloid markers CD13 
and/or CD33 and are also called ETP T-ALL154. The T-ALLs in the MEF2C cluster also have high 
expression of LYL1 and LMO2. High expression of LMO2 was also found in the LYL1 cluster in 
other studies while the latter cluster is characterized as immature42, 147, 155. Type B mutations 
include, amongst others, mutations in NOTCH1, CDKN2A, CDKN2B, FBWX7, IL7R and RAS153, 
156. To determine overexpression of genes in T-ALL it is necessary to have the right control 
samples from the corresponding developmental stage as some of the oncogenes have a high 
expression level during early stages of normal T-cell development157. Otherwise overexpression 
can be falsely claimed and T-ALLs will be assigned to a different cluster with different prognosis 
and treatment.






















P7 T-ALL CCND2 CDKN2A 5 (95)
X-SCID 
(Paris)3
P10 T-ALL LMO2, BMI1 NOTCH1 5 (95)
CGD4 Subject 1 MDS MDS1-EVI1





CGD4 Subject 2 MDS MDS1-EVI1



















t(1;8)(q31;q23) ¥ 2 (101)
WAS5 WAS6 T-ALL LMO2 TCRA/D-MYC-C¥ 2 (101)














The columns of the table indicate the trial (the type of immunodeficiency for which the trial was performed), 
the number of the patient that did develop leukemia, the type of leukemia, the genes in which insertions 
were found and other aberrancies that were detected in leukemic cells. X-SCID; X-linked SCID, CGD; X-linked 
chronic granulatomous disease, WAS; Wiskott-Aldrich Syndrome, T-ALL; T-cell acute lymphoblastic leukemia, 
AML; acute myeloid leukemia. * analysis of WAS10 was still ongoing at time of publication of manuscript by 
Braun et al.112, ¥ detailed data obtained from karyotyping can be found in manuscript of Braun et al.112, 1 patient 
has been described by Howe et al.108, 2 patients have been described by Hacein-Bey-Abina et al.107, 3 patients 
have been described by Hacein-Bey-Abina et al.106, 4 patients have been described by Stein et al.111, 5 patients 
have been described by Braun et al.112.
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a ubiquitously expressed protein, and interaction of both molecules inhibits phagocytosis. 
NSG mice show increased repopulation levels as compared to other humanized mouse models 
probably due to this polymorphism of SIRPα.
Besides allowing higher engraftment of human cells, the NOG and NSG mice also sustain human 
T-cell development in their thymus172, 173. It was shown that the developed lymphocytes were 
functional too, as demonstrated by production of cytokines, antibodies and HLA-restricted 
immune responses173-175. Engraftment capacity and lineage differentiation of expanded HSC 
have been studied in the NSG model176 and the model can even be used to study the phenotype 
and functionality of human LT-HSC by performing single cell transplantations in NSG mice10. 
Because the NSG mice allow for the development of different cell types of the human immune 
system after transplantation of human HSC, even at limiting, doses, this model offers a great 
potential for the studies of normal and pathological human T-cell development. Furthermore, 
the NSG mice are useful in testing preclinical gene therapy approaches120, since the viral doses 
needed and efficacy might be different between murine and human cells.
Outline of this thesis
Both in SCID and in the T-ALLs that developed due to LMO2 insertional mutagenesis there are 
problems in T-cell development. In this thesis the results of studying human T-cell development 
are described. The overall aim of the research described in this thesis is to study normal and 
pathological forms of human T-cell development in an in vivo setting to obtain insight into the 
regulation of human T-cell development. First, we have optimized the NSG humanized mouse 
model to allow for robust T-cell development from cryopreserved BM derived human HSCs. 
This model has been used for the other studies and is described in chapter 2. In chapter 3 
we describe the results obtained after transplantation of SCID-patient derived HSC in the NSG 
xenograft model in order to study the stages of developmental arrest for different types of 
SCID. Furthermore, the results gave new insights in human T-cell development. There are still 
patients suffering from SCID with an unknown genetic cause. One of these we have studied 
in chapter 4 to determine whether this patient suffered from a cell intrinsic defect or a niche 
problem. Here, we could identify the block in T-cell development and identify this patient as 
being a true SCID. With exome sequencing we identified a potential underlying genetic cause. 
By the use of cellular barcoding, we have studied the number of clones that seed the thymus 
and the restriction during T-cell development as described in chapter 5. With SCID, the absent 
expression of a gene causes the problem in T-cell development, however, overexpression of 
a gene can also results in arrests in development. In chapter 6 we have studied the effects of 
LMO2 overexpression, as was observed in the T-ALLs that developed in several gene therapy 
trials, and to determine the mechanisms that underlie the T-ALL development caused by 
LMO2. The data from the different chapters are put in perspective to each other and existing 
literature in chapter 7 together with suggestions for further research.
Humanized mouse model
It is difficult to study human T-cell development, especially in an in vivo system. Many studies 
on T-cell development have been performed in mice, where the thymus can be removed and 
studied and furthermore transgenic mice can be created to study the effects of genes on 
T-cell development. However, human and mouse T-cell development are quite similar but also 
differ in many aspects35, 37, 48, 158. As mentioned, markers to describe the DN compartments and 
ISP stage differ between mice and men. Ways to study human T-cell development are largely 
descriptive, including gene expression analysis and phenotyping by flow cytometry. The only 
models to study functionality and differentiation of human T-cell progenitors is the OP9-DL1 
model159, 160 and fetal thymic organ cultures (FTOC)161. Advantages of these models are the 
ability to study kinetics and follow differentiation over time, which cannot be done on ex vivo 
thymi. The disadvantage of these models is that it is an in vitro situation with supplemented 
cytokines and therefore might be different from the physiological situation. Furthermore, in 
OP9-DL1 cocultures the 3D architectural structure is lost, which is still present in FTOC cultures.
Humanized mice are a better alternative for studies on human T-cell development, as this 
offers the possibility to study the development in an in vivo setting. Development of humanized 
mice started with the description of the spontaneous Prkdcscid mutation in CB17 mice in 1983162 
and the observation that these mice could be engrafted with different types of human 
hematopoietic cells although no functional human immune system was generated (reviewed 
by Shultz et al.163). These CB17-scid mice were then crossed with the non-obese diabetic (NOD) 
mice to create NOD/Scid mice; mice that allowed a higher level of engraftment of human cells. 
For a long period these NOD/Scid mice have been used extensively to study human HSCs and 
their differentiation towards different lineages164. These mice do not have endogenous B cells 
and T cells due to the mutation in Prkdc and therefore human HSC are less frequently rejected 
and able to engraft. These mice have been used widely for e.g. HSC expansion protocols165 and 
gene therapy approaches166. Unfortunately, these mice do not allow for development of human 
T cells. In 2004, human CD34+ cells that were derived from cordblood were intrahepatically 
injected into newborn Rag2-/- γc
-/- mice167. These mice developed a human immune system, 
which was demonstrated to be functional too. In 2002 and 2005, new mouse models have 
been described that were an adaptation of the earlier NOD/Scid model; by crossing it with 
an Il2rg-/- (Il2rg encodes the γc chain) mouse to generate NOD/Shi-scidIl2rg
-/- (NOG)168 or NOD/
LtSz-scidIl2rg-/- (NSG)169 mice, respectively. These mice do not have NK-, B- and T cells whereby 
they are not able to reject human cells and these can engraft with higher efficiency than in 
the NOD/Scid model. The difference between both mouse strains is a small difference in the 
NOD background and in the type of Il2rg mutation, the NOG mice have a truncated form, 
which might be able to bind and capture cytokine, while the NSG mice carry a null mutation. 
Both mice have been compared side by side with the NOD/Scid model; both demonstrated 
higher engraftment of human lymphoid cells170. In addition, the NSG mice showed a higher 
engraftment in their BM especially when transplanting limiting cell doses. This might either 
be caused by the type of mutation in Il2rg or the difference in the NOD background. It has 
been described that mice on the NOD background have a different polymorphism of signal 
regulatory protein alpha (SIRPα)171. This polymorphism has enhanced binding to human CD47, 
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Hematopoietic stem cells (HSC) are defined by their ability to repopulate the bone marrow 
of myeloablative conditioned and/or (lethally)-irradiated recipients. To study the repopulating 
potential of human HSC, murine models have been developed that rely on the use of 
immunodeficient mice that allow engraftment of human cells. The NSG xenograft model 
has emerged as the current standard for this purpose allowing for engraftment and study of 
human T cells. Here, we describe adaptations to the original NSG xenograft model that can be 
readily implemented. These encompass use of adult mice instead of newborns and a short ex 
vivo culture. This protocol results in robust and reproducible high levels of lympho-myeloid 
engraftment. Immunization of recipient mice with relevant antigen resulted in specific antibody 
formation, showing that both T cells and B cells were functional. In addition, bone marrow 
cells from primary recipients exhibited repopulating ability following transplantation into 
secondary recipients. Similar results were obtained with cryopreserved human bone marrow 
samples thus circumventing the need for fresh cells and allowing the use of patient derived 
bio-bank samples. Our findings have implications for use of this model in fundamental stem cell 
research, immunological studies in vivo and pre-clinical evaluations for HSC transplantation, 
expansion and genetic modification.
Introduction
Transplantation of hematopoietic stem and progenitor cells (HSPC) is applied for a variety of 
diseases, including for patients with malignant diseases or congenital immune deficiencies. In 
spite of major improvements, HSPC transplantation is still associated with high morbidity and 
mortality.1-3 Gene therapy has emerged as an alternative for treatment of severe combined 
immunodeficiency (SCID).4
Repopulation of human HSPC is difficult to study experimentally in humans; therefore studies 
rely primarily on the use of xenotransplantation in mice. The most widely used mouse model for 
this purpose was the NOD-scid mouse strain, which can be engrafted with human HSPC.5 This 
mouse is deficient in B cells and T cells but develops functional NK cells. However, this model 
gives low levels of human blood cell chimerism and lacks proper human T cell development. 
Another disadvantage was the relatively short life-span of the mice due to development of 
thymic lymphomas.6 With the development of mouse strains with more severe immune 
deficiency it became possible to transplant human HSPC with higher efficiency. The first such 
mouse strain that became available was the Rag2-/-γc-/- mouse that is on a mixed background, in 
which both peripheral blood lymphocytes7 and CD34+ cells isolated from cord blood8 could be 
engrafted. This was followed by a report in which CD34+ HSPC were transplanted in newborn 
BALB/c-Rag2-/-Il2rg-/-.9 In these mice both human myeloid and lymphoid cells developed and it 
was demonstrated that the human adaptive immune system was functional.
Further improvement was obtained by crossing the NOD-scid mouse to an Il2rg-/- mouse 
(NOG mouse, NOD/Shi-scidIl2rg-/-)10 and later on by development of the NSG mice (NOD/LtSz-
scidIl2rg-/-)11, 12 These mice differ from the NOG mice10 in the substrain of NOD-scid that was used 
and their mutation in Il2rg. While the NOG mouse has a truncated non-signalling form of Il2rg, 
the NSG mouse has a null mutant of Il2rg and therefore is lacking the ability to bind cytokines. 
Both mouse strains were compared side by side, which demonstrated higher engraftment of 
human cells in the bone marrow of NSG mice, especially at limiting cell doses.13 This can either 
be caused by the difference in background or the different mutation in Il2rg.
In this study, we show the feasibility of using cryopreserved human BM following a short 
ex vivo culture in NSG mice. Engrafted cells differentiate into different cell lineages and are 
also functional. Furthermore, we introduced a short culture that would allow for genetic 
modification of HSPC. Thus, we provide an adaptation of the original NSG protocol that 
can be readily implemented and allows for wider and more robust use of this promising 
xenograft model.




Erythrocytes from spleen and peripheral blood samples were lysed using NH4Cl (8.4 g/L)/
KHCO3 (1 g/L) solution. Mononuclear cells were stained in fluorescence-activated cell sorter 
(FACS) buffer (PBS/0.2% bovine serum albumin/0.1% sodium azide). Staining was performed 
for 30 minutes at 4°C. The following anti-human antibodies were used: CD3-PECy5 (UCHT1), 
CD4-APCCy7 (RPA-T4), CD8-PECy7 (SK1), CD13-APC (WM15), CD14-PE (M5E2), CD16-PE (B73.1), 
CD19-APCCy7 (SJ25C1), CD33-APC (WM53), CD34-PE (8G12), CD45-V450, CD45RA-FITC (L48), 
CD56-PE (MY31) (all from BD Biosciences, San Jose, CA), CD38-PECy7 (HIT2), CD49f PerCP-
efluor710 (eBioGoH3) and CD90-APC (eBio5e10) (all from eBioscience, San Diego, CA). Data 
were acquired on a Canto II (BD Biosciences) and analyzed using FlowJo software (Treestar, 
Ashland, OR, USA).
Immunization
Mice were immunized by intraperitoneal injection of 100 µg TNP-KLH (Biosearch Technologies 
Inc., Novato, CA, USA) in 50% Imject Alum (Thermo Scientific, Rockford, IL, USA). The animals 
were boosted with 100 µg TNP-KLH in PBS by intraperitoneal injection 3 weeks after the first 
injection. Serum was collected one week after the last injection. TNP-specific IgG antibodies 
were determined by sandwich enzyme-linked immunosorbent assay (ELISA). Plates coated with 
TNP-KLH were incubated for 3 hours at room temperature with serial dilutions of the obtained 
sera. After washing with PBS/0.05% Tween 20 (Sigma Aldrich, St. Louis, MO, USA), plates 
were incubated with goat-anti-human-IgG conjugated to biotin (Biosource, Life Technologies, 
Bleiswijk, The Netherlands, kindly provided by dr. A. Mulder, Leiden University Medical Center, 
Leiden, The Netherlands) for 30 minutes at room temperature. After washing, plates were 
incubated with streptavidin conjugated to horseradish peroxidase (Jackson ImmunoResearch, 
Newmarket, Suffolk, UK) for 30 minutes at room temperature. Azino-bis-ethylbenzthiazoline 
sulfonic acid (ABTS, Sigma Aldrich, St. Louis, MO, USA) was used as a substrate for detection 
using a Bio-Rad Model 680 microplate reader (Bio-Rad Laboratories B.V., Veenendaal, The 
Netherlands) at a wavelength of 415 nm.
Immunohistochemistry
Paraffin sections of spleens obtained from NSG mice transplanted with human CD34+ cells 
were stained with Hematoxylin & Eosin. Final magnifications of images were 100x.
Results
Similar engraftment levels of cultured HSPC and fresh HSPC
For genetic modification, e.g. gene therapy, HSPC need to be cultured for a short period. To 
test whether this is feasible for the NSG model, we cultured HSPC isolated from UCB o/n to 
determine the effect on engraftment potential. NSG mice were transplanted with 0.5x105 
or 1.5x105 HSPC directly after isolation or after o/n culture in StemSpan supplemented with 
cytokines. The transplanted cells were analyzed for expression of surface markers that 
define human HSC subsets.14 An increase in the percentage of CD90+CD45RA- cells and, within 
Material and Methods
Isolation of human CD34+cells
Umbilical cord blood was obtained from the Diaconessenhuis Hospital Leiden (Leiden, the 
Netherlands) after informed consent of the parents. Human BM was obtained from healthy 
paediatric bone marrow donors at the Leiden University Medical Center (Leiden, The 
Netherlands). Informed consent was obtained from the parents for use of leftover samples 
for research purposes. The mononuclear cell fraction was isolated using Ficoll gradient 
centrifugation, frozen in FCS/10% DMSO (Greiner Bio-One B.V., Alphen aan den Rijn, The 
Netherlands and Sigma-Aldrich, St. Louis, MO, USA, respectively) and stored in liquid nitrogen 
until use. CD34+ progenitors were isolated using the CD34 Microbead Kit (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). Isolated cells were cultured overnight (o/n, unless 
indicated differently) in StemSpan serum-free expansion medium (StemSpan-SFEM, StemCell 
Technologies Inc., Vancouver, BC, Canada) in the presence of 10 ng/mL stem cell factor (SCF, 
a gift from Amgen, Thousand Oakes, CS, USA), 20 ng/mL recombinant human thrombopoietin 
(rhTPO, R&D Systems, Abingdon, UK), 20 ng/mL recombinant mouse insulin-like growth factor 
2 (rmIGF-2, R&D Systems) and 10 ng/mL recombinant human fibroblast growth factor-acidic 
(rhFGF-1, Peprotech, Rocky Hill, NJ, USA). After overnight culture, cells were washed and 
resuspended in Iscove’s Modified Dulbecco’s Medium (IMDM) without phenol red (Gibco, Life 
Technologies, Bleiswijk, The Netherlands).
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from Charles River Laboratories 
(UK) and bred in the animal facility at the Leiden University Medical Center. Experimental 
procedures were approved by the Ethical Committee on Animal Experiments of the Leiden 
University Medical Center. Mice aged 5-6 weeks were sublethally irradiated with 1.91 Gy 
using orthovoltage X-rays. Within 24 hours after irradiation, CD34+ cells were transplanted by 
intravenous (i.v.) injection (200 µL) in the tail vein. The first four weeks, mice were maintained 
on water containing 0.07 mg/mL polymixin B (Bupha, Uitgeest, The Netherlands), 0.0875 
mg/mL ciprofloxacin (Bayer, Mijdrecht, The Netherlands) and 0.1 mg/mL amphotericin B 
(Bristol-Myers Squibb, Woerden, The Netherlands) with ad libitum food pellets and DietGel 
Recovery (Clear H2O, Portland, ME, USA). After 4 weeks, mice were maintained on ad libitum 
water and regular chow. Peripheral blood was drawn from the tail vein every 4 weeks. At the 
end of experiments, mice were sacrificed by CO2 inhalation and thymus, spleen, peripheral 
blood, femurs and tibiae were obtained. Single cell suspensions were made from thymus and 
spleen using a 70 µm nylon cell strainer (BD Falcon, Franklin Lakes, NJ, USA). Bone marrow 
was obtained by flushing femurs and tibiae with IMDM (Gibco, Life Technologies, Bleiswijk, 
The Netherlands) 2.5% FCS (Greiner Bio-One B.V., Alphen aan den Rijn, The Netherlands) 
supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco, Life Technologies).
For secondary transplantations, half of the bone marrow from a donor was thawed and 
transplanted via i.v. injection in the lateral tail vein of irradiated NSG recipients.
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Specific antibodies are produced after immunization
To test the functionality of both T and B cells, we immunized the mice that were transplanted 
with cultured human HSPC with TNP-KLH, a T-cell-dependent-B-cell-antigen. One week after 
the last challenge an increase in the number of T cells in the peripheral blood of immunized 
mice was observed as compared to non-immunized mice (Fig. 2A). This increase in number 
of T cells was caused by an expansion of CD4+ T helper cells, which are the cells to provide 
crosstalk to B cells (p<0.05, Fig. 2B). To determine the functionality of the B cells, an ELISA for 
TNP-specific antibodies was performed. An increase of TNP-specific IgG was only measured 
in the serum of immunized animals (Fig. 2C). In addition, more plasma cells were observed in 
the spleens, but not in the BM, of immunized animals as compared to non-immunized mice 
(Fig. 2D). Germinal centers could also be detected by H&E staining of sections of the spleen of 
immunized mice (Fig. 2E). In conclusion, immunization of young NSG mice transplanted with 
o/n cultured human HSC showed that both T cells and B cells are functional.
Figure 2: Immunization of humanized NSG mice shows the functionality of both T cells and B cells. 
A) Expansion of T cells in peripheral blood after immunization. B) Number of CD4+ and CD8+ T cells in 
peripheral blood. C) Quantification of TNP-specific IgG in serum of immunized mice. D) Number of human 
plasma cells that were present in spleens after immunization. E) Detection of germinal centers in spleens 
of immunized mice by hematoxylin & eosin staining (100x final magnification). Data are represented as 
mean ± SD in A-D. HSPC were isolated from a pool of 5 UCB donors, 3 mice per group.
Secondary transplantation results in high multilineage engraftment
To determine the long-term repopulating ability of stem cells residing in the BM of humanized 
mice, we performed a secondary transplantation in a total of five mice. Half of the BM of 
primary recipients that had received cultured HSPC, was thawed and transplanted via i.v. 
injection in 1 (donor 9) or 2 recipients (donor 2 and 15) depending on the number of cells that 
was recovered. Yet the recipient of donor 9 received half of the number of HSC as compared 
to recipients from cells of the other 2 donors (Fig. 3D). Good engraftment was observed in the 
peripheral blood of all secondary recipients (Fig. 3A). The effect of cell number was reflected 
this population, CD49f+ cells was observed after o/n culture (Fig. 1A). This increase of more 
primitive HSC subsets was associated with similar engraftment of human cells in lymphoid 
organs (Fig. 1B) and similar contribution of cell lineages to engraftment in peripheral blood 
between recipients of fresh or cultured HSPC (Fig. 1C and 1D). Engraftment of human cells and 
lineage contribution were both unaffected by the number of transplanted cells. No differences 
in numbers of cells belonging to the most primitive human HSC subset were found in the BM 
of recipients of fresh and cultured HSPC, although there was a trend at lower transplanted cell 
numbers (0.5x105, 50k) for more primitive stem cells to be detected in the BM of recipients 
of cultured HSPC (Fig. 1E). This led us to conclude that the short o/n culture, as needed for 
genetic modification, does not compromise engraftment potential and lineage contribution of 
human HSPC in primary recipients. Furthermore, the described protocol allows for a high level 
of engraftment in different organs (Fig. 1B).
Figure 1: Engraftment capacity of HSPC is not affected by a short in vitro culture. A) Phenotype of 
transplanted cells. Plots are gated on the population indicated on top. B) Engraftment as measured by 
percentage of human CD45 expressing cells in peripheral blood of humanized NSG mice transplanted 
with different cell doses of either fresh or cultured HSPC isolated from UCB. C) Different cell lineages 
in peripheral blood of mice transplanted with 150k non-cultured HSPC isolated from UCB (top) or 150k 
cultured HSPC (bottom). Myeloid cells (left), B cells (middle) and T cells (right) were gated within human 
CD45+ cells D) Contribution of different cell lineages in peripheral blood at 18 weeks after transplantation. 
Percentages are gated within human CD45+ cells. E) Numbers of LT-HSC (hCD45+CD34+CD38-CD90+CD45RA-
CD49f+) present in BM of NSG recipients transplanted with different cell doses of either fresh or cultured 
HSPC isolated from UCB. Data are represented as mean ± standard deviation (SD) in (B, D, E). 50k, 0.5x105 
cells; 150k, 1.5x105cells. HSPC were isolated from a pool of 7 UCB donors, 3 mice per group.
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Transplantation of HSC from both UCB and BM results in high engraftment and 
development of all lineages
We tested whether our optimized protocol gave good engraftment of HSPC from 
cryopreserved BM and development of different lymphoid lineages. Different cell doses of o/n 
cultured HSPC from UCB and BM were transplanted in NSG mice. For both HSPC sources it was 
observed that there was a higher engraftment when more cells were transplanted (Fig. 4A). 
Although engraftment was consistently higher in mice transplanted with cryopreserved UCB, 
we observed good repopulation in mice transplanted with cells obtained from cryopreserved 
BM but higher cell doses are needed for robust engraftment compared to UCB. There was no 
difference observed in lineage contribution in peripheral blood between the two cell sources 
(Fig. 4B and 4C). This data shows that with our optimized protocol it is possible to get good 
engraftment and development of all lineages in NSG mice transplanted with HSPC isolated 
from cryopreserved human BM samples.
Figure 4: Transplantation of o/n cultured HSC from both cryopreserved UCB and cryopreserved BM 
results in development of all lymphoid lineages and high human chimerism. A) Engraftment in peripheral 
blood of hCD45+ cells in mice transplanted with different cell doses of HSC isolated from umbilical cord 
blood (UCB) or human bone marrow (BM). Contribution of different lineages in peripheral blood of NSG 
mice transplanted with 150,000 HSC obtained from UCB B) or 200,000 HSC obtained from BM C). Gated 
on human CD45+ cells. UCB: 3 different pools of at least 2 donors in a total of 13 recipients, BM: 3 different 
donors in a total of 13 recipients.
Discussion
Here we report on adaptations to the NSG mouse model to achieve high and robust 
engraftment even with HSPC isolated from cryopreserved human BM samples. An overnight 
culture of HSPC was introduced as this is needed to allow for genetic modification of HSPC. 
Using the described protocol, cryopreserved patient BM material could be used to test the 
efficacy of gene therapy in an in vivo setting. With culturing of HSPC for longer periods, the 
repopulation capacity can be lost.15 However, reports have shown that culturing in defined 
serum-free medium supplemented with different cytokines can enhance engraftment,16 even 
of HSPC in an allogeneic setting.17
in the level of engraftment as measured in peripheral blood. Also in all secondary recipients 
normal development of T cells was present (Fig. 3B, for gating strategy see Supplementary 
Fig. S1) and all major cell lineages were present in the BM (Fig. 3C). These data show that with 
this protocol engraftment can be observed in secondary recipients, indicating that there was 
no stem cell exhaustion in the primary recipients that were transplanted with cultured HSPC.
We compared the number of HSC that was transplanted with the number of HSC that 
was obtained 17 weeks after secondary transplantation. Cells were analyzed for different 
phenotypes that have been described to stage human hematopoietic stem and progenitor 
cells.14 Using this method, the CD34+CD38-CD90+CD45RA-CD49f+ population contains the 
highest frequency of long-term reconstituting HSC. For all different phenotypes we observed 
an expansion in the bone marrow obtained from both hind legs of the secondary recipient 
as compared to the number of cells that was transplanted (Fig. 3D-F, for gating strategy see 
Supplementary Fig. S2). This was observed for 2 out of 3 donors.
Figure 3: Secondary transplantation results in high engraftment and development of all lineages. A) 
Engraftment over time as measured by human CD45 expressing cells in peripheral blood of secondary 
recipients. B) Development of human T cells in the thymus of secondary recipients. Gated on human CD45+ 
cells, ISP; immature single positive, DP; double positive, SP; single positive. C) Development of lineages in 
the bone marrow of secondary recipients. Gated on human CD45+ cells. D) The number of cells that was 
transplanted into secondary recipients and E) the number of cells that was obtained from both hind legs 
of secondary recipients. Gated on human CD45+ cells. Data are represented as mean ± standard deviation 
(SD). F) When the numbers in D and E are divided, this results in the fold expansion of HSC in both hind legs 
of secondary recipients. Data are represented as mean ± SD in A-E. Half of total BM of 3 primary recipients 
was transplanted in 2 secondary recipients (donor 2 and 15) or 1 recipient (donor 9).
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hand, for HSPC isolated from UCB we do not observe a difference in repopulation between 
fresh and cultured HSPC. Furthermore, we do not know what the effect of cryopreservation 
is on engraftment potential of BM derived HSPC. It has been described that HSPC isolated 
from cryopreserved and fresh UCB perform equally well in engrafting NSG mice.20 Therefore, it 
seems that HSPC quality is not affected by cryopreservation.
In conclusion, the optimization of the NSG humanized mouse model as described here, 
facilitates the use of human HSC obtained from different sources with robust engraftment The 
described protocol does allow transplantation of HSPC derived from cryopreserved BM with 
good engraftment and robust T cell development. This might be very relevant for material 
present in bio-banks that could now be used for fundamental studies or pre-clinical evaluations 
of transplantation protocols regarding stem cell expansion and gene therapy approaches.
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We demonstrate reproducibly high engraftment in the NSG mouse model using a simple 
protocol of i.v. transplantation in the tail vein of young NSG mice. Here we obtained high 
engraftment of cultured HSPC transplanted in young adult NSG mice even when low cell 
numbers (25,000 cells) were transplanted. Using this protocol we observed T cell development 
similar to fresh human thymi,18 successful immunization leading to human antibody production, 
and successful engraftment into secondary recipients.
The humanized mouse model is frequently used when the immune system, HIV biology or stem 
cell expansion protocols are studied. Although myeloid and lymphoid cell lineages do develop 
and specific immune responses can be measured, it remains unclear how T cell progenitors are 
selected in the thymus of humanized mice due to MHC differences between species. However, 
it has been reported that a diverse repertoire is generated in NSG mice, and HLA-specific 
immune responses can be detected, although weak.19 Furthermore, it has been demonstrated 
that cryopreservation of UCB does not compromise the production of immunoglobulins 
in the NSG mouse model.20 Here, we have demonstrated that both T cells and B cells were 
functional by immunization with a T-cell-dependent-B-cell-antigen. Plasma cells and germinal 
centers were found in the spleen of immunized mice, as also shown by others.21, 22 Therefore, 
we think the NSG mouse is a good model to study human lymphoid cell development in an in 
vivo setting. Furthermore, LT-HSC were found in the BM of primary recipients and these were 
able to repopulate secondary recipients with development of myeloid and lymphoid lineages. 
This shows that the transplanted stem cells were not exhausted in the primary recipient and 
even expansion of HSC was observed. The number of primitive HSC tended to be increased in 
BM of primary recipients that were transplanted with 0.5x105 CD34+ cells. This is in line with 
work by Zheng et al.,17 who have shown using a similar cytokine cocktail that murine HSC can 
be transplanted over major MHC barriers because of up regulation of the CD47 molecule 
that gives an anti-endocytosis signal to macrophages. Extrapolating these findings to the 
current xenotransplantation data, we also found CD47 up regulation on human CD34+ cells 
after culturing (Supplementary Fig. S3). No increase in number of primitive HSC was observed 
when a higher dose of 1.5x105 CD34+ cells were transplanted, probably due to the already high 
engraftment observed with 0.5x105 CD34+ cells.
CD34+ cells can be readily isolated from mobilized peripheral blood, UCB or BM. It has been 
demonstrated using the NOD-scid model that there are differences in engraftment efficiency 
between the different sources, with HSPC from UCB being superior to HSPC obtained from 
mobilized peripheral blood and BM.23, 24 Furthermore, HSPC isolated from UCB have a higher 
cloning efficiency25 and UCB contains more primitive HSC.26 As NOD-scid mice do not allow proper 
T cell development and still have residual NK cell activity, causing much lower engraftment, 
it is not easy to compare this strain to the NSG mouse side by side. However, anecdotal 
information from various researchers also indicated that engraftment and T cell development 
from cryopreserved BM material was highly problematic in NSG mice. Here, we show that 
using the described protocol good engraftment was achieved when HSPC from cryopreserved 
human BM samples were transplanted. As we did not transplant uncultured BM derived HSPC 
it is hard to determine the effect of culturing on their engraftment potential. On the other 
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Supplementary figure S2: Gating strategy for human HSC in bone marrow of secondary recipient. CD34+ 
HSPC were gated within human CD45+ cells. Within the CD34+ a sequential gating was performed on CD38- 
cells, followed by CD90+CD45RA- cells and CD49f+ cells as described by Notta et al. in 2011 14.
Supplementary figure S3: Upregulation of CD47 on CD34+ cells after overnight culture. Expression of 
CD47 on human CD34+ UCB cells before (filled grey) and after (dashed black) overnight culture in StemSpan 
supplemented with SCF, TPO, IGF-2 and FGF-1. Representative figure of 3 independent experiments.
 
Supplementary figure S1: Gating strategy for T cell developmental stages in thymus of secondary 
recipient. Thymocytes were gated based on side scatter (SSC-A) and forward scatter (FSC-A) and thereafter 
on expression of human CD45 (hCD45). Four populations can be discriminated based on expression of CD4 
and CD8, within these we gated on CD3-TCRαβ- and CD3+TCRαβ+. ISP, immature single positive, CD4+CD3- 
TCRαβ-; DP CD3-, double positive CD3-, CD4+CD8+CD3- TCRαβ-; DP CD3+, double positive CD3+, CD4+CD8+CD3+ 
TCRαβ+; CD4 SP, CD4+ single positive, CD4+CD3+ TCRαβ+; CD8 SP, CD8+ single positive, CD8+CD3+ TCRαβ+.
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Background: Severe combined immunodeficiency (SCID) represents congenital disorders 
characterized by a deficiency of T cells due to arrested development in the thymus. Yet, the 
nature of these developmental blocks has remained elusive due to the difficulty of taking 
thymic biopsies from affected children. 
Objective: Identify the stages of developmental arrest in human T-cell development caused by 
various major types of SCID. 
Methods: Transplantation of SCID CD34+ bone marrow stem/progenitor cells into an optimized 
NSG xenograft mouse model, followed by detailed phenotypic and molecular characterization 
using flow cytometry, Ig and TCR spectratyping and deep sequencing of IGH and TRD loci. 
Results: Arrests in T-cell development caused by mutations in IL7RA and IL2RG were observed 
at the most immature thymocytes, much earlier than expected based on gene expression 
profiling of human thymocyte subsets and studies with corresponding mouse mutants. 
TCR rearrangements were functionally required at the CD4-CD8-CD7+CD5+ stage, given the 
developmental block and extent of rearrangements in mice transplanted with Artemis-SCID. 
The xenograft model used is not informative for ADA-SCID, while hypomorphic mutations lead 
to less severe arrests in development
Conclusion: Transplanting CD34+ stem cells from SCID patients into a xenograft mouse model 
provides previously unattainable insight into human T-cell development and functionally 
identifies the arrests in thymic development caused by several SCID mutations.
Key messages:
- The arrests in thymic development have been unknown for most types of human SCID
- Using a xenograft model, IL2RG- and IL7RA-SCID showed very early arrests in the 
thymus, followed by recombination defective SCID (Artemis), all blocking in the CD4-CD8- 
DN stages. 
- This approach can be used for other types of SCID and help in unraveling unknown 
SCID cases
Capsule summary: The nature of the blocks in T-cell development for SCID has remained 
elusive. Using a xenograft model, we show that different SCID-causing mutations lead to 
severe defects at different early developmental stages in the thymus.
Key Words: SCID, thymus, NSG, IL2Rg, IL7Ra, ADA, Artemis, T-cell development, B-cell 
development
Abbreviations: 
ADA; adenosine deaminase, BM; bone marrow, DN; double negative, FTOC; fetal thymic organ 
culture, HSC; hematopoietic stem cells, HSPCs; hematopoietic stem and progenitor cells, Ig; 
immunoglobulin, IGH; immunoglobulin heavy chain, IL2RG; interleukin-2 receptor gamma, 
IL7RA; interleukin-7 receptor alpha, ISP; immature single positive, NK cell; natural killer cell, 
NSG; NOD-Scid-Il2rg-/- mice, PB; peripheral blood, SCID; severe combined immunodeficiency, 
TCR; T-cell receptor, UCB; umbilical cord blood
Introduction
Severe combined immunodeficiency (SCID) comprises a series of congenital disorders 
characterized by a deficiency of (functional) T cells. This can be accompanied by deficiencies 
in either NK or B cells or both. These different phenotypes are caused by mutations in several 
genes1. It remains unknown where the blocks in human T-cell development reside for these 
different deficiencies, except for mutations in CD3D2, 3 and ZAP704. For the three major types 
of human SCID that represent >80% of known SCID mutations, the stage of arrest in T-cell 
development is unknown. These three types are: 1, receptor signaling defects reflecting for 
instance mutations in IL2RG, IL7RA and JAK3, 2, recombination defects (Artemis (DCLRE1C), 
RAG1, RAG2, LIG4, XLF, DNA-PKcs) and 3, metabolic enzyme deficiencies (ADA, PNP).
One approach to obtain insight into human T-cell development is the careful analysis of 
gene expression and T-cell receptor (TCR) rearrangement of ex vivo isolated developmental 
subsets5. While such studies have shown that murine and human T-cell development are 
overall very comparable, important differences in for instance the early double negative (DN) 
compartment and the thymus seeding progenitor have been described5, 6, 7, 8, 9.
Mice with targeted mutations in key genes, including SCID-causing genes, have provided 
important insights in T-cell development10, 11, 12, 13, 14, 15, 16. However, not all of these mice resemble 
the phenotype of SCID patients. For instance, Il7r-/- mice have a deficiency in both B and T 
cells12, while in humans only T cells are affected17. Whether genetic mouse models for SCID 
demonstrate comparable blocks in T-cell development to humans remains largely unanswered. 
Furthermore, gene expression analysis of known SCID genes in different stages of human 
T-cell development showed that there are differences in expression as compared to blocks 
observed in mice5. Recent advances in xenotransplantation models18 now allow for better 
definition of human T-cell development in vivo. Importantly, these models can also be used for 
transplantation of human stem cells isolated from cryopreserved bone marrow (BM) samples 
stored in bio-banks19, e.g. from SCID patients.
Using transplantation of CD34+ cells isolated from patients with proven functional null 
mutations in genes characteristic for each of the three major types of SCID, we aimed to 
study the functional roles of these genes for human T-cell development in vivo. This study 
provides for the first time a description of the arrests in T-cell development in SCID patients 
and functional insight into two important developmental checkpoints in the human thymus.




Isolation of human CD34+cells
Human BM was obtained from healthy pediatric donors at the Leiden University Medical 
Center (LUMC, Leiden, The Netherlands). Informed consent was obtained from the parents 
for the use of leftover samples for research purposes. Parents / guardians and donors have 
consented to the donation procedure, after psychological testing and approval of the Youth 
Court in case of children. If the genetic research studies show any abnormalities, the parents 
had the opportunity to be informed. The LUMC medical ethical board (IRB) has approved the 
use of left over material of normal marrow for research purposes in P01.028 and P08.001. 
BM samples from children diagnosed with SCID were obtained according to the guidelines 
of the Erasmus MC. The medical ethical committees of Leiden University Medical Center and 
of ErasmusMC approved this study and both served as institutional review boards. Informed 
consent was provided according to the Declaration of Helsinki. Cells were isolated and cultured 
as described previously 19. See the Methods section in the Online Repository for further details.
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from Charles River Laboratories (UK) 
and bred in the animal facility at the LUMC. Experimental procedures were approved by the 
Ethical Committee on Animal Experiments of the LUMC.
In vivo experiments were performed as described19. Female mice were transplanted with CD34+ 
cells by intravenous injection within 24 hours after irradiation with 1.91 Gy using orthovoltage 
X-rays.
Flow cytometry
Labelling of mononuclear cells has been described19. Data were acquired on a Canto II (BD 
Biosciences) and analyzed using FlowJo software (Treestar, Ashland, OR, USA). Flow cytometric 
analysis of different stages of human B-cell development was performed as described 
elsewhere20, 21.
Repertoire analysis
DNA was isolated from single cell suspensions made from total thymus, spleen and BM of 
transplanted NSG mice using the GeneEluteTM Mammalian Genomic DNA Miniprep Kit 
(Sigma Aldrich, St. Louis, MO, USA). Rearrangements were analyzed using the EuroClonality/
BIOMED-2 multiplex PCR protocol22. Amplification of IGH rearrangements was performed 
as previously described23. PCR products were sequenced on the Illumina Miseq sequencer 
using 300 base pairs paired-end sequencing (V3 chemistry). The sequence reads containing 
the IGH rearrangements were uploaded in IMGT HighV-Quest24. Subsequently the output files 
were analyzed using the IGGalaxy tool25. The TRDD2-TRDD3 rearrangements were analyzed 
by matching the constant genomic region outside the TRDD2 and TRDD3 sequence in the 
amplicons, after which the length of the TRDD2-TRDD3 regions was determined. Analysis was 
performed using Bioperl and R.
Statistics
The Wilcoxon rank-sum test was performed when possible. P < 0.05 was considered significant 
and indicated in figures with *.
Results
NSG mice transplanted with HSPCs from control samples display low degree of variation
Recently, we have shown that NOD-Scid-Il2rg-/- (NSG) mice engrafted with hematopoietic stem 
and progenitor cells (HSPCs) isolated from umbilical cord blood and, to a lesser degree, from 
human BM allow robust development of myeloid and lymphoid cells, with functional B cells and 
T cells19. First, we have transplanted NSG mice with HSPCs obtained either from umbilical cord 
blood (UCB) or human pediatric BM to determine the presence of different stages of human 
T cell development. We have transplanted 14 mice with CD34+ cells isolated from cord blood 
from different donors and 9 mice with CD34+ cells isolated from pediatric bone marrow, with 
cell doses ranging from 25,000 to 200,000 total cells per mouse. All stages were present in NSG 
mice transplanted with HSPCs obtained from UCB as well as human BM (Fig. 1A). Different DN 
subsets could be discriminated based on the expression of CD7 and CD5 within the CD4-CD8- 
DN compartment (Fig. 1B). Moreover, the relative presence of all subsets is highly comparable 
and showed a low degree of variation (Fig. 1A and B). Together these data demonstrate the 
reproducible presence of the different stages of human T-cell development. Therefore, the 
high robustness of the model allows us to study the effect of rare mutations in SCID on human 
T-cell development. In all the experiments performed hereafter, only BM-derived HSPCs and 
not UCB-derived HSPCs were used for transplantations as all SCID HSPCs used in this study 
were also BM-derived and some differences could be observed between mice engrafted with 
UCB-derived HSPCs compared to BM-derived HSPCs.
Figure 1: Low variation among stages of human T cell development in NSG mice transplanted with HSPCs 
from control umbilical cordblood and control human BM. A, B) Percentage of cells per different stage 
of human T cell development within thymi of NSG mice transplanted with HSPCs. A) Cells were gated 
within hCD45+ cells or B) within hCD45+CD4-CD8- (DN). Depicted is the mean and standard deviation (sd), 
* p < 0.05.
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SCID humanized mice display SCID-specific phenotypes
We have engrafted NSG mice with HSPCs isolated from BM of SCID patients with mutations 
in different genes, including ADA-SCID, Artemis-SCID, IL7RA-SCID and IL2RG-SCID (Table 1). 
No T cells were detected in peripheral blood (PB) when Artemis-, IL7RA- or IL2RG-SCID HSPCs 
were transplanted (Fig. 2A), as expected based on the disease-defining absence of T cells. 
However, for ADA-SCID T, B and NK cells were readily observed (Fig. 2A-C), likely caused by 
complementation by secreted murine ADA, comparable to the recovery seen in ADA-SCID 
patients treated with PEG-ADA enzyme replacement therapy. Therefore, we focused our 
further study on T- and B-cell development in Artemis-, IL7RA- and IL2RG-SCID compared to 
controls. The results from HSPCs transplanted into NSG mice copied the phenotype found in 
different types of SCID patients; for Artemis-SCID we observed a deficiency of T and B cells, 
for IL7RA-SCID an absence of T cells, and for IL2RG-SCID a deficiency of both T and NK cells 
(Fig. 2A-C, Table 1). In mice transplanted with IL7RA-SCID derived HSPCs the number of NK 
cells is somewhat lower as compared to controls. Unfortunately clinical data on NK cells in 
the IL7RA-SCID patient were not available and therefore it is hard to draw conclusions from 
this observation, but the transplantation data are consistent with a T-B+NK+ phenotype. 
Human myeloid cells developed in all mice, although in a higher percentage and number in 
mice transplanted with Artemis-SCID HSPCs (Fig. 2D). Besides myeloid cells, also NK cells 
were present both in higher percentages and numbers, probably due to the severe T- and 
B-cell deficiency observed with Artemis-SCID resulting in increased development of other cell 
lineages. B cells were present in higher numbers in mice transplanted with ADA-SCID derived 
HSPCs (Fig. 2B). Since the model used is B cell-prone, this most likely reflects the higher 
engraftment compared to controls. The same phenotypes as observed in peripheral blood of 
transplanted mice were observed in the spleen and BM (Fig. 2E and F). Some CD3 expression 
was observed within the spleens of NSG mice transplanted with Artemis-, IL7RA- and IL2RG-
SCID, however, these cells did not express TCR, CD4 or CD8 on their surface (data not shown) 
and likely represent staining artefacts.
Table I: Characteristics of SCID patients
SCID Mutation T cells (x109/L) B cells (x109/L) NK cells (x109/L)
ADA c.736C>T, p.Gln246Stp <0.01 <0.01 <0.01
Artemis c.220C>T, p.Arg74Stp 0.4a <0.01 0.5
IL7RA c.876+1G>A / c.898_902delCCTGA, 
p.Pro300LysfsX9
nab naa naa
IL2RG c.209T>G, p.Met70Arg 8.2c 4 0.06
IL2RG
hypomorphic
c.655T>A, p.Tyr219Asn 3.4 1.4 0.9
Counts of cells from different lineages from peripheral blood of patients as determined by flow cytometry 
and their mutation as determined by PCR. a all T cells were determined to be of maternal origin by their 
memory phenotype, b na = not available, c all T cells were of maternal origin (proven with STR analysis on 
sorted cells).
Figure 2: NSG mice transplanted with SCID HSPCs show same phenotype as patients in their peripheral 
blood. A-D) Cells present in PB in percentage of human CD45+ cells over time after transplantation (left 
panel) or in absolute numbers at the end of the experiment (right panel); A) T cells, B) B cells, C) NK cells 
and D) myeloid cells. E) Absolute numbers of different cell types within spleen or F, BM. Depicted is the 
mean and standard deviation (sd), * p<0.05.
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Artemis-SCID demonstrates a block in B-cell development before the cytoplasmic Igµ+ pre-B-
II stage
To further validate the NSG xenograft model, we first investigated B cell development in NSG 
mice transplanted with CD34+ SCID cells and compared this to the ex vivo composition of the 
B-cell precursor compartment in patients. In BM of NSG mice transplanted with Artemis-SCID 
derived HSPCs, we observed a decrease in percentage and number of CD19+ B cells when 
compared to BM from control mice (Fig. 3A and B). This was not observed for the other types 
of SCID, which were highly comparable to mice transplanted with HSPCs obtained from healthy 
pediatric donors. Different stages of B-cell development were determined within the B-cell 
compartment20. B-cell precursors derived from Artemis-SCID HSPCs blocked at the CD10+ stage 
of B-cell development in the BM (Fig. 3C). Furthermore, almost no surface expression of IgM 
was detected and the percentage of B-cell precursors that expressed IgM in the cytoplasm was 
decreased more than 18-fold in NSG mice transplanted with Artemis HSPCs when compared to 
controls (Fig. 3D). There was barely any expression of cytoplasmic Igµ present in the B-cell 
precursors, therefore precursor B-cell differentiation blocks before the cytoplasmic Igµ+ pre-
B-II stage. This block in B-cell development was identical to the phenotype observed in a BM 
aspirate of the Artemis-SCID patient (Fig. 3E). The block at the pre-B-II stage in Artemis-SCID 
leads to an absence of immature and mature B cells expressing IgM or IgD (Fig. 3F). We also 
observed a much lower percentage of B cells in spleens of NSG mice transplanted with Artemis-
SCID HSPC and no mature CD20+, IgM+ or IgD+ B cells were found (Fig. 3G).
Together these data confirm a block in B-cell development for Artemis-SCID, and not for 
IL7RA-SCID and IL2RG-SCID. This is highly similar to the observations in the BM aspirates of the 
corresponding SCID patients, demonstrating that HSPCs transplantation into the NSG model 
faithfully recapitulates human B-cell development, thereby validating the use of this model for 
studies of human lymphoid development.
Artemis-SCID cells do not generate a polyclonal IGH repertoire
We performed analysis of the immunoglobulin heavy chain (IGH) repertoire that was generated 
in the BM of transplanted NSG mice. Both for incomplete D-J (Fig. 4A) and complete V-DJ (Fig. 
4B) rearrangements, merely a few incidental rearrangements were observed for Artemis-SCID. 
For IL7RA- and IL2RG-SCID a polyclonal repertoire, comparable to that observed in controls, 
was generated (Fig. 4A and B). To determine the repertoire diversity of IGH, we performed 
deep sequencing using the Illumina Miseq platform. Analysis of D to J recombination showed 
that a less diverse repertoire was generated in the BM of mice transplanted with Artemis-SCID 
derived HSPCs while this was not observed for IL7RA- and IL2RG-SCID and controls (Fig. 4C). 
Thus, only for a recombination defect, as exemplified by Artemis-SCID, both phenotypic and 
IGH rearrangement analysis indicate an arrest in B-cell development at the pre-B-II stage, which 
in addition led to development of a less diverse repertoire.
Figure 3: Developmental block at the CD10+ stage for B cells in Artemis-SCID. A) Percentage and B) number 
of B cells in transplanted NSG mice BM. C, D) Maturational stages of B-cell development in BM of transplanted 
NSG mice. E) Comparison of B-cell precursors in ex vivo BM aspirates to BM of transplanted NSG mice. F) IgM 
and IgD expression on non-myeloid hCD45+ cells in BM and G) spleen of transplanted NSG mice.
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Figure 4: No polyclonal IGH repertoire was generated in developing B cells from Artemis-SCID. A) D-J and 
B) V-DJ rearrangement of IGH locus in total BM cells of NSG mice transplanted with SCID or control HSPCs. 
C) Heatmap depicting the unique junctions of D to J segments for the IGH locus in total BM cells of NSG 
mice transplanted with SCID or control HSPCs. Colors depict the relative length of CDR3.
Novel early blocks in T-cell development for SCID
For the vast majority of SCID patients, the blocks in T-cell development are only known 
by extrapolation from mouse models. Here, we directly determined the arrests in T-cell 
development for different types of human SCID by investigating thymi of NSG mice engrafted 
with SCID HSPCs. To discriminate different populations within the DN compartment, we 
measured expression of CD7 and CD5 within this population. Based on the observed 
developmental arrests at the CD4-CD8- DN stage, all types of SCID block much earlier than 
observed in corresponding mouse mutants (Fig. 5A). T-cell development in IL2RG-SCID was 
inhibited at the CD7-CD5- stage followed by IL7RA-SCID where one-third of the cells reached 
the subsequent CD7+CD5- DN stage (Fig. 5B), although these blocks are somewhat comparable. 
For Artemis-SCID the block in T-cell development was found at the DN CD7+CD5+ stage without 
expression of CD1a (Fig. 5B and C). As expected from these early blocks in T-cell development, 
there was no expression of either TCRαβ or TCRγδ on total thymocytes in mice transplanted 
with SCID-derived HSPCs, but readily detectable in control mice (see Fig. E1 in the Online 
Repository). These data demonstrate the stages of arrest in T-cell development for different 
types of SCID and show an absolute requirement for common-gamma type cytokine signaling 
at the most immature thymic stages as also illustrated by the decrease in total hCD45+ cells 
within thymi of these mice (Fig. 5D). We observed a high percentage of CD19+ B cells in thymi 
from NSG mice transplanted with HSPCs from Artemis-SCID (Fig 5E). Also for IL7RA- and IL2RG-
SCID an increase in the percentage of B cells in the thymus was observed, but not as much 
as for Artemis-SCID. The increase in B cells that was observed was only relative and not in 
absolute numbers (Fig. 5F).
Importantly, we also transplanted CD34+ cells from a SCID patient with a hypomorphic mutation 
in IL2RG. This patient had low numbers of peripheral T cells and NSG mice transplanted with 
HSPCs derived from this patient indeed showed a much milder block, with only a lower 
percentage of DP thymocytes (Fig 5G). This demonstrates that less severe mutations lead to a 
less pronounced arrest in development. In addition, T cells also were detected in the peripheral 
blood mice transplanted with hypomorphic mutant IL2RG HSPCs (data not shown).
Figure 5: Early blocks in human T-cell development for different types of SCID. A) Phenotype of 
hCD45+ thymocytes and B, C) DN thymocytes in NSG mice transplanted with SCID or control HSPCs. 
D) Quantification of total human CD45+ cells in thymi of NSG mice transplanted with SCID or control 
HSPCs. E, F) Presence of CD19+ B cells in thymi of transplanted NSG mice. G, NSG mice transplanted with 
hypomorphic IL2RG-SCID or control HSPCs.
TCR rearrangement starts very early after thymus entry
TCR rearrangement starts at the TRD locus5. Since the observed blocks in T-cell development 
were very early, we focused TCR repertoire analysis on the TRD locus, of which Dδ2-Dδ3 is 
rearranged first. IL7RA- and IL2RG-SCID T-cell progenitors only showed incidental products 
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of this rearrangement in accordance with the early blocks observed using flow cytometry 
(Fig. 6A). Using spectratyping of T-cell receptor CDR3 length distribution, Artemis-SCID T-cell 
progenitors showed a broad repertoire for Dδ2-Dδ3 comparable to NSG mice transplanted with 
control HSPCs. These spectratyping data were confirmed using next generation sequencing of 
the TCR Dδ2-Dδ3 locus. Again, we observed a very limited number of reads for IL7RA- and 
IL2RG-SCID, while the normalized read numbers of Artemis-SCID were similar to those of mice 
transplanted with wild type cells (Fig. 6B). For the second step of TRD rearrangement, Dδ2-Jδ1, 
the repertoire was more oligoclonal in Artemis-SCID T-cell progenitors, while in IL7RA- and 
IL2RG-SCID such rearrangements were undetectable (Fig. 6C). However, none of the different 
types of SCID generated a broad Dδ-Jδ or even Vδ-Jδ repertoire (Fig. 6D). TRG is rearranged 
after TRD5 and for IL2RG-SCID no rearrangement could be observed of TRG while for IL7RA-
SCID merely a clonal rearrangement was observed, confirming the later block in development 
of IL7RA-SCID as compared to IL2RG-SCID (Fig 6E). While Artemis-SCID T-cell progenitors were 
able to perform the first steps of TRD rearrangement, they did not rearrange TRG and TRB loci 
(Fig. 6E and F). For both loci only a few incidental peaks were detected in Artemis-SCID T-cell 
progenitors as compared to NSG mice transplanted with control HSPCs. Judging from these 
clonal peaks, rearrangement of TRG is already initiated at the DN CD7+ stage and TRB at the DN 
CD7+CD5+ stage of T-cell development.
Figure 6: Hierarchical blocks in human T-cell development as demonstrated by TCR repertoire analysis. 
A, C-F) Rearrangement of TCR loci in total thymocytes of transplanted NSG mice; A) TRD Dδ2-Dδ3, C) TRD 
Dδ2-Jδ1, D) TRD Dδ-Jδ (blue) and Dδ-Dδ (green) E) TRG and F) TRB. B) Assigned fragments of TRDD2-
TRDD3 were calculated by dividing the number of assigned reads by the number of identified fragments.
Discussion
SCID is a rare disease caused by different genetic defects leading to T cell deficiency that 
can be accompanied by deficiencies in B and/or NK cells. Here we demonstrate for the 
first time the arrests in T-cell development for the major types of human SCID using an in 
vivo model; data which typically is not available because thymic biopsies are almost never 
obtained. Our approach allows for comprehensive loss-of-function insight for two important 
developmental checkpoints; common-gamma chain cytokine signaling and the initiation of 
TCR rearrangements.
The arrests in T-cell development observed for the different types of SCID demonstrate 
a hierarchy in TCR rearrangement and the corresponding phenotypes. The earliest block in 
T-cell development is observed in IL2RG-SCID, followed by IL7RA-SCID, demonstrating an 
almost immediate requirement for common-gamma chain cytokine signaling after seeding of 
the thymus.
Artemis is involved in opening of the hairpin sealed coding ends during recombination26. Here, 
we observed that Artemis-SCID cells are able to initiate rearrangement of the TRD locus as 
demonstrated by polyclonal Dδ2-Dδ3 and oligoclonal Dδ2-Jδ1 rearrangements. However, 
no complete TCRδ was formed. Apparently, Artemis is not needed for the first steps of TRD 
rearrangement, as confirmed by next generation sequencing, but is needed for complete 
rearrangement of TRD. An explanation would be that in absence of Artemis, the hairpin sealed 
coding ends are opened by other enzymes27. As this process is less efficient, the chance of 
successful two-step rearrangement is low and only partial rearrangements would be formed, 
as observed here.
We here demonstrate that rearrangement of TRG is initiated at the DN CD7+ stage and TRB 
loci is already initiated at the DN CD7+CD5+ stage of T-cell development, in contrast to previous 
models where TRB rearrangement was proposed at the immature single positive (ISP)28, 29 or 
DN3 stage of development30. As these DN CD7+CD5+ cells were devoid of CD1a expression that 
marks human DN3 cells8 this stage is reminiscent of the DN2 compartment in the mouse. While 
in the mouse rearrangement of TRB starts in the DN3 stage31, in the human thymus this process 
seem to start earlier based on our data. In mice, mutations in Il2rg lead to reduced thymic 
cellularity but are permissive for thymocyte development10, 11, whereas here we observed an 
absolute and very early requirement for IL2RG signaling. The blocks in IL7RA-SCID and IL2RG-
SCID are not completely identical, suggesting that cytokines other than IL-7 may also signal 
through the common-gamma chain in the early steps after thymus seeding. Cytokines that 
might be involved in proliferation and development in this very immature stage could be IL-
2, IL-4 or IL-1532, 33, 34. IL-15 is an important NK cell growth factor and in IL7RA deficiency this 
cytokine can signal normally via the IL2RG-IL15RA complex. Thus some of the CD7+CD5+ DN 
cells observed may contain mature NK cells, rather than solely uncommitted thymocytes 
with T/NK cell potential9, 35. The increased percentage of B cells observed in thymi of NSG 
mice transplanted with Artemis-SCID HSPCs is in line with data from the mouse where very 
early thymic blocks also lead to increased percentages of B cells, which developed from DN 
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thymocytes underlying the developmental plasticity of these cells that can still develop in non 
T-lineage cells in mice and men9, 36.
The point at which in IL2RG deficiency blocks development has sometimes been suggested 
to occur before thymic seeding. Our data combined with data by Kohn et al., who showed 
no differences in hematopoietic stem cells (HSC) and pre-thymic progenitors of IL2RG-SCID 
patients indicates that this is not the case. Rather, very soon after thymic seeding, there is an 
absolute requirement for gc signaling (see Fig 5). Since Six et al. showed that human thymic 
progenitors (in contrast to mouse) express IL7Ra and IL2Rg37, expression and functional 
requirement for gc are independently regulated.
To the best of our knowledge, only one paper has addressed the effect of human IL2RG 
deficiency in T cells before. Using an in vitro OP9-DL1 system, an arrest in development was 
shown at the CD7+CD5+CD1a- stage38. As no data are available on the nature of the IL2RG-SCID 
patient described by Six et al., it is impossible to say if the observed differences are based on 
differences between an in vitro model system versus in vivo transplantation data or reflect 
inherent differences based on different mutations with different residual signaling properties. 
Furthermore, the OP9-DL1 system can only address development until the earliest DP stages 
and is very sensitive to subtle differences in cytokines and labile contents of culture media38. 
Development proceeds a bit further in fetal thymic organ cultures (FTOC), but fully matured T 
cells and thymic egress do not occur, limiting the development of human thymocytes. In the 
NSG model as we describe it, the thymic phenotypes are highly similar to those obtained from 
human thymi, underscoring the validity of this model to identify the thymic defects in human 
SCID patients. Another approach to model T-cell developmental blocks in SCID patients, 
is by measuring rearrangement of TCR loci and TREC levels in peripheral blood T cells39, 40. 
However, many SCID patients do not have peripheral T cells to perform these analyses on and 
no phenotype of thymocytes is available. The low level of TRD D2-D3 in another IL2RG-SCID 
patient39 corroborates our data described here for thymocytes, demonstrating a very early 
block in T-cell development.
We have chosen SCID patients with mutations that are deleterious for function as this would 
lead to functional null mutants and included a hypomorphic patient, who had clinically a mild 
SCID phenotype that was only found because of an affected cousin. This mutation indeed 
showed a much less severe phenotype and no clear developmental block. This helps explain 
the divergent findings with IL2RG-SCID thus far and, importantly, validates our approach for 
genotype-phenotype studies with SCID mutations.
In summary, combining the flow cytometric and molecular data obtained from the engrafted 
NSG thymi leads to a proposed model for the development of human thymocytes (Fig. 7), in 
which there is a prominent role for cytokine signaling and initiation of TRB rearrangement marks 
the presumed b-selection point, as Artemis deficient cells block at this stage. It was shown 
previously that, indeed, pTα (PTCRA) is abundantly expressed at this point in development5.
Figure 7: Proposed model for human T-cell development. Indicated are the blocks in human T-cell 
development for different types of SCID as observed in this study. ETP; early thymic progenitor, ISP; 
immature single positive, DP; double positive, SP; single positive.
In a xenograft model, it could be argued that the defects observed are not cell-intrinsic but 
result from incompatibilities between mouse microenvironment and human hematopoietic 
cells. However, in the NSG model, human T cells develop with all the developmental 
stages known from ex vivo removed human thymi41. In addition, Parietti et al. were able to 
reproduce the development of human pro-thymocytes in the NSG xenograft model42 and it 
was demonstrated that human thymocytes can respond to murine MHC signals and have 
comparable migration on murine and human thymic slices43. Furthermore, for B cells the 
xenogeneic environment shows a block identical to the block in development directly found in 
the Artemis-SCID patient and B-cell development in controls was highly comparable to normal 
human BM. Taken together, this validates the use of xenografted mice for studies of human 
lymphoid development.
There is much attention for improving thymic output after allogeneic bone marrow 
transplantation; for acquired immune deficiencies, and during ageing44. In particular, strategies 
targeting the earliest human thymocytes, such as administration of IL-7, growth hormone or 
TSH or sex hormone ablation44, 45. Our results suggest that IL-7 combined with other early acting 
factors, e.g. Wnt46, may be promising to restore the early human thymocyte compartment 
which is expected to sustain thymopoiesis by providing a pool of DN progenitor cells.
In conclusion, we here report loss-of-function data on human T-cell development, demonstrating 
earlier blocks in T-cell development than proposed before5, 30. The obtained insights might give 
opportunities for treatment of ETP-ALL by interfering with common-gamma signaling which is 
active in these very early stages of T-cell development. It would be of great interest to study 
arrests in development for other types of human SCID in this xenograft model. Finally, the 
xenotransplantation method we here describe may prove useful in unravelling unknown types 
of human SCID for which the genetic defect has remained elusive and aid diagnosis in cases 
with blurred phenotypes, e.g. when maternal T cells are present.




We thank F. Koning for critical reading of the manuscript. 
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Cryopreservation of human bone marrow-derived mononuclear cells
Mononuclear cells were isolated using Ficoll gradient separation and washed once with 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with supplemented with 100 U/
mL penicillin and 100 µg/mL streptomycin (Gibco, Life Technologies) and 2.5% heat-inactivated 
FCS (Greiner Bio-One B.V., Alphen aan den Rijn, The Netherlands). Cells were resuspended in 
FCS/10%DMSO (Greiner Bio-One B.V., Alphen aan den Rijn, The Netherlands and Sigma-Aldrich, 
St. Louis, MO, USA, respectively) or in 50% RPMI/40% FCS/10% DMSO and frozen in 1 ml aliquots 
with a maximum of 50*106 cells per cryovial. Cryovials were placed in a freezing container in 
-80°C and relocated to liquid nitrogen storage on the following day.
Isolation of human bone marrow-derived CD34+cells
Cryopreserved vials were thawed in a 37°C waterbath after which the cell suspension was 
transferred to a 15 mL conical tube. Medium (IMDM supplemented with penicillin/streptomycin 
and 2.5% heat-inactivated FCS) was added dropwise to the cells. Labelling and isolation of 
CD34+ cells was performed according to the manufacturer’s protocol (CD34 Microbead Kit, 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Cells were centrifuged and resuspended 
in 300 µL Running Buffer (PBS pH 7.4, 2mM EDTA, 0.5% w/v bovine serum albumin (BSA, Sigma-
Aldrich, St. Louis, MO, USA). Add DNAse I (final concentration 5 U/mL, Sigma-Aldrich, St. Louis, 
MO, USA) together with 100 µL FcR blocking reagent and 100 µL anti-CD34 Microbeads. Cells 
were not counted before labelling as we never had more then 100*106 mononuclear cells and 
with counting we would lose cells. Cells were incubated for 30 minutes in the refrigerator while 
shaking every 10 minutes. Isolation of CD34+ cells was performed using 2 times an LS column 
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Cells were eluted in 3 mL Running Buffer using the supplied plunger. Eluted cells were 
centrifuged and resuspended in 500 µL StemSpan serum-free expansion medium (StemSpan-
SFEM, StemCell Technologies Inc., Vancouver, BC, Canada) in the presence of 10 ng/mL stem 
cell factor (SCF, a gift from Amgen, Thousand Oakes, CS, USA), 20 ng/mL recombinant human 
thrombopoietin (rhTPO, R&D Systems, Abingdon, UK), 20 ng/mL recombinant mouse insulin-
like growth factor 2 (rmIGF-2, R&D Systems) and 10 ng/mL recombinant human fibroblast 
growth factor-acidic (rhFGF-1, Peprotech, Rocky Hill, NJ, USA). Cells were counted using a 
Bürker chamber and trypan blue. Cells concentration was adjusted to 1*106/mL. Cells were 
cultured overnight in tissue-culture treated 48-well plates (Corning Incorporated, Corning, NY, 
USA) with 500 µL cell suspension per well. Then, cells were harvested by resuspension and 
transferred to a 15 mL conical tube. The well was washed by resuspension with 500 µL IMDM 
without phenol red (Gibco, Life Technologies, Bleiswijk, The Netherlands), which was added to 
the harvested cells. Cells were counted and an aliquot was taken for flow cytometry analysis 
to determine purity of CD34+ cells.
Transplantation into NSG mice
Cells were centrifuged and resuspended in IMDM without phenol red for intravenous injection 
into the tail vein of sublethally irradiated female NSG mice (200 µL/mouse). Mice were 
irradiated with with 1.91 Gy using orthovoltage X-rays one day before injection of the cells. 
Mice were transplanted within 24 hours after irradiation. Peripheral blood of transplanted 
mice was analysed every 4 weeks and mice were sacrificed 20-22 weeks after transplantation.
Table E1: Xenograft transplantation details




Transplanted number of 
CD34+ cells/mouse
ADA 3 200,000 197,540
Artemis 2 78,000 73,593
IL7RA 1 22,000 19,518




Healthy donor 1 33,000 29,555
Healthy donor 4 200,000 167,480
Healthy donor 3 100,000 86,740
Indicated are the numbers of NSG mice in which the sample was transplanted and the total mononuclear 
cell number and number of CD34+ cells transplanted per mouse.
Figure E1: Absence of TCR expression on SCID thymocytes. A) Expression of TCRαβ and B) TCR γδ on total 
hCD45+ thymocytes from transplanted NSG mice. 
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More than 16 genes have been shown to be causative for severe combined immunodeficiency 
(SCID). However, around 20% of patients remain without molecular diagnosis. Here, we present 
data on a female patient with an atypical presentation of SCID whose initial diagnosis was 
hard to make. By transplantation of patient derived hematopoietic stem and progenitor cells 
in immunodeficient mice, we could demonstrate that this case was a T-B+NK+-SCID. Phenotypic 
analysis of the thymocytes of these mice demonstrated an arrest in T-cell development at the 
CD3-- to CD3+-CD4+CD8+ double positive and the subsequent CD4+- and CD8+-single positive 
transition. Using whole exome sequencing, we identified a de novo heterozygous missense 
mutation in VPS4B that potentially could lead  to SCID with atypical presentation.
Introduction
Severe combined immunodeficiency (SCID) is a congenital disorder that is characterized by a 
deficiency of T cells in peripheral blood (PB). This deficiency in T cells can be accompanied by 
defects in either B or NK cells or both and can be categorized in 2 groups: T-B+-SCID and T-B-
-SCID1, 2. SCID affects approximately 1 in 100,000 live births and the patients present, mostly 
within their first year of life, with opportunistic infections and a failure to thrive3, 4. Currently, 
the best treatment option is a hematopoietic stem cell transplantation (HSCT) although clinical 
trials are ongoing with gene therapy approaches for SCID caused by mutations in either IL2RG 
or ADA5, 6, 7, 8, 9. Patients suffering from SCID caused by a mutation in ADA also benefit from 
enzyme replacement therapy10. Besides IL2RG and ADA, many genes can underlie this disease; 
up to now more than 16 have been described2, 10. However, a substantial fraction of patients 
without an identified disease-causing mutation is still remaining. Different fractions of SCID 
patients without a molecular diagnosis have been reported, ranging from 7 to 33%10, 11, 12, 13, 14.
A new approach to search for disease-causing genes is whole exome sequencing. This can be 
done by sequencing the coding sequences of the genome of a group of patients, as has been 
shown for Bartter Syndrome15 and Miller Syndrome16. Due to the rarity of SCID, especially the 
ones without a molecular diagnosis, it is very difficult to obtain a patient group for exome 
sequencing with the same molecular defect. In these cases whole exome sequencing of a 
single patient and both parents can be useful, in which the exome of the patient and both 
parents are compared to exclude inherited non-damaging single nucleotide variations (SNVs), 
instead of multiple patients and a control group. This approach has proven successful, for 
instance, by demonstrating that a mutation in CARD11 causes SCID17.
Here, we report on a patient with atypical presentation of SCID. Using the novel approach of 
transplanting patient derived hematopoietic stem and progenitor cells (HSPCs) in the NOD/
Scid-Il2rg-/- (NSG) mouse model, we could demonstrate that this patient has a hematopoietic 
cell-intrinsic defect and identified the stage of arrest in T-cell development. Using exome 
sequencing combined with whole exome sequencing analysis of patient and both parents 
we identified a de novo mutation in VPS4B that might be causative for T-B+NK+-SCID as it is 
predicted to act as dominant negative molecule.
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separated on a 2% gel and fragments were isolated using the Zymoclean Gel DNA Recovery Kit 
(Zymo Research Corporation, Irvine, CA, USA) for Sanger sequencing.
Whole exome sequencing
Exome sequencing was performed at GATC BioTech (Constance, Germany) using Agilent 
SureSelect post-capture and enrichment protocols together with Illumina HiSeq 2500 
platform. Reads were aligned using an in-house developed GNU Makefile-based pipeline 
(‘Magpie’, https://git.lumc.nl/rig-framework/magpie), based on the GATK 2.7 best practices21. 
Briefly, each FASTQ pair was processed using Sickle (version 1.33, https://github.com/najoshi/
sickle) with default settings to trim low-quality bases. Remaining reads were mapped to the 
hg19 human genome sequence using Burrows-Wheeler Aligner (BWA)-MEM (version 0.7.5)22. 
The resulting alignment was then compressed using the Samtools (version 0.1.19) suite23. 
Duplicates were removed using Picard Mark Duplicates (https://broadinstitute.github.io/
picard/) and data was subsequently processed through the GATK tools RealignTargetCreator, 
IndelRealigner, BaseRecalibrator, and PrintReads according to the GATK version 2.7 best 
practices and using the provided GATK 2.5 data bundle. The resulting alignment file was then 
used as input for the GATK variant callers HaplotypeCaller and UnifiedGenotyper, followed 
by variant recalibration. The generated VCF file was annotated using the Seattleseq web 
service (http://snp.gs.washington.edu/SeattleSeqAnnotation141/) and various other publically 
available databases (see results).
Results
Clinical presentation of the patient
The patient was a girl born at gestational age of 39 weeks and 5 days with a birth weight of 
4120 g. Her parents were non-consanguineous and the pregnancy was without complications. 
At the age of 5 months she was admitted to the hospital for failure to thrive. An auto-immune 
thyroiditis with hypothyroidism was detected and levothyroxine treatment was initiated. Nine 
months later, at the age of one year and two months, she developed a severe bronchiolitis 
secondary to a bocavirus and adenovirus infection. Because of respiratory failure she was 
admitted to the intensive care unit and subsequently developed progressive respiratory failure 
during mechanical ventilation, for which she was treated with extra-corporal membrane 
oxygenation (ECMO) for 5 days. During ECMO two infusions of high dose methylprednisolon 
were given. Bronchoscopy showed trachomalacia of the right main bronchus. Immunological 
examination revealed a severe T-cell cytopenia (Fig. 1A), B-cell cytopenia (Fig. 1B) and a mild 
hypogammaglobulinemia (IgG: 2.5 g/L, IgA: 0.56 g/L, IgM: < 0.3 g/L). NK cell numbers were low 
at diagnosis but recovered quickly (Fig. 1C). Initially these abnormalities were thought to result 
from methylprednisolone treatment, but T-cell lymphopenia persisted, whereas B-cell and NK-
cell lymphopenia recovered (Fig. 1A-C). At the time when B-cell numbers were spontaneously 
recovered, examination of the bone marrow showed no block in precursor B-cell development 
(Fig. 1D). Response to booster vaccination with tetanus, diphtheria and polio was normal, but 
no response could be detected to pneumococcal conjugate vaccine.
Materials and methods
Human CD34+ bone marrow derived cells
Human bone marrow (BM) was obtained from healthy pediatric BM donors at the Leiden 
University Medical Center (LUMC, Leiden, The Netherlands). Informed consent was obtained 
from the parents for the use of leftover samples for research purposes. BM from the patient 
was obtained according to the guidelines of the Erasmus MC. The medical ethical committees of 
LUMC and of Erasmus MC approved this study and both served as institutional review boards. 
Informed consent was provided according to the Declaration of Helsinki. Mononuclear cells 
were isolated using Ficoll gradient centrifugation, frozen in fetal calf serum (FCS)/10% DMSO 
(Greiner Bio-One B.V., Alphen aan den Rijn, The Netherlands and Sigma-Aldrich, St. Louis, MO, 
USA, respectively) and stored in liquid nitrogen. Cells were isolated and cultured as described 
previously18.
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from Charles River Laboratories 
(Kent, United Kingdom) and bred in the animal facility at the Leiden University Medical Center. 
Experimental procedures were approved by the Ethical Committee on Animal Experiments of 
the LUMC. Female NSG mice were transplanted with CD34+ cells by intravenous injection within 
24 hours after irradiation with 1.91 Gy using orthovoltage X-rays as described previously18, 19. 
Mice transplanted with CD34+ cells derived from healthy pediatric bone marrow are historical 
controls, due to the rarity of this material, and have been described elsewhere19.
Flow cytometry
Analysis of lymphocyte populations in peripheral blood and composition of the B-cell precursor 
compartment in the BM of the patient was performed as previously described20.
Labeling of mononuclear cells of transplanted NSG mice has been described18. The following 
anti-human antibodies were used: CD3-PECy5 (UCHT1), CD4-APCCy7 (RPA-T4), CD5-FITC 
(UCHT2), CD7-PECy5 (M-T701), CD8-PECy7 (SK1), CD13-APC (WM15), CD16-PE (B73.1), CD19-
APCCy7 (SJ25C1), CD20-PE (L27), CD33-APC (WM53), CD34-PE (8G12), CD45-V450, CD56-PE 
(MY31), TCRαβ-PE (T10B9.1A-31), streptavidin-PerCPCy5.5 (all from BD Biosciences, San Jose, 
CA) and CD10-biotin (eBioCB-CALLA) (eBioscience, San Diego, CA). Data were acquired on a 
Canto II (BD Biosciences) and analyzed using FlowJo software (Treestar, Ashland, OR, USA).
Sequence analysis
DNA was isolated from peripheral blood mononuclear cells from patient and both parents 
using the GeneEluteTM Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich, St. Louis, MO, 
USA) according to the manufacturer’s protocol. Sanger sequencing of known genes causative 
for SCID (ADA, RAG1, RAG2, IL2RG, CD3D, CD3E, CD3G, and CD3Z/CD247) was performed by 
PCR analysis (primers and amplification protocol are available upon request). The following 
primers were used for amplification and Sanger sequencing of the VPS4B gene: Forward 
5’-ATCTGGGAGATTTGATTCAT-3’, Reverse 5’-ATGAAAGACAGAAGTGTGTG-3’. Amplification 
was performed using the following protocol: 2 minutes 94°C, followed by 35 cycles of 94°C 
15 seconds, 60°C 30 seconds, 72°C 2 minutes, followed by 10 minutes at 72°C. Products were 
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At the age of one year and seven months she underwent a HSCT from her HLA-identical 
brother. Post transplantation she developed a severe Coombs positive hemolytic anemia for 
which high dose IVIG, methylprednisolon, rituximab and erythrocyte transfusions were given. 
Because no donor chimerism was present a second HSCT with the same donor was performed, 
which resulted in 100% donor chimerism. Post HSCT, ongoing hemolysis was treated with 
bortezomib and adenovirus reactivation with cidofovir. Later, she developed a progressive 
severe neurological deterioration; no spontaneous motor activity or tendon reflexes could be 
detected, and responses to visually evoked potentials were absent. CSF examination revealed 
no abnormalities. Cerebral MRI showed generalized atrophy and leukoencephalopathy. Next, 
she developed a severe lower respiratory infection that was fatal. Post mortal examination 
of the brain showed severe encephalopathy and gliosis, without signs of inflammation 
or infection. 
T-cell deficiency is caused by a cell intrinsic defect
Patient derived hematopoietic stem and progenitor cells (HSPCs) were isolated from a 
cryopreserved BM aspirate taken at the time when B-cell numbers had recovered. The HSPCs 
were transplanted in NSG mice to determine whether the immunological defects that were 
observed in the patient were caused by niche/stromal defects or by a hematopoietic cell 
intrinsic deficiency. Previously, we have used this approach to determine the arrests in T-cell 
development for different types of SCID that were caused by different known underlying 
genetic defects19. During follow-up of the mice transplanted with patient-derived HSPCs, there 
was outgrowth of both myeloid and B cells in peripheral blood, but T cells were not detected 
at any of the time points, whereas in mice transplanted with normal control HSPCs T cells 
were readily detected (Fig. 2A). In addition, at the end of the experiment, T cells were hardly 
detectable in mice transplanted with patient-derived HSPCs while they were present in UCB 
and BM transplanted control NSG mice (Fig. 2B, C). Taken together, the phenotype observed 
in mice transplanted with patient-derived HSPCs was consistent with a T-B+-SCID diagnosis.
Arrest in T-cell development at DP stage
As virtually no T cells could be detected in peripheral blood of both the patient and NSG mice 
transplanted with patient derived HSPCs, we examined T-cell developmental stages in thymi of 
transplanted NSG mice. Total thymocyte counts did not differ between mice transplanted with 
patient derived HSPCs or control HSPCs (Fig. 3A). We then analyzed the thymus of transplanted 
NSG mice for the presence of the different stages of T-cell development. The percentage of 
both mature CD4+ single positive (SP) and CD8+ SP was drastically decreased when patient 
derived HSPCs were transplanted (Fig. 3B, C). Furthermore the percentage of CD3+ CD4+CD8+ 
double positive (DP) cells was lower while there was an increase in the percentage of CD3- 
DP cells. The level of both CD3 and TCRαβ expression was decreased in the total thymocyte 
population as compared to mice transplanted with UCB derived HSPCs (Fig. 3D). In addition, no 
CD5hi expressing cells could be detected (Fig. 3E), a molecule known to be upregulated upon 
TCR signaling24. From these phenotypic data, we could confirm that this patient suffered from 
SCID. Together these data point to an arrest in development that is most pronounced at the 
CD3+ DP to SP transition while there might also be problems in TCR expression and signaling, 
as indicated by the increase in CD3- DP and decrease of CD3+ DP (Fig. 3C).
Figure 1: Lymphocyte characteristics in suspected SCID patient. A) B cell counts in peripheral blood of 
patient over time. B) T cell counts in peripheral blood of patient over time. C) NK cell counts in peripheral 
blood of patient over time. A-C) Horizontal lines indicate reference values. D) Developmental stages of B 
cell progenitors in BM of patient at two time points and of healthy controls.
Suspicion of SCID
Due to the persisting T-cell lymphopenia there was a suspicion of SCID and therefore 
genetic and metabolic analysis for ADA and PNP deficiency was initiated, but this showed no 
abnormalities. Also in the RAG1 and RAG2 genes no pathogenic mutations could be detected 
(data not shown). On karyotyping examination the patient was chromosomally 46,XY. External 
genital organs had a normal female appearance, except for partial fusion of the labia minora, 
and abdominal ultrasound revealed the presence of a uterus, but ovaries or testes could not be 
detected. Diagnostic SNP-array CGH analysis confirmed the chromosomal 46,XY and reported 
a heterozygous 450kb 4q23 micro-deletion (arr[hg18] ch4:108.60-109.05) of unknown clinical 
relevance. This variant was also present in her father and therefore presumed unlikely to be 
pathogenic. Subsequent IL2RG analysis was normal (data not shown).
Because of suspected SCID she was treated with (intravenous and later subcutaneous) 
intravenous immunoglobulin (IVIG) substitution, cotrimoxazol and valaciclovir prophylaxis. 
For the hypogonadism, treatment with sex hormones was given. Post ECMO she developed 
recurrent convulsions with multifocal epileptic activity and a delirium, for which she was 
treated with anti-epileptic drugs (levetiracetam) and haloperidol.
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NK cells were present both in PB and BM (Fig. 4A, B) and no aberrancies were detected within 
the B-cell compartment in the BM of transplanted NSG mice (Fig. 4C), further supporting that 
this patient is a T-B+NK+-SCID.
Figure 4: No aberrancies in NK cells and B cells in NSG mice transplanted with patient derived HSPCs. 
A) Percentages and B) numbers of NK cells (CD16/56+CD13/33-) in peripheral blood and bone marrow 
of NSG mice. Percentages are within hCD45+ mononuclear cell fraction. C) B-cell developmental stages 
characterized by expression of CD20 and CD10 in bone marrow of NSG mice. Fractions are within 
hCD45+CD19+ mononuclear cell fraction.
Causative genetic defect
Since the arrest in T-cell development was most profound at the DP stage, percentages of CD3 
expressing cells were lower and CD5hi expressing thymocytes were absent, mutations in one of 
the genes encoding the CD3 complex were suspected. Previous analysis had demonstrated that 
no abnormalities were present in ADA, PNP, RAG1, RAG2 or IL2RG. Therefore, we used Sanger 
sequencing to determine whether mutations were present in any of the genes encoding the 
different CD3 chains. No mutations were detected in CD3D, CD3E, CD3G or CD247 (CD3Z) (data 
not shown). As other SCID genes had been excluded during diagnosis, exome sequencing 
was performed on DNA of the patient and both parents. Trio-analysis was performed using 
the Modular GATK Pipeline (Magpie), which is a variant-calling pipeline based on GATK best 
practice recommendations to analyze multiple samples simultaneously. More than 177 million 
raw reads were obtained. Almost 164 million reads (92.5%) were uniquely aligned to hg19 using 
Burrows-Wheeler Aligner (BWA). Median exome coverage was 61-fold both for the exome of 
the mother and the patient and 57-fold for the reads obtained from the father. In the patient, 
381712 SNVs were identified (Fig. 5A). SNVs were called using both HaplotypeCaller and 
UnifiedGenotyper from the Genome Analysis Toolkit (GATK). High-quality non-synonymous 
variants in exons were filtered out and sequentially we only filtered for SNVs that were not 
Figure 2: T-cell deficiency is caused by a hematopoietic cell intrinsic defect. A) Percentages of cells from 
different lineages in peripheral blood of NSG mice transplanted with HSPCs from patient or control UCB 
and BM. Percentages are within hCD45+ mononuclear cell fraction. B) Cell counts of cells from different 
lineages in peripheral blood of NSG mice at the end of the experiment. C) FACS plots showing CD3 and 
TCRαβ expression in peripheral blood of NSG mice at the end of the experiment. Cells were gated within 
hCD45+ mononuclear cell fraction.
Figure 3: T-cell development is arrested at the transition from CD3+ DP to SP. A) Absolute cell numbers of 
total thymocytes. B) FACS plots depicting CD8 and CD4 expression on mononuclear hCD45+ thymocytes in 
thymi of transplanted NSG mice. C) Frequencies of cells from different T-cell developmental stages within 
hCD45+ cells in thymi of transplanted NSG mice. D) Expression of CD3 and TCRαβ within hCD45+ cells in thymi 
of transplanted NSG mice. E) Expression of CD5 within hCD45+ cells in thymi of transplanted NSG mice.




Up to now, more than 16 genes have been identified to be causative for SCID that give rise 
to different phenotypes based on absence and presence of B cells and NK cells besides the 
T-cell deficiency2. However, there remains a large fraction of patients with an unidentified 
underlying genetic defect and in addition still new SCID causing genes are being identified. 
Here, we describe a young patient with atypical presentation of SCID for who no mutation 
could be detected in genes known to be causative for SCID using standard Sanger 
sequencing protocols.
Previously, we have optimized the NSG humanized mouse model for efficient and robust 
engraftment of human BM derived HSPCs while maintaining multilineage differentiation and 
lymphocyte functionality18. In addition, we have used this model to determine the arrests 
in T-cell development for different types of SCID that were caused by a known underlying 
genetic defect. We also showed that the model faithfully recapitulates the arrests in B-cell 
development thereby validating this model for studies of human lymphoid development19. 
Here, we demonstrate the use of the NSG humanized mouse model for detection of SCID 
and determination of the stage of arrest in T-cell development. In addition, we confirmed 
that the patient with a suspected diagnosis of SCID indeed suffered from this disease with 
a T-B+NK+ phenotype. When the patient was admitted to the intensive care unit, there was a 
drop in number of B cells that recovered to normal levels. In line with this, no aberrancies in 
B-cell development were observed in NSG mice transplanted with patient-derived HSPCs. We 
demonstrated that solely the T-cell lineage was affected and the arrest in T-cell development 
was found at the DP to SP transition with an accumulation of CD3- DP at the expense of CD3+ 
DP. Arrests in T-cell development can also be studied using cocultures of HSPCs on OP9-DL1 
stromal cells as this model is used to study normal T-cell development in vitro28, 29. However, it 
remains difficult to reach the more mature stages, i.e. true DP stages and beyond, using these 
cultures. Therefore it would have been impossible to identify the late stage of arrest in human 
T-cell development that was identified here using the humanized mouse model.
A heterozygous microdeletion on chromosome 14 was found using a diagnostic SNP array 
CGH approach, however, this feature was also present in the father and therefore presumed 
unlikely to be pathogenic (data not shown). Therefore, we used whole exome sequencing 
to determine the causative defect using a trio analysis to exclude inherited polymorphisms, 
which were presumed unlikely to be causative. This approach has been proven successful in 
studies where they, for instance, identified a mutation in CARD11 to be causative for SCID17, 30, 
31. Here, we filtered the data obtained with whole exome sequencing by using 2 different SNV 
callers, exclusion of SNVs present in either dbSNP or the 1000 Genomes Project and prediction 
of the possible effect of the SNV by PolyPhen and SIFT prediction tools. Furthermore, we 
excluded SNVs that were present in the parents. This step is crucial to come to disease-
causing SNVs, because the genetic heterogeneity as well as low incidence of SCID make it 
impossible to analyze large numbers of phenotypically identical patient samples. Furthermore, 
it allowed us to screen for the presence of compound heterozygous mutations in genes known 
present in either dbSNP (v137) or in the 1000 Genomes Project, leaving 29 variants. Genes that 
have been previously associated with SCID were checked manually because these could have 
been filtered out in the previous steps. These genes were also checked for the presence of 
compound heterozygous mutations, which were not detected. None of these known SCID 
genes was affected in any of the methods used. Using the trio analysis of patient and both 
parents, we selected SNVs that were not present in one of the parents as they were both 
asymptomatic for de novo autosomal dominant (AD) modeling. For autosomal recessive (AR) 
modeling, we filtered SNVs that were homozygous in the patient and heterozygous in at least 
one parent. X-linked modeling was comparable to AR modeling except that the mother was 
heterozygous for the SNV and that the SNV was not present in the father. These filtering steps 
resulted in 13 SNVs (Fig. 5A). Autosomal dominant (AD) de novo modeling resulted in a total 3 
SNVs, autosomal recessive (AR) in 9 SNVs and X-linked recessive inheritance pattern in 1 SNV. 
PolyPhen25 and SIFT26 databases were used to determine whether variations were predicted 
as benign and tolerated in which case we did not consider them as being causative of the 
phenotype observed in the patient. Hereafter, we were left with 1 de novo SNV with a possible 
AD inheritance pattern. This SNV is located in VPS4B (vacuolar protein sorting 4 homolog B, 
NM_004869.3, NP_004860.2) encoding a heterozygous G to A mutation (c.869G>A) resulting 
in a predicted amino acid change at position 290 from arginine to glutamine (p.Arg290Gln). 
The variant is located in the AAA-ATPase domain of the protein27, which is needed for proper 
function of VPS4B. Validation by Sanger sequencing verified the heterozygous genotype of the 
patient for the mutation in VPS4B and the absence of the SNV in both parents (Fig. 5B).
Figure 5: Detection of a de novo mutation in VPS4B. A) Filtering of data derived from exome sequencing of 
DNA from the patient and both parents. B) Sanger sequencing results of VPS4B gene in patient and both 
parents. Top; patient, middle; father, bottom; mother. AD; autosomal dominant, AR; autosomal recessive.
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(iPSC) differentiated to the neuronal cell lineage37. The same approach could be used together 
with the CRISPR/Cas9 technology38 for site-directed repair of the mutation to determine 
whether this alleviates the phenotype. Unfortunately, it is still a challenge to differentiate 
repaired iPS cells into HSPCs that can be used for transplantation purposes in e.g. humanized 
mouse models.
Figure 6: Expression of VPS4B in different stages of human T-cell development. Data was mined from 
microarray data of sorted populations from human thymus material35.
To conclude, here we have identified a gene that potentially could be causative for T-B+NK+-
SCID. A de novo G to A mutation at position c.869 resulting in an amino acid substitution from 
the negatively charged arginine to the uncharged glutamine that could result in a dnVPS4B 
protein was identified by exome sequencing of the index patient and both parents. Functional 
experiments are needed to confirm whether the identified dominant negative mutant indeed 
leads to an arrest in T-cell development. Furthermore, the NSG humanized mouse model was 
demonstrated to be useful in the determination whether the patient indeed suffered from 
SCID. Due to the long duration of the transplantation experiment, this will not be useful to aid 
in diagnosis. However, by identification of VPS4B as a potential candidate gene for SCID and 
after confirmation by functional experiments, this could be included for screening of other 
patients suffering from SCID without a known genetic cause39.
to be associated with SCID, which were not found. In addition, by reporting single patient 
studies, other patients suffering from SCID without a known genetic cause can be screened 
for identified mutations as was also done for Bartter syndrome15. The use of whole exome 
sequencing technology for the use of diagnosis in orphan diseases such as SCID remains 
challenging and time consuming due to single patient analyses caused by low prevalence, 
however, we demonstrate here that it is possible.
After filtering of the exome data, we have identified a de novo heterozygous missense 
mutation in VPS4B in the patient that most likely has caused the observed immunodeficiency. 
The heterozygous mutation leads to a change in amino acids from Arginine to Glutamine at 
codon 290 and was confirmed by Sanger sequencing. We hypothesize that this might translate 
into a dominant negative form of VPS4B (dnVPS4B) as multiple dnVPS4B sequence variants 
have indeed been described that interfered with the normal function of VPS4B protein32, 
33. One described form of dnVPS4B has an amino acid change from the negatively charged 
glutamic acid to glutamine, which is uncharged and this mutation prevents binding of ATP30. 
The mutation described here leads to a change of the positively charged amino acid arginine 
to the uncharged glutamine. It is possible that this change leads to a disruption of the function 
of the AAA-ATPase domain similar to the described dnVPS4B mutant, which had a mutation in 
the same domain and acts as dominant negative molecule preventing VPS4 function. VPS4B 
binds to the Endosomal Sorting Complexes Required for Transport (ESCRT)-III complex that is 
involved in multivesicular endosome (MVE) biogenesis and the final steps of vesicle fission34. 
It has been described that VPS4B mediates scission of microvesicles that contain TCRs from 
the T-cell plasma membrane at the immunological synapse32. Furthermore, expression of 
a dnVPS4 disrupted the function of endogenous VPS4 resulting in an altered distribution 
of TCRs at the immunological synapse. In addition, we mined microarray data from sorted 
human thymus subsets35 and it was observed that the expression of VPS4B increased in the 
SP stage of human T-cell development (Fig. 6). It is likely that the mutated VPS4B identified in 
the current study functions as a dominant negative mutant that interferes with endogenous 
VPS4B function, which is normally needed to progress to the SP stage of T-cell development. 
Moreover, thymocytes from mice that are double knockouts for Stam1 and Stam2, components 
of the ESCRT-0 complex that initiates the endosomal sorting process34, have a block in T-cell 
development at the SP stage and these mice demonstrated defective proliferative responses 
after TCR stimulation36. This demonstrates that processes in which ESCRT-complexes are 
involved, are needed for the transition from the CD3- DP to the CD3+ DP and subsequent 
SP stage and most likely affect TCR signaling as also indicated by the observed decrease 
in CD5 expression.
The patient also suffered from neurological problems besides SCID, which are not possible to 
test in the humanized mouse model that was used in this study. However, it has been described 
that mutations in components of the ESCRT-III complex are involved in neurodegenerative 
diseases, such as amyotropic lateral sclerosis and frontotemporal dementia (reviewed in34). 
The involvement of the predicted p.Arg290Gln mutation in VPS4B in neuronal aberrancies 
could possibly be tested by generation of patient specific induced pluripotent stem cells 
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The fate and numbers of hematopoietic stem cells (HSC) and their progeny that seed 
the thymus constitute a fundamental question with important clinical implications. HSC 
transplantation is often complicated by limited T-cell reconstitution, especially when HSC 
from umbilical cord blood are used. Attempts to improve immune reconstitution have until 
now been unsuccessful, underscoring the need for better insight into thymic reconstitution. 
Here we made use of the NOD-SCID-IL2Rgamma-/- (NSG) xenograft model and lentiviral cellular 
barcoding of human HSCs to study T-cell development in the thymus at a clonal level. Barcoded 
HSCs showed robust (>80% human chimerism) and reproducible myeloid and lymphoid 
engraftment, with T cells arising 12 weeks after transplantation. A very limited number of HSC 
clones (<10) repopulated the xenografted thymus, with further restriction of the number of 
clones during subsequent development. Nevertheless, T-cell receptor rearrangements were 
polyclonal and showed a diverse repertoire, demonstrating that a multitude of T-lymphocyte 
clones can develop from a single HSC clone. Our data imply that intra-thymic clonal fitness is 
important during T-cell development. As a consequence, immune incompetence after HSCT is 
not related to the transplantation of limited numbers of HSC but to intrathymic events.
Significance statement
The number of hematopoietic stem cell clones contributing to T-cell development is restricted 
at entry of and during further development inside the thymus. However, despite this severe 
restriction, a fully diverse T-cell receptor (TCR) repertoire can be generated, indicating that 
haematological and immunological clonality are independently regulated.
Introduction
Hematopoietic stem cell transplantation (HSCT) has become common clinical practice in the 
treatment of leukemia, lymphoma and certain inherited immune and metabolic disorders. 
After transplantation there is an immediate need for de novo production of granulocytes, 
erythrocytes and platelets referred to as hematopoietic reconstitution, later followed by 
recovery of lymphocyte numbers termed immune reconstitution. While often successful, 
HSCT is associated with a number of complications arising from poor immune reconstitution, 
which presents one of the most important causes of morbidity after HSCT1, 2. Poor myeloid 
reconstitution is directly linked to low numbers of HSCs in the transplant, the reasons for poor 
immune and in particular, T-lymphocyte reconstitution are much less clear.
A study on the application of anti-thymocyte globulin (ATG) in cord blood transplantation 
showed that ATG administration in pre-transplantation conditioning results in decreased T-cell 
reconstitution and survival3, indicating the need for a better understanding of de novo T-cell 
development after HSCT. As T cells develop in the thymus in contrast to all other blood lineages 
that develop in the BM, HSC-derived progenitors need to seed the thymus. Earlier work in mice 
has indicated that relatively few progenitors seed the thymus4, 5 yet their numbers and the 
subsequent fate of the progeny derived from a HSC clone has remained elusive. The nature 
of the thymus seeding cell has been subject of much debate, certainly in humans. CD34+CD38-
CD7+ cells6, 7, CD34+CD38-CD10-CD62L+ cells8 and others have been proposed as thymus seeding 
cells in the human situation. In contrast to mice, the earliest human thymocytes show a much 
broader lineage developmental potential, including low levels of erythroid and megakaryocytic 
potential9, and may be therefore be much closer related to HSCs or the proposed myeloid 
lymphoid precursors (MLP).
In this study, we aimed to address the functional relationship between HSCs and developing T 
cells by using DNA barcoding. This method allows marking of each stem cells and its progeny 
by a unique, neutral DNA sequence that can be retrieved by next generation sequencing. 
Here we used replication deficient lentiviruses to transfer a DNA barcode and the GFP green 
fluorescent protein into phenotypically defined human HSCs. These marked HSCs were 
transplanted, using an optimized protocol10, into NOD/SCID/Il2rgamma-/- (NSG) mice11 which 
allowed us to determine the dynamics of clonal reconstitution in the thymus in great detail. 
We used umbilical cord blood (UCB) as source of human stem cells, because UCB is frequently 
used as readily available HSC source with less stringent HLA-matching requirements12. Yet, 
T-cell immune reconstitution, a general problem in allogeneic HSCT, is more problematic in 
UCB. Therefore UCB provides an appropriate HSC source to address questions of lineage 
tracing and clonality in the blood and immune system. As we demonstrate here only a fraction 
of HSC clones in UCB contributes to the T cell pool, yet a fully diverse TCR repertoire can be 
generated in the thymus.
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orthovoltage irradiation and transplanted 24 hour after irradiation via tail vein injection with 
the indicated cell numbers. Mice were fed Diet Gel recovery (Clear H2O, Portland, MA, USA) and 
kept on antibiotics (560µg/l polymixin B (Bupha, Uitgeest, Netherlands), 700 µg/l ciprofloxacin 
(Bayer, Mijdrecht, Netherlands) , 800 µg/l amphotheracin B (Bristol-Myers Squibb, Woerden, 
Netherlands) in autoclaved acidified drinking water until white blood cells counts were 
recovered at 4 weeks post-transplant. Blood samples were obtained at 4, 8, 12, 16 and 21 weeks 
by lateral tail vein incision. At 16 or 21 weeks, mice were killed by O2/CO2 inhalation and thymus, 
BM, PB, and spleen were isolated. BM cell suspensions were made by crushing the bones in 
IMDM (Lonza) and passing the remaining cells through a 70µm filter. Spleen and thymus were 
homogenized by passing them through a 70 µm filter.
Flowcytometry
Erythrocytes in the PB samples were lysed using an isotonic NH4Cl buffer (LUMC apothecary), 
after which the cells were stained with the indicated antibodies in phosphate buffered saline 
(PBS)/0.2% bovine serum albumin/0.1% sodium azide buffer for 30 minutes on ice. Cells were 
subsequently sorted using a FACS Aria II SORP (BD)
Spleen and PB cells were stained using anti-human CD45 (HI30) V450, CD19 (SJ25C1) APCCy7, 
CD3 (SK7) PE, CD4 (RPA-T4) V500, CD8 (SK1) PECy7, CD13 (WM15) APC and CD33 (WM53) APC 
(all BD). PB cells were sorted into T cells (huCD45+CD3+) B cells (huCD45+CD19+) and myeloid 
cells (huCD45+CD13/CD33+) and splenocytes into B cell (huCD45+CD19+) and T cell (huCD45+CD3+) 
populations. Bone marrow cells were stained using anti-human CD45 (HI30) V450, CD34 (8G12) 
PE, (all BD), CD38 (HIT2) PECy7, CD90 (ebio5e10) APC and CD49f (ebioG0H3) PerCP-efluor710 (all 
eBioscience). HSC (huCD45+CD34+CD38-CD90+CD49f+) were sorted. Thymus cells were stained 
using human CD45 (HI30) V450, CD1a (HI149) APC, CD34 (8G12) PE, CD3e (UCHT1) PECy5, CD4 
(RPA-T4) APCCy7 and CD8 (SK1) PECy7 (all BD) after which DN1/2 (huCD45+CD3-CD34+CD1a-) 
and DN3 (huCD45+CD3-CD34+CD1a+), DP (huCD45+CD3+CD4+CD8+) and SP (huCD45+CD3+CD4+ 
and huCD45+CD3+CD8+) were sorted.
Spike-in experiment
Plasmid DNA with a known barcode was mixed with DNA from polyclonally transduced 
population of cells at 0, 1, 3, 10, 30 and 100% based on the estimation that one virus was inserted 
per genome (3.3 x 109 bp). The size of the plasmid was 10201 bp and carried one DNA barcode. 
The samples were then processed for barcode determination as described below.
DNA preparation and deep sequencing
DNA from the sorted populations was extracted using Sigma GenElute columns (Sigma-Aldrich, 
Zwijndrecht, The Netherlands), according to the manufacturer’s instructions with the addition 
of 5µg herring sperm DNA as carrier material. The DNA barcode was amplified using LWGFP_
pTGZ (CACATGCACTTCAAGAGCGCCAT) and LWPRE_pTGZ (TGAAAGCCATACGGGAAGCA) 
primers (Sigma-Aldrich), at 0.6 µM, using GoTaq polymerase (Promega) and a temperature 
profile of 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 60° for 30 s and 72°C for 30s, with 
a final extension of product at 72°C for 10 min. The 379 bp resulting product was cleaned using 
Qiagen PCR cleanup columns according to the manufacturer’s instructions (Qiagen, Hilden, 
Materials and methods
CD34+ and HSC isolations from UCB
Human CD34+ cells were isolated from umbilical cord blood (UCB) samples. Mononuclear cells 
of UCB were isolated by Ficoll (LUMC apothecary) density centrifugation, washed and stored in 
liquid nitrogen until further use. Single UCB units (HSC transplantation) or five to ten combined 
UCB units (CD34+ transplantations) were selected, thawed and selected for CD34+ progenitors 
using the CD34 Microbead Kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according 
to the manufacturers protocol. Purity of the CD34 selection was verified by flowcytometry and 
exceeded 95% purity. HSCs were isolated by staining with anti-human CD38 (HIT2) PECy7, CD90 
(ebio5e10) APC, CD49f (ebioG0H3) PerCP-efluor710 (all eBioscience, San Diego, CA, USA ), CD34 
(8G12) PE, CD45 (HI30) V450, CD45RA (L48) FITC (BD, Franklin Lakes, NJ, USA) and subsequent 
sorting of CD34+CD38-CD45RA-CD90+CD49f+ cells using a BD Aria II SORP cell sorter (Beckton-
Dickinson). The cells were subsequently cultured in Stemspan (Stem Cell Technologies), in the 
presence of 10 ng/ml stem cell factor (SCF, a gift from Amgen, Thousand Oakes, CS, USA), 20 
ng/ml recombinant human thrombopoietin (rhTHPO, R&D systems, Abington, UK), 20 ng/mL 
recombinant mouse insulin-like growth factor 2 (rmIGF-2, R&D systems, Abington, UK) and 
10 ng/ml recombinant human fibroblast growth factor 1 (rhFGF1, Peprotech GmbH, Hamburg, 
Germany) and penicillin/streptomycin (Lonza, Basel, Switzerland) on retronectin coated plates 
(Takara, Otsu, Japan). The cells were incubated for 24 hr at 37°C and 5% CO2 .
Virus production and transduction procedure
Lentiviral vector pTGZ is derivative of pGIPZ (Thermo, Openbiosystems, USA) where 
Puromycin-IRES-MCS site locus (BsrGI-MluI) was replaced first by BsrGI-ClaI-BamHI-MluI 
adapter, then a barcode linker was integrated via BsrGI-BamHI sites between tGFP and 
the WPRE element as described13, 14. The barcode sequence, named B322, was as follows: 
AGGNNNACNNNGTNNNCGNNNTANNNCANNNTGNNNGAC. Viral particles were generated 
in 293T cells by transfection of pEnv VSVG, pMD2 GagPol, pREV and the barcoded vector 
backbone pTGZ-B322. Titers were determined on isolated CD34+ cells to achieve a transduction 
efficiency of 20% in order to minimize the occurrence of multiple virus integrations per cell, while 
maintaining a reasonably high marking rate. UCB CD34+ cells were cultured as decribed above 
at 6500 cells/cm2 density. After 24 hr, the cells were spinoculated with virus supernatant at MOI 
= 1, after which the supernatant was replaced with fresh Stemspan medium with cytokines. 
The cells were kept for 16 hr at 37°C and 5% CO2 and then prepared for transplantation. Because 
lentiviral vectors cause pseudo-transduction (protein expression from the pre-integration 
complex, PIC) assessment of the transduction rate at the moment of transplantation is not 
accurate. Instead, a fraction of transduced cells was kept in culture for an additional week until 
the non-integrated PICs were diluted out and the transduction rate could be determined by 
flow cytometry.
Animals and transplantation
NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NSG) were obtained from Charles River Laboratories 
(UK) and bred in individually ventilated cages (IVC) under specific-pathogen free (SPF) 
conditions. Mice (aged 5-6 weeks) were sublethally irradiated with 1.91 Gy X-rays using 
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CD3 cells) multiplied by the fraction of each clone as determined by barcode sequencing (shown 
in Fig. 3A) for all reads making up more than 1% of the reads recovered in these tissues. The 
Shannon indices obtained in this way were then normalized per animal to allow comparison 
between animals. Differences in Shannon diversity between subsets were analyzed using a 
Wilcoxon rank sum test, considering p<0.05 significant.
Study approval
Experimental procedures were approved by the Ethical Committee on Animal Experiments 
of the Leiden University Medical Center (Leiden, The Netherlands). The umbilical cord blood 
samples used in this study were collected at the Diakonessenhuis Hospital, Leiden after 
informed consent was given by the parents. Peripheral blood control samples were obtained 
with informed consent under guidelines issued by the Medical Ethics Committee of the Leiden 
University Medical Center.
Results
We set out to better understand the functional relationship between HSCs in the bone marrow 
and developing T cells in the thymus. Cellular barcoding allows this question to be addressed in 
a quantitative sense. To do so, human HSC were isolated from umbilical cord blood and were 
transduced with a lentiviral DNA barcoding vector that carried 485 individual barcodes13, 14 (Fig. 
1A). We aimed to transduce <20% of the target cells to limit the occurrence of multiple lentiviral 
insertions per cell. A well-defined library with restricted complexity was used to allow full 
quantification yet also to contain enough diversity to individually track HSC given the number 
of transduced HSCs per mouse. In three independent experiments, a total of 17 mice were 
transplanted with either low (26,000; n=4) or high dose (150,000; n=4) of CD34+ cells or ~1000 
highly purified HSCs (n=9), defined as CD34+CD38-CD45RA-CD90+CD49f+ 15.
To ensure that viral DNA barcoding methodology allows quantification of marked clones, 
calibration experiments were performed. The mixtures of DNA barcodes resulting from 
the spike-in experiments demonstrate a decrease of the sample from the 100% down to the 
1% spike-in sample (Supplementary Fig. 1A). Linear regression analysis showed a Pearson 
correlation coefficient R2=0.994 (Supplementary Fig. 1B). In a separate experiment, nine repeat 
measurements of the polyclonally transduced samples were analyzed for reproducibility. Read 
fractions below 0.5% of the sample threshold were progressively more difficult to quantify 
reliably as demonstrated by the increase in coefficient of variation at lower fractions of reads 
(Supplementary Fig. 1C). Deep sequencing is prone to generate sequence misreads at low 
frequency, and because our analysis is dependent on the ability to assign and distinguish 
individual barcodes, we compared all identified DNA barcodes against each other and 
determined their dissimilarity. We considered barcodes with up to 2 dissimilar bases to 
originate from the same original barcode (Supplementary Fig. 1D). Repeated measurements 
on CD19+ cells isolated from PB (Supplementary Fig. 1E) also demonstrated that the method 
results in limited variation between samples. Thus, the applied barcoding strategy can reliably 
quantify progeny of individual HSC clones in this setting. 
Germany). The cleaned products were then multiplexed by adding an Iontorrent adapter with 
sample multiplexing barcodes to one side CCATCTCATCCCTGCGTGTCTCCGACTCAG[8 base 
multiplexing barcode] GCAGATGCCGGTGAAGAATAATGTAC and a common IonTorrent adapter 
CCTCTCTATGGGCAGTCGGTGATAGTCAATCTTTCACAAATTTTGTA to the other side (95°C for 5 
min, followed by 35 cycles of 95°C for 30 s, 60° for 30 s and 72°C for 30s). The resulting 208 
bp amplicons were separated on a 2% agarose gel, the products were excised and cleaned 
using Qiagen gel extraction columns, mixed in equimolar amounts and submitted to the 
LUMC sequencing core facility (LGTC) where library concentration was determined using a 
High Sensitivity DNA kit on an Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA). The library 
was amplified using emulsion PCR using the Ion PGM Template OT2 200 kit (Agilent) and 
subsequently sequenced using the Ion PGM Sequencing 200 Kit v2 (Agilent) and 314 or 316 
chips according to the manufacturer’s instructions.
Sequence analysis
FASTQ files were retrieved from the sequencer and underwent overall quality control using 
FASTQC (Simon Andrews, Babraham Institute,Cambridge, UK available at (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/), after which the sequences were separated by 
sample multiplexing barcode using a custom BioPerl script(http://www.bioperl.org) that uses 
regular expressions to determine primer and sample barcode sequences. From the resulting 
FASTA files, the DNA barcodes were extracted using a custom BioPerl script that determined 
barcode location based on a regular expression matching the surrounding virus sequences 
and the invariable doublets within the DNA barcode. Samples with >100 associated reads were 
considered for analysis. These barcodes were clustered using R (R-3.0.0, www.r-project.org) 
by calculating dissimilarity between all barcodes for all samples of an animal. Read numbers 
for barcodes with dissimilarity of less than 2 nt were clustered and added together, thereby 
correcting for sequencing errors46. Simulation of random sets of 485 barcodes showed that 
the frequency of 1-2 nt distances would occur in less than 1/1000 reads, therefore a dissimilarity 
threshold of 2 nt seems appropriate to eliminate false barcode reads in sequencing results, 
caused by PCR and sequencing errors. By applying this strategy to the sequenced library pool 
this resulted in a set of barcodes that agreed with the expected size of our DNA barcode library 
(485 barcodes by sequencing with noise removal, compared to the 500 single bacterial clones 
that were selected for the preparation of the vector library). The contribution of each clone to 
a particular tissue was normalized by dividing the reads for each clustered clone by the total 
number of reads per sample. The resulting fraction of contribution was then displayed.
TCR analysis
Rearrangements of TRB, TRG, and TRD loci were analyzed by means of BIOMED-2 multiplex 
PCR assays47 and visualized via GeneScan analysis. All assays were performed using the proper 
clonal, polyclonal and negative controls, and according to the published BIOMED-2 multiplex 
PCR protocol.
Statistics 
To describe the population diversity in the thymus, we calculated the Shannon diversity index 
using the cell number isolated from a tissue (HSC or thymus DN1/2, DN3, DP and SP or spleen 
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HSC isolated from the NSG mice was also detected in CD19+ B cells or CD3+ T cells in the spleen. 
The ternary plots (Fig. 2 and Supplementary Fig. 4) showed that a considerable fraction of 
single clones was shown to be present in two or three of these three cell types, demonstrating 
contribution to sorted HSC as well as the adaptive lymphoid lineage. This confirms that true 
HSCs with multi lineage differentiation capacity were marked by lentiviral barcoding. The 
existence of myeloid, lymphoid or mixed progenitors is in line with previous reports in mice16 
and human cells in the NSG xenograft model17. However, none of these studies specifically 
addressed the thymus or T-cell reconstitution.
Figure 2: Clonal contribution to HSC and adaptive immune cells. Multilineage engraftment is demonstrated 
by contribution of barcoded clones to HSC, splenic CD3+ T cells and CD19+ B cells in 9 NSG mice that were 
transplanted with purified barcoded human HSCs are shown. The barcode content of these compartments 
was determined by comparing the normalized contribution of clones. The relative contributions to the 
total human HSC (BM) and T- and B-lymphoid lineages (spleen) in each mouse are shown as a ternary plot. 
Each point represents the contribution of a clone to HSC, CD19+ B cell and CD3+ T cell lineages. The extent 
of contribution is depicted by the location of the point along the three axes with clones contributing 
equally to all lineages being closer to the center of the triangle. In most mice, but especially in mouse 
8 and 9 true multilineage contribution of HSC clones can be observed. The numbers at the points of the 
triangle indicate the number of detected clones for which contribution to only one lineage was detected.
Transplantation of human HSC from umbilical cord blood resulted in a robust reconstitution 
(median 81%, range 53-92% at 16 weeks, Fig. 1B) in all 9 mice. Green fluorescent protein (GFP) 
marking was initially around 20% and stabilized at 16 weeks at median 8.9% (range 4.5-20%, 
Fig. 1C), consistent with the intended low transduction rate, which limits the occurrence of 
multiple integrations per cell. After 12 weeks, CD3+ T cells were detectable for the first time 
(Fig. 1D), which coincides with a concomitant reduction in the percentages CD19+ B cells (Fig. 
1F), which form the majority of repopulating human cells.
Figure 1: Barcoding human HSC and xenotransplantation. A) Human HSC (CD34+CD38-CD45RA-
CD90+CD49f+) or CD34+ cells were isolated and transduced with the PTGZ barcode library carrying 21 
variable bases in the barcode with a total complexity of 485 different barcodes. The transduced cells were 
transplanted in to 5-6 week old sublethally irradiated NSG mice. The mice were bled monthly and myeloid 
cells, T cells and B cells were isolated from PB. At 16 or 21 weeks, the experiment was terminated and, 
in addition to PB, cells isolated from thymus, spleen and bone marrow were sorted as indicated and the 
barcode content of the samples was analyzed. From the thymus, double negative (DN), double positive 
(DP), and single positive (SP) cells were isolated using the indicated markers. B) Chimerism in PB of 9 mice 
transplanted with 1000 purified human HSCs as determined by human CD45 expression, C) GFP marking 
of human cells. D) Development of CD3+ T cells, E) CD13/CD33+ myeloid cells and F) CD19+ B cells within the 
human CD45+ population were followed in time after transplantation of the transduced cells.
Analysis of the barcodes present during repopulation demonstrated that a limited repertoire 
of hematopoietic clones was responsible for the generation of myeloid cells, B cells and T cells. 
We detected a median number of 70 clones (range 51-88) per mouse in the peripheral blood, 
rising to a median of 83 (range 57-107) when bone marrow and thymus samples with different 
barcodes were included. Because the barcodes in purified HSCs are inherited by the daughter 
cells, we could also investigate the contribution of the marked clones in HSC to the B- and 
T-cell lineage. We therefore analyzed the extent to which a clone retrieved from the human 
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To study thymic repopulation, various stages of human T-cell development, ranging from 
early double negative (DN, CD4-CD8-) cells to double positive (CD4+CD8+) and single positive 
mature cells (CD4+ or CD8+) were isolated from the thymus as described (DN1/2: CD3-CD4-
CD8-CD34+CD1a-, DN3: CD3-CD4-CD8-CD34+CD1a+, DP: CD4+CD8+, SP, CD3+CD8+ or CD3+CD4+, 
Fig. 3A)18. During differentiation from polyclonal HSC to mature CD3+ T cells a dramatic clonal 
skewing was seen in the form of reduction of the number of clones contributing more than 1% 
of the thymic populations. We employed the Shannon diversity index, a measure that can be 
used to describe biological diversity19, to capture the frequency and abundance of barcoded 
clones. Using this parameter, the HSC (Fig. 3B) and high dose CD34+ (Supplementary Fig. 2A, C) 
experiments show high diversity in BM but much lower in thymus, with clear clonal restriction 
at DN1/2 and subsequently a further restriction at the DN3 and DP stages. The reconstitution 
with the 26,000 CD34+ cell dose containing lower numbers of true HSCs led to lower diversity in 
the BM, but still only one clone dominates at the thymic SP or DP stage (Supplementary Fig. 2B, 
D). Analysis of the DN3, DP and SP compartments indicated a further reduction in the number 
of hematopoietic clones (Fig. 3B and Supplementary Fig. 2A), while the numbers of isolated 
cells actually increase going from DN1/2 through DN3 to DP, which demonstrates that clonal 
restriction is not due to smaller thymic subpopulations investigated.
To investigate whether the restriction of clones is due to a limitation in the number of 
transplanted cells, we performed similar experiments with 150,000 or 26,000 CD34+ cells 
per mouse (containing approximately 625 and approximately 108 HSC respectively15). While 
150,000 CD34+ cells are capable to generate a repopulation pattern in the thymus similar 
to the that observed after transplantation of 1000 purified HSC (Supplementary Fig. 2C), 
transplantation of 26,000 CD34+ cells per mouse shows more limited clonal diversity, with 
most compartments consisting of a few clones (Supplementary Fig. 2D). Nevertheless, further 
clonal restriction during T-cell development was observed in spite of the transplantation of a 
6-fold higher number of CD34+ cells, or when a 10-fold higher number of phenotypically defined 
HSC was transplanted , suggesting that thymic clonality is primarily determined by intrathymic 
events rather than based on cell dose. Hence, clinically there is merit in transplanting a higher 
dose of CD34+ cells to obtain a more diverse repertoire, yet a plateau is readily reached.
Having observed the limited number of hematological clones in the thymus, we asked the 
question whether this restricted number of cells would negatively influence the T-cell receptor 
(TCR) repertoire. At DP and SP stages a fully polyclonal pattern of TRB rearrangements 
is visible, with even further diversity in the splenic CD3+ T cells (Fig. 4). From this data, we 
conclude that a fully diverse TCR repertoire can be generated from progeny with a high level 
of clonal restriction. It needs to be noted that the polyclonality in the spleen can be interpreted 
as the result of ongoing thymic output while the thymic analysis is more of a snapshot. 
Nevertheless, even at this “snapshot” the progeny of HSC clones is very small while thymic 
DP and SP cells have a fully diverse TCR repertoire which is further expanded in the spleen by 
the accumulation of cells egressing from the thymus. Because only a portion of the cells in 
the thymus and spleen were lentivirally transduced, the untransduced cells might contribute 
to this diverse repertoire, we therefore also sorted GFP+ transduced cells from the spleen to 
Figure 3: Clonal restriction during T cell development. A) Thymus was homogenized and cells were sorted 
into their developmental stages (DN1/2, DN3, DP, SP). B) The number of clones contributing >1% of the 
sample in 9 mice transplanted with barcoded HSCs or CD34+ cells were counted, and the Shannon diversity 
index calculated. The normalized Shannon diversity was compared between HSC in the BM and the 
developmental stages in the thymus. Mean normalized Shannon diversity indices for 9 mice transplanted 
with 1000 HSC are shown with error bars indicating SEM. Wilcoxon p-values are shown in B. C) Clonal 
repertoire, as determined by barcode analysis of sorted population in the thymus in stacked area graphs, 
with colors identifying the individual clones. Note that the colors are chosen for the purpose of display, 
which means that the same color depicts different clones in different mice.
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Intrathymic events that regulate TCR repertoire and the integrity and quality of thymic epithelial 
cells are likely an important factor. As a consequence, efforts to improve thymic reconstitution 
using cytokines (IL725,SCF, KFG26, 27, FLT3L28) or hormones (GH29, TSH30) and ablation of sex 
hormones31 are only likely to be effective if they selectively act on the thymic microenvironment 
or mimic signals given by the thymic epithelial cells to developing thymocytes. Transplantation of 
committed T-cell progenitors together with HSCT, as shown before with mouse hematopoietic 
cells cultured ex vivo on OP9-DL1 expressing stromal support, which provide the cells with the 
Notch signals required to direct T-cell development32, as well as diminishing the influence of 
male sex hormones known to deregulate intrathymic Notch ligand DLL431 may work well to 
improve thymic function and support diverse TCR repertoire formation. There is one interesting 
physiological situation in which hematopoietic reconstitution can be stimulated namely by 
exposure to non-inherited maternal antigens (NIMA) of the HLA-locus33. This phenomenon is 
now widely recognized in UCB transplantations and indicates that effective T-cell responses 
can be mounted with beneficial (e.g. graft vs leukemia) effects34, 35. While such exposure would 
theoretically lead to increased thymic output, the effect on TCR repertoire is expected to be 
limited, hence efforts directed at increasing overall thymic output are warranted.
Xenotransplantation of human cells in mice is a valuable approximation of the normal 
development of human cells. In NSG mice, the human cells develop into mature functional T 
cells that are responsive to immunization10, 36, the thymus shows highly similar phenotype to 
normal human thymi37. When compared to human control samples (Supplementary Fig. 6), 
xenotransplanted NSG mice show lower CD3+ cell counts (Wilcoxon test, p=0.0015), but within 
the CD3+ cells, the percentage of CD4+ and CD8+ T cells is comparable. Furthermore, human and 
xenografted CD8+ T cells show similar distribution of CD45RA+ naive cells and CD45RO+ memory 
cells, but CD4+CD45RO+ memory T cells are present in a significantly higher proportion in the 
transplanted NSG mice (p=0.009), which might point to ongoing homeostatic proliferation in 
the CD4 compartment. Analysis of the interaction between murine thymic stroma and human 
T cells cells showed that T cells are capable of migrating to the site where they are expected 
to reside corresponding to their developmental stage in mouse thymus in response to murine 
Ccl25, Cxcl12 and Ccl21, all chemokines that attract T cells to the thymus38. Several papers have 
addressed the TCR repertoire in NSG mice in the presence or absence of transgenic human 
HLA-A2. First, Shultz et al.39 demonstrated a functional EBV infection in xenografted NSG 
mice and compared the responses of xenografted NSG or NSG with transgenic expression 
of HLA-A2. No differences were observed in the frequency of naive, central memory and 
effector memory CD8+ T cells in the spleen nor for Granzyme A and B or Perforin expression. 
The only demonstrable difference between NSG and HLA-A2 expressing NSG is seen in 
response to HLA-A2 restricted BMLF and LMP1 proteins. Second, the issue of interaction of the 
xenografted cells with transgenic human HLA-A2 was elegantly addressed by Halkias et al.40 
where HLA-A2 transgenic NSG were compared to normal NSG after transplantation of HLA-A2 
positive or negative human UCB cells. No differences were observed in repopulation and T 
cells in the spleen. Thus, the reported findings on T-cell development appear to be relevant for 
allogeneic human HSCT transplantation. However, being a xenograft model some aspects of 
the results should be interpreted with caution. Important T-cell subsets such as regulatory T 
confirm that the TCR repertoire of the transduced cells was indeed polyclonal. This analysis 
demonstrated diverse repertoires in TRD, TRG and TRB, thereby confirming that the limited 
clonal repertoire of transduced cells does lead to the observed TRB repertoire (Supplementary 
Fig. 3). Our data show strong intrathymic competition between the progeny of stem cell 
clones. Therefore, clonality at the HSC level (hematological clonality) and a fully diverse TCR 
repertoire (immunological clonality) are independently regulated.
Figure 4: Separation of hematological and immunological clonality. TRB repertoires in DP and SP 
thymic subsets and sorted CD3+ splenocytes of mice transplanted with human HSC were determined. 
Electropherograms of two collections of primers amplifying the TRB locus (green and blue) show the TRB 
diversity for a representative mouse. The positive control shows PBMC of a healthy individual.
Discussion
The relationship between hematopoietic stem cells and T cells in quantitative terms previously 
was largely unexplored. Previous studies in mice showed that a limited number of HSC can be 
marked, transplanted and identified this way. Initially, such studies were performed using the 
unique marks that virus insertion form when they integrate into the host genome20, 21. From 
these studies several models for behavior of the hematopoietic system were postulated and 
mathematically modelled22. DNA barcoding technology allowed a much more refined insight 
into the composition of the blood compartments and allowed the study of aging HSC13 and 
distribution of HSC clones through the different locations in the body14 in addition to the clonal 
dynamics of repopulation of the bone marrow subset hierarchy after transplantation23, 24. The 
existence of myeloid, lymphoid or mixed progenitors, that had previously been observed in 
mice16, was demonstrated with human cells in the NSG xenograft model17 and while these 
seminal studies in the xenograft system demonstrated the dynamics of lymphoid development, 
they did not address T-cell development nor thymic function.
Using lentiviral cellular barcoding of purified human HSCs or CD34+ progenitor cells we here 
show at least 10% of the HSC clones are GFP marked in the thymus (Supplementary Fig. 5) 
and show considerable barcode-defined clonal restriction. How this restriction in clonal 
repertoire in the thymus occurs is not yet understood. It is conceivable that competition of DN 
cells for thymic niches (specific locations in the thymus which need to be reached for further 
development), fitness of the individual clone for progression in development or stochastic 
events drive competition between clones.
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cells40 and PLZF1+ innate T cells41 which are both critical components of immune competence 
do not develop or function properly in NSG mice. This likely relates to the fact that MHC 
restriction occurs mostly on mouse epithelial cells and less frequently on human APC or via 
T-T interactions. Thus, clinically significant differences in the TCR repertoires of T cells selected 
on mouse thymus versus T cells that are selected on human thymus exist.  Nevertheless, in 
experiments where CD34+ cells were transplanted into NSG mice, a survey of the IgH locus and 
TCR showed a comparable combinatorial diversity42, although the screening method employed 
in this study (multiplexed PCR of V-J rearrangements) might not be sensitive enough to detect 
small differences in TCR repertoire between human and xenografted T cell samples. Moreover, 
in similar experiments using the same barcode library with mouse LSK hematopoietic stem/
progenitor cells transplanted into congenic mice, we observed a similar thymic clonal 
restriction (not shown), suggesting a general applicability of the observed clonal restriction 
for the overall T-lymphocyte pool, with a caveat on their MHC restriction and development of 
specialized T-cell subpopulations.
Recent work by Rodewald and co-workers proposed cell competition as a mechanism underlying 
selection for cellular fitness during T-cell development43. This hypothesis explains the further 
clonal restriction at DN3, DP and SP stages that we observe in many mice. Apparently there is 
selection for progeny of certain HSCs clones while others are selected against. While this could 
be merely stochastic (neutral competition), the possibility that clonal fitness (e.g. metabolic 
activity, quiescence, other factors) plays a role is not unlikely given the existence of thymic 
stem cell clones with differential gene expression programs43. We therefore propose that the 
progeny from different HSC clones have inherently different capacity to pass through various 
developmental checkpoints in the thymus. Alternatively, in the experiments were barcoded 
CD34+ cells were transplanted, we cannot exclude that in some cases progenitors rather than 
bona fide HSCs would be the ancestors of the developing thymocytes. These progenitors are 
likely to have reduced fitness as well. In the experiments where phenotypically defined HSCs 
were transplanted, a role for such progenitors seems much less likely due to the purity of the 
transplanted cells. This notion is supported by the fact that in human gene therapy settings, 
a considerable fraction of T cells may have arisen from progenitors rather than from HSCs44.
As a consequence, immune incompetence after HSCT is not related to the transplantation 
of limited numbers of HSC but to intrathymic events. While transplantation of more HSC 
may improve hematological reconstitution, our data suggests it will do little to improve 
immunological reconstitution. Thymus seeding is quickly saturated when the transplanted cell 
dose increases, therefore, efforts aimed at improving function of the thymic epithelium45 most 
likely will be most successful in improving immunological immune reconstitution after stem 
cell transplantation.
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Supplementary Figure 1: Spike-in experiments to calibrate the DNA barcoding method. A plasmid sample 
was spiked in at equimolar ratio and diluted into a bulk barcoded sample. A) The bargraph shows the 
measured fraction of deep sequencing reads in each sample, with the lowest blue bar in the graph indicating 
the spiked-in plasmid. B) Triplicate analysis of the fraction of reads made up by the spiked-in barcode 
shows the least squares fitted line and the Pearson correlation coefficient. C) In an additional experiment, 
9 repeated measures of the same sample were performed and the coefficient of variation was determined 
and plotted against the mean fraction of reads, showing that the precision of quantification increases 
with the amount of reads. D) A higher number of barcodes than the library complexity was retrieved 
from the analysis of these samples. To correct for these sequencing errors the number of dissimilar bases 
between all barcodes was determine and a directed acyclic graph was built for all barcodes that had less 
than 3 bases difference. Using this graph and an empirically determined threshold of 2 bases differences 
between barcodes, the reads of barcodes with <3 bases difference were combined. All barcoding data 
in the manuscript was processed using this procedure. E) Samples of PB CD19+ B cells were analyzed in 
triplicate to determine the variation of the method between samples.
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Supplementary Figure 3: Hematological and immunological clonality in splenocytes. Rearrangements 
of TRD, TRG, and TRB of sorted transduced human splenic CD3+ cells are shown using two collections of 
primers to amplifying the respective loci. PBMC of a healthy individual was used a positive control and 
clonal rearrangements in Nalm-16 (TRD), MOLT3 (TRG), ALL-1 (TRB-A) and Jurkat (TRB-C) are shown for 
comparison. 
 
Supplementary Figure 2: Clonal restriction during T cell development after CD34+ cell transplantation. 
Similar to the data in Fig. 2, the normalized Shannon diversity was compared between the developmental 
stages in the thymus A) of 4 mice transplanted with 150,000 CD34+ cells or B) 4 mice transplanted with 
26,000 CD34+ cells. Kruskal-Wallis p-values are shown in A and B. The clonal contribution in the thymic 
subsets of mice transplanted with 150,000 or 26,000 barcoded human CD34+ cells is shown in stacked area 
graphs using colors to mark the individual barcoded clones in mice receiving a high (150,000 cells, C) or low 
(26,000 cells, D) dose of barcoded CD34+ cells.
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Supplementary Figure 5: GFP marking in the thymus. The percentage of GFP marking in the different 
thymocyte subsets after transplantation of barcoded HSC is displayed as mean + SEM (n=9).
Supplementary Figure 6: Comparison of T cell subsets in human peripheral blood and xenografted NSG 
mice. Peripheral blood of NSG mice (n=8) transplanted with lentivirally-transduced umbilical cord blood 
CD34+ cells at 20 weeks post transplantation and human peripheral blood control samples (n=7, female, 
ages 20-52 years old) were analyzed for the expression of CD45RO and CD45RA in the CD4+ and CD8+ T cells 
by flow cytometry. Wilcoxon p-values smaller than 0.05 are indicated with *.
Supplementary Figure 4: Barcoded HSC result in multlineage engraftment in NSG mice. NSG mice were 
transplanted with barcoded HSC and after 21 weeks, barcode content in CD19+ B cells, CD3+ T cells and 
CD13/CD33+ myeloid cells was determined. Ternary plots show the contribution of a clone to each lineage. 
Multilineage contribution is defined as contribution of a clone to each of these three lineages. The total 
number of clones retrieved from these spleen samples is indicated, as is the number of these clones that 
contribute to all three lineages.
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Overexpression of LMO2 is known to be one of the causes of T-ALL development; however the 
mechanisms behind its oncogenic activity are incompletely understood. LMO2 overexpressing 
transgenic mouse models suggest an accumulation of immature T-cell progenitors in the 
thymus as main pre-leukemic event. The effects of LMO2 overexpression on human T-cell 
development in vivo, however, are unknown. Here we report studies of a humanized mouse 
model transplanted with LMO2 transduced human hematopoietic stem and progenitor cells. 
The effects of LMO2 overexpression were confined to the T-cell lineage although initially 
multipotent cells were transduced. Three effects of LMO2 on human T-cell development were 
observed: 1) a block at the DN/ISP stage, 2) an accumulation of CD4+CD8+ double positive CD3- 
cells and 3) an altered CD8/CD4 ratio with enhanced peripheral T lymphocytes. Microarray 
analysis of sorted DP cells overexpressing LMO2 led to identification of an LMO2 gene set 
that clustered with human T-ALL patient samples of the described “Proliferative” cluster. In 
summary, we demonstrate previously unrecognized mechanisms by which LMO2 alters human 
T-cell development in vivo that correlate with human T-ALL leukemogenesis.
Introduction
Animal models of leukemia have been indispensable in the study of this deadly disease. 
Initially, carcinogen-induced or virus-induced leukemia models were used1, 2, 3, soon followed by 
transgenic models. As the latter are very labor-intensive to produce and can have effects outside 
the hematopoietic system, mosaic models in which hematopoietic stem cells (HSCs) taken 
from mice, manipulated ex vivo by retroviral transduction, and transplanted into autologous 
recipients, have gained much popularity. Finally, in recent years murine xenograft models have 
been developed to allow engraftment of primary patient samples and cell lines, as even very 
aggressive leukemias seldom grow in in vitro culture systems. With the establishment of the 
NSG immune deficient model4, 5, theoretically a combination of xenotransplantation and mosaic 
models is possible, in that human HSCs modified in vitro to express leukemic oncogenes, can 
be studied in vivo. Here we describe for the first time such a model, in which human CD34+ 
stem/progenitor cells genetically modified to overexpress the LMO2 gene were transplanted 
into NSG mice. The nature of this model is very suitable to gain insight into the early stages 
of leukemogenesis through careful dissection of cellular differentiation processes. It is less 
suitable for studying frank leukemia given the limited life span of humanized NSG mice6.
Around 25 years ago, LMO2 was discovered and shown to be frequently translocated with T-cell 
receptor (TCR) loci in T-cell acute lymphoblastic leukemia (T-ALL) (reviewed in7). In childhood 
T-ALL, 9% of the cases had a translocation that involved LMO28, while in 35% of T-ALL cases there 
is increased expression9. Using different conditional knockouts for Lmo2 it was demonstrated 
that Lmo2 is not needed for normal T-cell development10. Effects of Lmo2 overexpression have 
been studied using different transgenic mouse models10, 11, 12, 13.These studies demonstrated 
an accumulation of CD4-CD8- double negative (DN) cells within the thymus at the expense of 
CD4+CD8+ double positive (DP) cells. However, development of leukemia was heterogeneous 
and had a long latency, indicating that secondary mutations are needed. One of these models 
used the ubiquitously expressed methallothionein-1 promoter to drive the expression of Lmo2 13 
and demonstrated that the effects of Lmo2 overexpression were confined to the T-cell lineage.
LMO2, which is highly expressed in hematopoietic stem cells (HSC)14, is also required in normal 
hematopoiesis as illustrated by the fact that knockout mice are embryonic lethal due to absence 
of erythrocyte development15. In gene therapy trials that have been conducted for X-linked 
SCID and Wiskott-Aldrich Syndrome (WAS), T-ALLs have occurred as the result of insertional 
mutagenesis, frequently leading to ectopic expression of LMO216, 17, 18, 19. Integration of the viral 
vector in or in proximity to the LMO2 locus caused the overexpression of this oncogene and 
effects were only observed within the T-cell lineage. The development of T-ALL had a relatively 
long latency and additional hits, e.g. in CDKN2A, were found in these leukemias19. We have 
shown that overexpression of LMO2, using  fetal thymic organ cultures, leads to an arrest in 
normal development, which is not seen with the therapeutic gene in X-SCID gene therapy, the 
IL2RG gene20, 21.
Normal T-cell development follows a developmental trajectory starting from the CD4-CD8- 
double DN stage to the immature single positive stage (ISP), which in mice is characterized 
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thrombopoietin (rhTPO, R&D Systems, Abingdon, UK), 20 ng/mL recombinant mouse insulin-
like growth factor 2 (rmIGF-2, R&D Systems) and 10 ng/mL recombinant human fibroblast 
growth factor-acidic (rhFGF-1, Peprotech, Rocky Hill, NJ, USA). Retronectin (50 µg/mL,Takara 
Bio Inc, Otsu, Japan) was coated on non-tissue culture treated 48-wells plates (BD Falcon, 
Bedford, MA, USA) o/n at 4°C. Virus (500 µL) was centrifuged onto the plate for 2 hours at 
32°C 1000xg. Supernatant was removed and 1.5*105 isolated cells were added per well and 
transduced for 2 days.
Gene expression
RNA was isolated using the Qiagen RNeasy mini kit or micro kit according to manufacturer 
protocol (Qiagen). cDNA was prepared using SuperScript III and random primers (Life 
Technologies, Bleiswijk, The Netherlands). For qRT-PCR, the Universal Probe Library (Roche 
Diagnostics, Almere, The Netherlands) was used to design primer/probe combinations (except 
for ABL). Samples were run on the StepOnePlus machine (Applied Biosystems, Life Technologies, 
Bleiswijk, The Netherlands) using the TaqMan® Universal Master Mix II with UNG (Applied 
Biosystems). ABL was used as housekeeping gene. The following primers were used: LMO2 
Forward 5’-CGAAAGGAAGAGCCTGGAC-3’ Reverse 5’-AAGTAGCGGTCCCAATGTT-3’, HES1 Forward 
5’-GAAGCACCTCCGGAACCT-3’ Reverse 5’-GTCACCTCGTTCATGCACTC-3’, ABL as described 
before21. Expression was calculated relative to ABL and for correction of transduced cells this 
was divided by the fraction of transduced cells as was assessed by flow cytometry for GFP.
RNA expression analysis by microarray
Single stranded cDNA was synthesized from 1000 pg total RNA using the Ovation Pico WTA 
System V2 Module (NuGEN Technologies Inc, Leek, The Netherlands) in combination with 
the Encore Biotin Module (NuGEN Technologies Inc) according to the instructions of the 
manufacturer. Biotin labeling and fragmentation was performed and fragmented cDNA was 
hybridized onto Affymetrix Gene Atlas human U219 arrays. Microarray analysis was done 
in accordance with previously described guidelines29 by the I-BFM-SG Task Force on gene 
expression profiling. Raw expression values were normalized using RMA30 and the log2 
expression values were compared between IRES-GFP DP cells and three LMO2-IRES-GFP 
samples. A gene set was created of the 136 probe sets with highest differential expression (|FC| 
> 0.7) corresponding to 110 genes, which was clustered using Euclidean distance Ward’s method 
and used in a gene set enrichment analysis31 against a dataset of human T-ALL27 (available at 
http://www.ncbi.nlm.nih.goc/geo/ under accession number GSE26713). Gene expression data 
is available under GEO accession number: GSE79625.
LM-PCR
Ligation-mediated PCR was performed as described32. Fragments were cloned in pGEM-T 
Easy vector (Promega Benelux b.v., Leiden, The Netherlands) and sequenced using the m13 
reverse primer.
Statistical analysis
Two-way ANOVA was used to test for statistical. For expression of HES1, a student t-test was 
used. A p-value smaller than 0.05 was considered significant. *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001
by the expression of CD8 and absence of CD322. In humans, however, ISP are CD4+ instead of 
CD8+23. From the ISP stage, the cells differentiate to the CD4+CD8+ DP stage to become either 
a CD4+ single positive (SP) or CD8+ SP after positive and negative selection now expressing 
a functional T cell receptor (TCR)24. The DN compartment can be further subdivided, but for 
human and mouse these compartments are characterized by different markers and DN stages 
have been described in more detail for murine T-cell development23, 24, 25, 26.
During normal human T-cell development LMO2 is quickly downregulated in the DN stages21, 
24. Ectopic expression of LMO2 after this stage might therefore be able to deregulate normal 
thymopoiesis as a first step, eventually resulting in T-ALL. Here, we demonstrate the different 
effects of LMO2 overexpression on human T-cell development in vivo and report that 
differentially expressed genes are associated with the previously identified “Proliferative” 
cluster in human T-ALL27.
Materials & Methods
Isolation of human CD34+cells
Umbilical cord blood (UCB) was obtained from the Diaconessenhuis Hospital Leiden (Leiden, 
the Netherlands) after informed consent of the parents. CD34+ progenitors were isolated 
from a pool of 5 to 6 donors using the CD34 Microbead Kit (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany).
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from Charles River Laboratories 
(Kent, United Kingdom) and bred in the animal facility at the Leiden University Medical Center. 
Experimental procedures were approved by the Ethical Committee on Animal Experiments of 
the Leiden University Medical Center. Maintenance and irradiation of mice was performed as 
described28. Female mice were used at 5-6 weeks of age. Three different experiments were 
performed, with in total 10 GFP transplanted mice and 12 LMO2 transplanted mice.
Flow cytometry
The following anti-human antibodies were used: CD3-PECy5 (UCHT1), CD4-APCCy7 (RPA-T4), 
CD7-PECy5 (M-T701), CD8-PECy7 (SK1), CD13-APC (WM15), CD16-PE (B73.1), CD19-APCCy7 
(SJ25C1), CD20-PE (L27), CD33-APC (WM53), CD34-PE (8G12), CD45-V450 (HI30), CD56-PE 
(MY31), TCRαβ-PE (T10B9.1A-31) (all from BD Biosciences, San Jose, CA, USA). Data were 
acquired on a Canto II (BD Biosciences) and analyzed using FlowJo software (Treestar, Ashland, 
OR, USA).
Virus production and transduction
Virus of LZRS-IRES-GFP and LZRS-LMO2-IRES-GFP were produced as described21. Isolated 
CD34+ cells were cultured overnight in StemSpan serum-free expansion medium (StemSpan-
SFEM, StemCell Technologies Inc., Vancouver, BC, Canada) in the presence of 10 ng/mL stem 
cell factor (SCF, a gift from Amgen, Thousand Oakes, CS, USA), 20 ng/mL recombinant human 
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LMO2 overexpressing cells cause increased outgrowth of T cells in humanized mice
Human engraftment reached 70% and no differences were observed between mice transplanted 
with GFP or LMO2 samples, indicating that overexpression of LMO2 does not lead to increased 
engraftment (Fig. 2A). Mice were sacrificed 17 to 18 weeks after transplantation. The thymus of 
mice that were transplanted with LMO2 transduced CD34+ cells showed a significantly increased 
percentage of hCD45+ cells (Fig. 2B). However, this did not lead to an increase in absolute 
hCD45+ cell numbers (Fig. 2C). Transduced cells, which were detected by their expression of 
GFP, were more abundant in mice transplanted with LMO2 transduced cells as compared to 
the GFP control mice, possibly indicating a growth advantage of LMO2 overexpressing cells 
(Fig. 2D). Levels of transduced cells declined over time but surprisingly increased at 16 weeks 
in mice transplanted with LMO2 transduced cells. The relative frequency of both GFP+ myeloid 
cells and B cells was significantly different 4 weeks after transplantation in mice transplanted 
with LMO2 transduced cells (Fig. 2E,F), but the reliability of the measurement at 4 weeks might 
be limited by the small amount of human cells that were available for acquisition at this time 
point. At later time points no differences were detected for GFP+ myeloid and B cells between 
both groups. The frequency of GFP+ T cells in peripheral blood was significantly higher in 
LMO2 overexpressing cells 16 weeks after transplantation (Fig. 2G), coinciding with the overall 
increase of GFP levels (Fig. 2D). In addition, we performed a different gating strategy in 
which we determined the frequency of different immune cell subsets within GFP- and GFP+ 
cells that were positive for hCD45+ (Supplementary Fig. 1A). This demonstrated that within 
GFP- cells of both GFP and LMO2 mice the percentages of myeloid cells, B cells and T cells 
were highly comparable (Supplementary Fig. 1B,D,F). Within the GFP+ cells a highly significant 
increase of T cells at 16 weeks after transplantation was observed in LMO2 mice which led to 
a concomitant decrease in percentages of both myeloid cells and B cells (Supplementary Fig. 
1C,E,G). Furthermore, the frequency of transduced cells in the thymi of humanized mice was 
significantly higher in mice transplanted with LMO2 transduced CD34+ cells at the end of the 
experiment (Fig. 2H). When comparing the percentage of T cells within GFP- and GFP+ of both 
GFP and LMO2 mice, there is a significant increase of the GFP+ cells in LMO2 mice compared to 
the other three groups at 16 weeks (Fig. 2I). Overall, the data indicate increased outgrowth of 
T cells together with increased engraftment of the thymus caused by the LMO2 overexpressing 
cells.
No clonal outgrowth in NSG mice transplanted with LMO2 overexpressing CD34+ cells
To check for possible clonal outgrowth of transduced cells, we performed ligation-mediated 
(LM)-PCR. Gel electrophoresis of vector-genome boundaries showed an oligoclonal integration 
pattern, which did not differ between the two groups (Fig. 3A and Supplementary Fig. 4).This 
indicates that outgrowth of specific clones could not be detected. The most prominent 
bands were excised from the gel and sequenced to determine whether integration sites 
were preferentially selected. No such preferential integration was observed (Supplementary 
Table 1). Often cells need multiple hits before they develop into leukemic cells and NOTCH1 
mutations are frequently detected in T-ALL. To determine whether NOTCH activation might 
act as a secondary hit, we determined the expression levels of HES1, one of the NOTCH target 
genes. Both in the thymus and the spleen no increased expression of HES1 was observed, 
Results
Transduction and overexpression of LMO2 in human CD34+ cells
Previously, it has been shown that by transplantation of CD34+ cells from either UCB5 or 
human bone marrow (BM) in NSG mice a human immune system develops in these mice28, 33. 
Furthermore, T-cell developmental stages comparable to ex vivo human thymi were detected 
in the thymi obtained from transplanted NSG mice28, 33. We transduced the isolated CD34+ 
with LMO2-IRES-eGFP as used previously by our group for in vitro studies21. As a control, a 
virus without LMO2 only containing IRES-eGFP was used (Fig. 1A). We obtained transduction 
efficiencies of 35% for GFP and 43% for LMO2 in primary human CD34+ cells (Fig. 1B). The total cell 
sample, containing both transduced and untransduced cells, was transplanted into sublethally 
irradiated NSG mice two days after transduction. We on purpose chose not to sort for LMO2 
expressing cells via the GFP marker, as the co-transplanted untransduced cells allow for an 
internal, negative control in each individually transplanted mouse. Peripheral blood was drawn 
every 4 weeks from these mice to monitor engraftment of human cells and lineage outgrowth 
(Fig. 1C). A sample of the transduced cells was expanded for an additional 6 days and then 
sorted based on GFP expression. The overexpression of LMO2 was determined using qPCR 
and was 135 times higher in LMO2 transduced cells as compared to the sorted GFP- cells from 
the same sample (Fig. 1B). No overexpression of LMO2 was detected in GFP+ cells that were 
transduced with the control vector.
Figure 1: Overexpression of LMO2 in CD34+ HSPCs using gammaretroviral vector. A) Schematic 
representation of gammaretroviral LZRS constructs that were used in this study. B) Transduction 
efficiency of both vectors in human CD34+ cells isolated from umbilical cord blood (left panel). Level of 
LMO2 expression relative to ABL in transduced cells that were expanded for 8 days and sorted on GFP 
expression (mean ± sd) (right panel). C) Schematic representation of experimental set up.
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were sequential arrests in development at different immature stages of T-cell development, 
leading to an accumulation of cells in these stages.
Figure 3: LM-PCR shows no evidence for preferential integration. A) LM-PCR analysis of total cells from 
different organs 17 to 18 weeks after transplantation of GFP or LMO2 transduced HSPCs in NSG mice. B=BM, 
S= spleen, T=thymus, L=100 bp ladder. B) Expression of HES1 relative to ABL corrected for percentage GFP+ 
cells in total thymocytes (left) and spleen cells (right) (mean ± sem).
Figure 4: Delayed T-cell development in LMO2 transduced GFP+CD45low cells. A) Flow cytometry plot 
depicting the expression of hCD45 and GFP  and the gates (top) that were used for the subsequent 
plots depicting CD34 and CD7 (middle) and CD8 and CD4 (bottom). B) Distribution of GFP- cells and 
C) GFP+CD45low cells from thymi of mice transplanted with LMO2 transduced HSPCs over the different 
stages of human T-cell development (n=2) (mean ± sem).
LMO2 overexpression results in accumulation of DP CD3- cells and an altered CD8/CD4 ratio
Different levels of GFP expressing cells (named GFP+ and GFP++) were present in the thymi 
of humanized mice. The gating strategy for GFP levels and different stages of human T-cell 
development are depicted in Fig. 5A. We determined the frequencies of different T-cell 
developmental stages within the GFP-, GFP+ and GFP++ populations of all 10 GFP- and 12 
LMO2-transplanted mice. The frequencies within the GFP- cells were highly comparable 
demonstrating that Notch signaling is not increased in these mice (Fig. 3B). The expression 
of HES1, which was corrected for the percentage of transduced cells, was actually decreased 
in the spleens of LMO2 transplanted mice compared to GFP transplanted mice. Combining 
the increased frequency of T cells with the absence of clonality and lack of increased Notch 
signaling, we conclude that the LMO2 mice likely demonstrate a preleukemic T-ALL stage.
Figure 2: LMO2 enhances thymic engraftment and outgrowth of peripheral T cells. A) Engraftment was 
measured as the frequency of hCD45+ cells within live cells in peripheral blood of NSG mice transplanted 
with GFP or LMO2 transduced HSPCs. B) Engraftment in different organs 17 to 18 weeks after transplantation 
and the C) absolute numbers of hCD45+ cells calculated from this. D) Percentage of transduced cells 
within total hCD45+ cells, E) myeloid cells (CD13/33+), F) B cells (CD19+) and G) T cells (CD3+) over time 
after transplantation of GFP or LMO2 transduced HSPCs in NSG mice. H) Percentage of transduced cells 
within hCD45+ cells in different organs 17 to 18 weeks after transplantation. I) Percentage of T cells over 
time within hCD45+ GFP- and GFP+ populations in GFP or LMO2 transplanted mice. Green asterisks depict 
significance of GFP:GFP+ compared to GFP:GFP- and LMO2:GFP-. Purple asterisks depict significance of 
LMO2:GFP+ compared to GFP:GFP- and LMO2:GFP- at 12 weeks and to all three other groups at 16 weeks. A, 
D, E, F, G) Depicted is the mean ± sd. B, C, H) Depicted is the mean.
Overexpression of LMO2 causes delayed development in human T cell progenitors
Based on the expression of hCD45 and GFP, multiple populations could be discriminated in the 
thymus (Fig. 4A). In 2 out of 12 mice transplanted with LMO2 transduced cells, a GFP+CD45low 
population was observed. This population was never observed in NSG mice transplanted with 
GFP alone (Supplementary Fig. 5). A fraction of LMO2 overexpressing cells retained expression 
of CD34 reminiscent of highly immature cells (Fig. 4A). In addition, the percentage of CD4+CD8+ 
DP cells was severely reduced, while the relative abundance of both ISP and CD4-CD8-CD3- triple 
negative (TN) was increased as compared to the untransduced cells (Fig. 4B,C). Thus, there 
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GFP transplanted mice in PB, spleen and BM (Fig. 6A). The same was also reflected in absolute 
T cell numbers in PB and spleen, but not in BM (Supplementary Fig. 3A). High overexpression of 
LMO2 was found in the thymus and spleen, but not in BM (Fig. 6B). The frequency of T cells was 
increased at the expense of B cells within the transduced cells in spleens of mice transplanted 
with LMO2 overexpressing cells (Supplementary Fig. 3B). Cells that were isolated from spleens 
of these mice were sorted for different immune cells and here we found high overexpression 
of LMO2 only in the T cells (Fig. 6C). Together, these data indicate that overexpression of LMO2 
in CD34+ cells leads to increased percentages of T cells in lymphoid organs and that these 
effects are confined to the T-cell lineage.
Figure 6: Increased frequency of T cells in lymphoid organs caused by LMO2 overexpression. A) Percentage 
of T cells in GFP- and GFP+ in peripheral blood (left panel), spleen (middle panel) and bone marrow (right 
panel) of mice transplanted with GFP or LMO2 transduced HSPCs 17 to 18 weeks after transplantation. 
B)Fold overexpression of LMO2 in LMO2 mice over GFP mice within total cells of different lymphoid 
organs and C) different cell types sorted from spleens of transplanted NSG mice. B, C) LMO2 expression 
relative to ABL expression. Expression was corrected for the frequency of transduced cells in each sample. 
A) Depicted is the mean. B, C) Depicted is mean ± sem.
Different mechanisms underlie delayed and accelerated development as caused by LMO2 
overexpression
To gain insight into the molecular mechanism underlying the effects of LMO2 on human T 
cell development, we performed transcriptome analyses. We sorted the DP cells from single 
cell suspensions made from the thymus of transplanted NSG mice as we had observed an 
accumulation of DP CD3- cells (for sorting strategy see Supplementary Fig. 6). The genes 
that were differentially expressed between LMO2 and GFP were used as a gene set (see 
Supplementary Table 2 and 3) and the expression of this gene set was determined in 117 human 
T-ALL microarray expression sets described by Homminga et al.27. We observed clustering 
of our gene set of 52 upregulated genes with the described “Proliferative” and “TALLMO” 
signatures (Fig. 7A). Gene set enrichment analysis was subsequently performed with the 52 
between GFP and LMO2 transplanted mice (Fig. 5B, left panel). Within the GFP+ cell fraction, 
an increased percentage of DP CD3- cells was observed in NSG mice transplanted with LMO2 
overexpressing CD34+ cells (Fig. 5B, middle panel). This was also observed within the GFP++ 
cell fraction in which it was accompanied by a decrease in DP CD3+ cells (Fig. 5B, right panel). 
The same patterns were observed when absolute numbers were compared (Supplementary 
Fig. 2). These data indicate an accumulation of DP CD3- cells caused by LMO2 overexpression 
in human thymocytes. Furthermore, when the level of GFP increased, the ratio of CD8 over 
CD4 SP cells was different between GFP and LMO2 transduced cells, which was even stronger 
in peripheral T cells (Fig. 5C). This indicated that overexpression of LMO2 not only led to an 
accumulation of DP CD3- cells but also to an altered CD8/CD4 ratio, which was sustained in the 
peripheral blood.
Figure 5: LMO2 overexpression leads to accumulation of DP CD3- cells and an altered CD8/CD4 ratio. 
A) Gating strategy of flow cytometry data used for gating of different GFP levels. Depicted is an LMO2 
transplanted mouse. B) Distribution of GFP- cells (left panel), GFP+ cells (middle panel) and GFP++ cells 
(right panel) over the different stages of human T-cell development within thymi of NSG mice 17 to 18 
weeks after transplantation. C) Ratio of CD8/CD4 cells within the different GFP levels in mice transplanted 
with GFP or LMO2 transduced HSPCs (left panel) and in peripheral blood of NSG mice 17 to 18 weeks after 
transplantation. B, C) Depicted is mean ± sd (n=10 GFP transplanted mice, n=12 LMO2 transplanted mice).
Overexpression of LMO2 increases T cells in lymphoid organs
As described, we observed an increased frequency of GFP+ cells within T cells of peripheral 
blood (Fig. 2G) and an increased percentage of T cells within GFP+ cells (Supplementary Fig. 1G) 
at 16 weeks after transplantation in the LMO2 group. Mice were sacrificed 17 to 18 weeks after 
transplantation and again we observed more T cells in LMO2 transplanted mice compared to 




Although murine and human T-cell development are largely similar, differences exist, which 
could have implications for the extrapolation of mechanisms found in mice to human T-ALL 
development. Here, we have tested the effect of LMO2 overexpression on human T-cell 
development in an in vivo model and, to the best of our knowledge, this study shows for the 
first time the role of LMO2 overexpression on human T-cell development in vivo. We have 
observed that LMO2 overexpressing CD34+ cells demonstrate a preferential outgrowth of T 
cells after transplantation in a humanized mouse model. As corollary, in mice that express Lmo2 
under the inducible methallothionein-1 promoter there is a long latency of T-ALL development 
with a median of 51 weeks13 while 50% of CD2-Lmo2 transgenic mice develop leukemia at an 
age around 10 months11. Unfortunately, humanized NSG mice cannot be maintained for such 
periods as human HSCs do not provide red blood cells in these mice and due to increasing 
engraftment of human cells over time these mice succumb to anemia6. On the other hand, as 
the mice were sacrificed before onset of leukemia, we were able to study the mechanisms by 
which LMO2 alters T-cell development, independent of secondary mutations that affect the 
development of T-ALL in full-blown leukemia.
We observed 3 effects of LMO2 overexpression on human T-cell development: 1) a small subset 
of mice displayed a delayed development with a block in the DN/ISP compartment, 2) in the 
majority of mice an accumulation of DP CD3- cells 3) and an altered CD8/CD4 ratio. Both the 
accumulation of DP CD3- cells and the altered CD8/CD4 ratio became more prominent with 
higher GFP levels and the altered CD8/CD4 ratio was also found in the peripheral blood. The 
delayed development of human T cells has also been shown using human/mouse fetal thymic 
organ cultures21, but the other two mechanisms have not been described previously. This is 
inheritant to this type of in vitro studies in which it is difficult to study human T-cell development 
up to the mature stages. Such approaches also preclude finding the whole spectrum of effects 
caused by LMO2 overexpression, including the accelerated development (using either fetal 
thymic organ cultures or the OP9-DL1 stromal cell line), demonstrating the strength of the 
described humanized mouse model. In both types of transgenic Lmo2 mice, an increased DN 
cell frequency was found while in some mice DP cells were also present but decreased leading 
to T-ALL with more mature phenotypes11, 13. Here, we observed the increased DN frequency 
only in 2 out of 12 mice while the increased DP CD3- frequency was ubiquitous as well as the 
alteration of the CD8/CD4 ratio.
Effects of LMO2 overexpression were only observed on T-cell development although 
hematopoietic progenitors with multilineage developmental potential were transduced. This 
is concordant with data from the transgenic mouse model using the ubiquitously expressed 
methallothionein-1 promoter where effects were also confined to the T-cell lineage13. 
Furthermore, the insertional mutagenesis that led to T-ALL development in gene therapy trials 
also came from integrations resulting from transduction of human hematopoietic progenitor 
cells. Even though multipotent cells were transduced, cells with integration in or near LMO2 
only caused development of T-ALL and did not affect other lineages17, 18, 19. Patients in the 
upregulated genes in our sorted LMO2 DP samples. A significant negative enrichment was 
found with the “Immature” cluster (NOM p = 0.008) and a significant positive correlation 
with the “Proliferative” cluster (NOM p = 0.038) and the set of genes that was upregulated in 
LMO2 mice compared to GFP mice (Fig. 7B,C). Of note, in previous transgenic mouse studies 
overexpressing LMO2, the retinaldehyde dehydrogenase 2 (RALDH2) gene was identified 
as prominent target gene. Nowadays, this gene is referred to as aldehyde dehydrogenase 
1A (ALDH1A2) which is up regulated in our LMO2 experiments (~3 fold) and also found 
upregulated in the so-called “Proliferative” cluster of T-ALL samples. The correlation of this 
and other upregulated genes indicates that the effects and mechanisms that were observed in 
patients suffering from T-ALL is also found after transplantation of LMO2 overexpressing cells 
in NSG mice.
Figure 7: Correlation between significantly upregulated genes with human T-ALL samples. A) Clustering 
of 52 genes that were significantly upregulated in sorted DP cells from thymi of GFP and LMO2 transplanted 
NSG mice with 117 human T-ALL samples, which have been described previously27. B) Gene set enrichment 
analysis of the 52 upregulated genes demonstrate a negative enrichment with the previously described 
“Immature” cluster (NES=-1.73, NOM p=0.008, FDR q=0.085) and C) a positive enrichment with the 
previously described “Proliferative” cluster (NES=1.65, NOM p=0.038, FDR q=0.085).
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In conclusion, this is the first study to describe the role of LMO2 overexpression on human 
T-cell development using an in vivo model. Our results suggest new mechanisms that have not 
been identified before in human cells but that correlate with an expression signature of human 
T-ALL with a proliferative phenotype. Therefore, besides arrests in normal development, 
accelerated development that bypasses normal checkpoints should also be considered as a 
mechanism for leukemogenesis.
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study by Braun et al.17 that developed T-ALL, all with LMO2 integrations, which in some cases 
coincided with TAL1 integrations, had a CD4+CD8+CD3-CD7+ phenotype. We also observed an 
accumulation of DP cells without expression of CD3 in our humanized mice transplanted with 
LMO2 overexpressing HSPCs.
It was observed that Lmo2 increased the expression of CD4 in a murine cell line34. Our data also 
demonstrate differences in the CD8/CD4 ratio, however, here we observed fewer CD4 and more 
CD8 T cells. As one of the main differences between murine and human T-cell development is 
the phenotypic difference of the ISP stage it might be that in human T-cell development LMO2 
exerts effect on CD8 instead of CD4. This, however, needs to be further investigated.
McCormack et al. found that the leukemia-initiating cell (LIC) is established in the thymus 
of CD2-Lmo2 transgenic mice and not in the BM12. This is in agreement with our data using 
human cells as we did not find increased frequencies of transduced cells in the BM but did 
in the thymus and in addition only very low overexpression of LMO2 was found in the BM of 
transplanted mice. Furthermore, no preferential outgrowth of T cells was observed in LMO2 
secondary transplanted mice (data not shown), illustrating that the oncogenic event most 
likely occurs after thymic entry in agreement with the data published by McCormack et al.12. 
Using CD2-Lmo2 mice, two different mechanisms have been described; one involving activation 
of Hhex, Lyl1 and Mycn resulting in an ETP-ALL like pathway, the other showed upregulation 
of Notch135. Here, we have described 3  effects of LMO2 overexpression of which the delayed 
development that was observed in 2 of 12 mice might resemble the ETP-ALL like pathway. 
However, we did not find activation of the NOTCH signaling pathway. In mice, overexpression 
of Lmo2 results in a block at immature stages of T-cell development while giving rise to T-ALL 
with more mature phenotypes11, 12, 13, 35. In humans, T-ALL with a more mature phenotype are 
found27, 36 and also in patients that did develop T-ALL as result of insertional mutagenesis in 
or near LMO217, 18, 19, 37. This suggests that there might be different mechanisms in human and 
murine T-ALL development as a consequence of LMO2 overexpression, which might explain 
the differences between our data and the data obtained using transgenic Lmo2 mice. Our 
data therefore provide an explanation for the more mature T-ALL subtypes in which LMO2 
overexpression is found.
The accelerated T-cell development with quicker thymic output seen in most mice 
overexpressing LMO2 bears significance in relation to gene therapy trials for SCID. While in 
the first X-linked SCID trials using now obsolete viral vectors, 5 out of 20 patients developed 
T-ALL as a consequence of integrations near and activation of proto-oncogenes18, 19, most often 
LMO2, the same vectors in the ADA-SCID trial did not cause leukemias38, 39. As there normally 
is severe clonal restriction in the thymus40 and X-linked SCID leads to an extreme early block in 
T- cell development33 the selective pressure in X-linked SCID on T-cell progenitors is extremely 
high. An accelerated development caused by LMO2 may then be selected for. In ADA-SCID 
it is possible that non transduced progenitors benefit from ADA enzyme expressed on the 
surface41 or leaking out of corrected cells thereby causing less severe selective pressure. As 
the exact block in human T-cell development caused by ADA deficiency is currently unknown, 
future studies should shed further light on this intriguing observation.
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Supplementary Figure 4: LM-PCR shows no evidence for preferential integration. LM-PCR analysis of 
total cells from different organs 17 to 18 weeks after transplantation of GFP or LMO2 transduced HSPCs in 
NSG mice. B=BM, S= spleen, T=thymus, L=100 bp ladder.
Supplementary Figure 5: GFP+CD45low population is not present in GFP transplanted NSG mice. Flow 
cytometry plot depicting the expression of hCD45 and GFP of three mice transplanted with GFP transduced 
HSPCs. Gating strategy is similar as described in Fig. 4.
Supplementary Figure 2: LMO2 overexpression leads to accumulation of the number of DP CD3- cells. 
Absolute number of cells for different stages of human T-cell development of GFP- (left), GFP+ (middle) and 
GFP++ cells (right). Gating strategy of flow cytometry data for gating of different GFP levels was performed 
as depicted in Fig. 2. Depicted is mean ± sd.
Supplementary Figure 3: Increased number of T cells in lymphoid organs and altered lineage distribution 
in spleens of mice transplanted with LMO2 overexpressing HSPCs. A) Absolute number of T cells in GFP- 
and GFP+ in peripheral blood (left panel), spleen (middle panel) and bone marrow (right panel) of mice 
transplanted with GFP or LMO2 transduced HSPCs 17 to 18 weeks after transplantation. B) Percentage of 
cells within GFP- (left) and GFP+ (right) cells in spleens of transplanted NSG mice. A, B) Depicted is the mean.
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RAP1A 4,733 11,396 10,526 8,382 2,134 5,368
ALDH1A2 3,854 7,246 6,969 6,849 1,822 3,167
F13A1 3,366 7,294 6,475 5,826 1,941 3,166
OAS3 4,629 7,507 8,248 7,477 1,673 3,115
AURKA 4,632 7,599 7,207 8,299 1,663 3,070
ALDH1A2 4,364 7,541 7,442 6,747 1,660 2,879
FOS 2,732 2,776 6,450 7,249 2,010 2,760
TSPAN7 5,124 8,024 7,693 7,802 1,530 2,716
ALDH1A2 5,134 8,171 8,055 7,230 1,523 2,684
RMI1 3,329 5,590 5,590 6,424 1,762 2,538
RCBTB2 5,397 7,557 7,600 8,561 1,465 2,509
CDC25A 3,873 5,479 6,281 7,196 1,632 2,446
CDH2 4,426 5,992 7,189 7,141 1,530 2,348
PTP4A3 4,149 5,585 6,273 7,469 1,553 2,293
E2F7 3,330 5,316 4,958 6,343 1,663 2,209
PM20D2 3,787 5,187 6,362 6,418 1,581 2,202
JUN 2,991 3,874 6,408 5,238 1,730 2,183
ZNF423 3,700 5,876 6,875 4,808 1,582 2,153
USP44 4,086 6,140 6,310 6,267 1,527 2,153
TMEM107 3,619 5,322 6,156 5,754 1,587 2,125
CEP76 3,727 6,506 5,126 5,910 1,569 2,120
EIF4E3 4,878 7,002 7,050 6,937 1,434 2,118
CKAP2 4,333 6,618 6,048 6,346 1,463 2,005
SPIN4 3,554 5,374 5,748 5,491 1,558 1,984
CNN3 3,128 4,043 4,339 6,955 1,634 1,984
HELLS 3,096 4,498 4,875 5,624 1,615 1,903
YEATS4 4,031 5,891 5,634 6,148 1,461 1,860
CPT1A 3,659 6,345 4,763 5,439 1,507 1,857
MME 4,404 6,197 6,346 6,143 1,414 1,825
TFRC 3,832 5,173 5,706 6,086 1,476 1,824
SLC25A40 2,986 4,745 4,688 4,985 1,609 1,820
RHOU 3,763 5,001 5,563 6,112 1,477 1,795
RAD51AP1 3,251 4,410 5,071 5,636 1,550 1,787
RMI1 4,171 5,624 5,624 6,578 1,425 1,771
MYH10 3,260 4,621 5,778 4,621 1,536 1,747
PMS1 4,113 5,432 6,190 5,878 1,418 1,720
KIAA0101 3,182 4,203 4,203 6,282 1,539 1,714
Supplementary Figure 6: Sorting strategy of CD4+CD8+ DP cells for microarray analysis. hCD45+ single 
lymphocytes, either GFP- or GFP+ were gated (top), which were then selected based on expression 
of CD4 and CD8 (middle). The bottom row depicts the expression of CD3 within the sorted CD4+CD8+ 
DP population.
Supplementary Table 1: Upregulated genes sorted by Fold change. 
GFP Thymus Arpin isoform
Zinc finger protein 710
LMO2 BM Phorbol-12-myristate-13-acetate-induced protein 1
LMO2 BM Probable E3 ubiquitin-protein ligase HERC1 isoform
Death-associated protein kinase 2
LMO2 BM Septin-6 isoform
Ankyrin repeat domain-containing protein SOWAHD
LMO2 BM Actin-related protein t3
LMO2 BM Predicted: homo sapiens tight junction protein 1 (TJP1)
LMO2 BM RP11-143J12
LMO2 BM DEP-domain-containing mTOR-interacting protein isoform
Collagen alpha-1 (XIV) chain precursor
Log2 expression values were compared between IRES-GFP DP cells and three LMO2-IRES-GFP samples. 
Listed are the 60 probesets corresponding to 52 genes that were upregulated with highest differential 
expression (|FC| > 0.7).
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C2CD4B 6,854 3,241 3,255 3,241 0,474 -3,608
IFT172 6,676 3,265 3,371 3,038 0,483 -3,451
BAZ1A 9,462 6,129 6,190 5,951 0,644 -3,372
TMEM181 6,141 2,930 2,915 2,896 0,474 -3,227
BLMH 7,471 4,329 4,044 4,605 0,579 -3,146
H1F0 7,436 4,565 2,819 5,872 0,594 -3,017
REXO2 7,541 5,117 4,842 3,645 0,601 -3,007
ITM2C 6,142 3,450 3,211 2,898 0,519 -2,956
RASSF6 7,458 3,882 4,656 5,089 0,609 -2,915
TNKS 6,511 3,734 3,734 3,576 0,565 -2,829
REXO2 7,224 4,871 4,520 3,856 0,611 -2,808
REXO2 6,388 3,935 3,802 3,110 0,566 -2,772
H1F0 8,257 5,200 5,339 6,237 0,677 -2,665
SOCS4 7,965 5,084 5,427 5,427 0,667 -2,652
CALN1 6,617 3,907 3,368 4,843 0,610 -2,577
SNX16 7,421 5,327 4,228 5,327 0,668 -2,460
NRDE2 6,848 4,743 4,375 4,056 0,641 -2,457
THEMIS2 6,380 4,099 4,099 3,805 0,627 -2,379
MRPL15 7,558 5,355 5,475 4,766 0,688 -2,359
ENPP2 6,485 3,110 5,352 4,059 0,644 -2,311
LHFPL2 6,590 4,686 4,127 4,176 0,657 -2,260
ZNF418 5,272 2,753 3,169 3,177 0,575 -2,239
CENPC 6,351 3,790 4,273 4,273 0,648 -2,239
MTSS1 5,737 3,577 3,564 3,449 0,615 -2,207
TIAM1 6,613 4,764 4,862 3,851 0,679 -2,120
DMXL2 6,355 4,065 4,494 4,170 0,668 -2,112
CREB1 6,668 5,609 4,854 3,263 0,686 -2,093
CCDC112 5,859 3,925 3,469 3,928 0,644 -2,085
CCDC112 6,092 4,212 3,930 3,914 0,660 -2,073
C11orf54 6,328 4,564 4,342 3,913 0,675 -2,054
TMEM155 6,581 4,226 3,747 5,621 0,688 -2,050
RDH10 5,618 3,495 3,541 3,689 0,636 -2,043
CPLX1 5,008 2,969 2,915 3,146 0,601 -1,999
SYK 6,608 4,669 4,669 4,522 0,699 -1,988
AKNA 5,859 4,198 3,995 3,428 0,661 -1,985
COQ10B 5,409 3,719 3,170 3,390 0,634 -1,982
EIF2AK3 4,838 2,954 2,922 2,773 0,596 -1,955
EIF4E3 4,033 5,756 5,575 5,878 1,422 1,703
MAD2L1 3,108 4,597 5,038 4,781 1,546 1,697
CENPK 2,855 3,860 4,214 5,443 1,578 1,651
DEPDC1 3,442 4,662 5,043 5,574 1,479 1,650
OAS3 3,112 4,177 4,994 5,097 1,528 1,643
RAD51AP1 2,818 3,958 4,096 5,215 1,569 1,604
ANXA1 3,292 4,045 5,811 4,794 1,483 1,591
CDKN3 3,544 5,106 4,587 5,647 1,443 1,569
MTHFD2 2,894 3,899 4,229 5,229 1,538 1,558
BTN3A2 2,982 4,599 3,608 5,404 1,522 1,555
DONSON 3,352 5,170 4,619 4,908 1,462 1,547
ARMC8 3,453 4,409 4,259 6,293 1,444 1,535
SPAG5 3,541 4,811 4,773 5,486 1,418 1,482
RNF144A 2,769 3,472 4,310 4,765 1,511 1,414
TSPAN7 3,132 4,416 3,995 5,180 1,447 1,399
CLIP4 3,103 3,677 4,555 5,141 1,437 1,355
ETS2 3,067 3,698 4,197 5,314 1,436 1,336
ZNF135 3,089 3,095 2,819 7,198 1,415 1,282
RTKN2 2,553 3,706 3,952 3,734 1,487 1,245
ANXA1 2,662 3,194 4,800 3,617 1,454 1,209
SMC2 2,562 3,055 3,307 4,769 1,448 1,149
SMC1A 2,755 3,281 3,628 4,794 1,416 1,146
ARMCX1 2,551 3,265 3,273 4,407 1,430 1,097
Log2 expression values were compared between IRES-GFP DP cells and three LMO2-IRES-GFP samples. 
Listed are the 65 probesets corresponding to 58 genes that were upregulated with highest differential 
expression (|FC| > 0.7).
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DOCK1 6,059 4,077 3,969 4,365 0,683 -1,922
DPPA4 5,150 3,005 3,450 3,286 0,630 -1,903
ITCH 5,862 4,088 3,829 4,063 0,681 -1,868
DUSP18 5,780 4,071 4,158 3,511 0,677 -1,866
DOCK1 4,584 2,760 2,730 2,701 0,596 -1,854
CCDC107 6,065 5,888 3,338 3,481 0,698 -1,829
CALN1 5,542 3,735 3,350 4,174 0,677 -1,789
GNE 5,749 3,726 3,932 4,253 0,691 -1,779
LMO7 5,038 3,299 3,326 3,154 0,647 -1,778
MAN1A1 5,541 3,692 3,888 3,932 0,693 -1,703
CCNT1 5,526 3,995 4,067 3,422 0,693 -1,698
LOC100506797 4,791 3,007 3,470 3,026 0,661 -1,623
SH3RF1 4,585 3,094 3,042 2,925 0,659 -1,565
ENPEP 4,782 3,176 3,277 3,277 0,678 -1,538
SMAD1 5,140 3,588 2,995 4,260 0,703 -1,526
GP1BA 4,800 3,432 3,310 3,089 0,683 -1,523
PLEKHA1 4,516 2,577 3,597 2,892 0,669 -1,494
CIDECP 4,714 3,254 3,287 3,134 0,684 -1,489
WSB1 4,912 4,250 3,390 2,676 0,700 -1,473
MRPS11 4,883 3,510 3,649 3,146 0,703 -1,448
NDUFS2 4,843 3,631 3,399 3,206 0,705 -1,431
TMEM181 4,665 3,347 3,347 3,014 0,694 -1,429
RRAGD 4,356 3,046 2,986 2,782 0,674 -1,418
GALK2 4,650 3,450 3,054 3,250 0,699 -1,399
SUFU 4,342 3,017 2,980 2,875 0,681 -1,385
TRAK1 4,627 3,098 3,423 3,219 0,702 -1,380
BCAR3 4,489 3,037 3,137 3,205 0,696 -1,363
CNN2 4,192 3,095 3,067 2,414 0,682 -1,334
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The hematopoietic stem cell (HSC) maintains all the different cells present in our blood 
during our life by a delicate and balanced process of both self-renewal and differentiation. 
These processes are controlled by intricate networks of many signaling pathways regulating 
the different lineage choices. Most of the cells from the different cell lineages develop within 
the bone marrow (BM) except for T cells that need another specialized environment, which 
is provided by the thymus1. In mice, T-cell development has been studied extensively and in 
depth due to availability of transgenic mice, which enables studying the effects of genes on 
T-cell development. In addition, different ex vivo and in vitro assays exist to study development 
of T cells, such as gene expression studies of subsets, fetal thymic organ cultures (FTOC) and 
cocultures on different OP9 stromal cell lines to study kinetics and differentiation potential of 
precursor populations. For studies on human T-cell development researchers were only able 
to use these last assays as transplantation assays that supported human T-cell development 
were not available. With the development of humanized mouse models these assays have 
become available as now it is possible to transplant human precursor populations in severely 
immunodeficient mice that do allow for development of human lymphoid cells2-4.
In this thesis, one of these immunodeficient mouse strains has been used to study different 
aspects of human T-cell development in an in vivo setting. Using these mice with an 
optimized transplantation protocol provided new insights in human T-cell development, 
thereby demonstrating the localization of several developmental checkpoints. Furthermore, 
this approach was used together with whole exome sequencing to determine the gene 
causative for a form of atypical severe combined immunodeficiency (SCID) and the precise 
developmental arrest. By overexpression of LMO2 in HSPCs, it was demonstrated how LMO2 
can cause aberrant human T-cell development.
Humanized mouse models
Transgenic mouse models have been proven very useful in studies on hematopoiesis, as 
the effects of overexpression and absence of genes can be studied and more insight into 
underlying mechanisms can be obtained. Many of the obtained data can be extrapolated to 
humans, however, for T-cell development there are also many differences, as observed for 
mouse models of SCID compared to patient phenotypes. This disease, which is characterized 
by a deficiency of functional T cells, can be caused by mutations in several genes as described 
in chapter 1. The mouse model for RAG1-SCID mirrors the human situation in peripheral blood 
as both patients and mice show a deficiency in both T cells in B cells5. On the other hand, Il7ra 
knockout mice suffer from a deficiency in B cells besides their T-cell deficiency6, while this is not 
observed in IL7RA-SCID patients7. This illustrates that some genes have comparable function in 
both humans and mice while other genes might have additional functions in one of the species.
The development of humanized mouse models2-4 has allowed for studies on human 
hematopoiesis8. In chapter 2 it was demonstrated that with a short culture a robust 
engraftment was obtained using one of these mouse models, the NOD/Scid-Il2rg-/- (NSG), with 
outgrowth of different cell lineages. Both T cells and B cells that did develop were functional 
and secondary transplantations were performed, which demonstrated that the hematopoietic 
stem cells (HSCs) were not exhausted. Most importantly, the optimized protocol did allow 
for transplantation of HSPCs obtained from cryopreserved human bone marrow (BM). The 
level of engraftment of BM-derived HSPCs was lower as compared to mice transplanted with 
cord blood-derived HSPCs but both lineage development and relative abundance of different 
cell types was highly comparable. This made it possible to perform studies on arrests in 
development for different types of SCID as described in chapter 3 and chapter 4.
One drawback of humanized mouse models is the xenograft setting; what effect does this 
have on selection of T-cell progenitors and to what extent are cytokines cross-reactive? T-cell 
progenitors undergo both positive and negative selection in the thymus whereby binding to 
MHC is crucial. Most probable, the progenitors will be selected on murine MHC as expressed 
by the thymic epithelial cells but also on human MHC, which is expressed on dendritic cells 
and B cells that did develop from transplanted HSPCs and have migrated to the thymus9. 
This is illustrated by the finding that both murine MHC restricted4 and human MHC restricted 
responses have been detected in humanized mice2, 4, 10. In addition, the same populations 
were found both in thymi from engrafted NSG mice as in ex vivo human thymi as described in 
chapter 2. By studying the migrational patterns of thymocytes on slices of murine and human 
thymus it was demonstrated that these patterns were not altered when human thymocytes 
were put on murine thymic stroma and that migration was induced by the same chemokines 
in both species11. Collectively, these results demonstrate interspecies crosstalk and suggest 
no large abnormalities in thymocyte selection in this xenograft setting. In addition, it was 
demonstrated in chapter 3 that the relative frequencies of different stages of B-cell precursor 
populations in the BM of transplanted NSG mice is highly comparable to the corresponding ex 
vivo BM aspirate of the donor. This further validates the use of this model for studies on human 
lymphopoiesis.
Different adaptations have been made to the NSG mouse model that, depending on the 
research question, might lower interspecies burdens. Human leukocyte antigen (HLA)-A2 
transgenic NSG mice have been generated12 and they have been compared side by side with 
NSG mice9. No differences in conventional human T-cell development were observed between 
the two strains and this was not different from fetal and postnatal human thymi9. In addition, 
we have detected a normal polyclonal TCR repertoire in humanized NSG mice (see chapter 
3), thereby demonstrating that MHC differences did not lead to development of a skewed 
repertoire of the TCR. However, it was found that in both normal NSG mice and HLA-A2+ NSG 
mice transplanted with human hematopoietic stem and progenitor cells (HSPCs) there were 
differences in FOXP3+ thymocytes when compared to human thymi, probably caused by lack 
of cytokine crosstalk9.
It has also been suggested that there is restricted crosstalk in cytokines needed for myeloid 
development, such as M-CSF. To overcome this, the MITRG and MISTRG mouse strains have 
been developed13; both are Rag2-/-Il2rg-/- mice that are knock-ins for the human alleles of M-CSF, 
IL-3/GM-CSF and TPO and the MISTRG mice are also transgenic for the human SIRPα gene. 
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number of hematopoietic clones was observed between HSCs sorted from BM and DN1/2 
cells sorted from thymi of NSG mice transplanted with barcoded HSCs (see chapter 5). This 
might be correlated with cytokine driven expansion of a limited number of clones directly after 
seeding of the thymus. It has indeed been suggested that IL-7 and SCF have both a proliferative 
and survival effect on early thymocytes19, 20. Both in Il7r-/- and Il2rg-/- mice the defect in survival 
of early thymocytes could be rescued by expression of the anti-apoptosis Bcl2 protein21, 22. It is 
unknown whether in human T-cell development IL-2 and IL-7 play the same role, however, in 
chapter 3, we show an early block in T-cell development for both IL2RG- and IL7RA-SCID. Using 
TREC analysis it was demonstrated that DN cells have a high proliferative history23. Combined 
with the clonal restriction in these same stages as described in chapter 5 this might suggest 
that also in human T-cell development there is expansion of a limited number of hematopoietic 
clones, which could be driven by IL-2 and IL-7.
In human T-cell development the point of β-selection has been ascribed to different stages; the 
immature single positive (ISP)24-26 or the DN3 stage17. Transplantation of Artemis-SCID HSPCs in 
the NSG mouse model demonstrated that the initiation of TRB rearrangement might be earlier 
than previously described (chapter 3), namely at the CD7+CD5+CD1a- DN stage. The number of 
hematopoietic clones was also decreased between the DN1/2 and DN3 stage, in which DN3 was 
characterized by expression of CD1a (chapter 5). It remains difficult to determine the precise 
stage of β-selection as the DN compartment of human T-cell progenitors is not characterized in 
detail and different markers are being used. Based on above described data, a model of human 
T-cell developmental stages is herewith proposed (Fig. 1) that indicates the checkpoints that 
we described.
Figure 1: Proposed model of human T-cell development. Model based on data described in chapter 3 and 
literature indicating the arrests in human T-cell development for different types of SCID. Indicated are the 
stages of rearrangement of T cell receptor (TR) loci and markers to identify different stages in the CD4-CD8- 
double negative (DN) compartment. TSP; thymus seeding progenitor, ISP; immature single positive, DP; 
double positive (CD4+CD8+), SP; single positive.
In this thesis, we demonstrated the arrests in T-cell development for SCID caused by mutations 
in 3 different genes, for which patients were selected with a null mutation (i.e. no residual 
activity of the mutated protein). Many patients exist that do have residual activity of the protein 
SIRPα recognizes CD47, which is expressed on hematopoietic cells, and this interaction 
reduces phagocytosis of the transplanted human cells14. Both mouse strains better support 
the development of human myeloid cell subsets and NK cells and functionality13. Although 
NSG mice are severely immunodeficient, a sublethal dose of irradiation is needed for efficient 
engraftment of human HSPCs. Irradiation causes the release of free radicals and cytokines, 
which might have effect on the fitness of the HSPCs that will be transplanted thereafter. 
To circumvent this problem, NSG mice carrying a mutation in their Kit receptor have been 
created15. The ligand of this receptor is stem cell factor (SCF) a cytokine needed for stem cell 
self-renewal. The murine stem cells in the NSG-Kit-/- mouse are unfit as their receptor cannot 
respond to SCF and therefore they will be outcompeted upon transplantation of other 
HSPCs. Therefore, irradiation prior to transplantation is not needed in these mice, which 
allows for better studies on HSC capacities and clonality as demonstrated by an increased 
SCID repopulating cell (SRC) frequency in these mice (also called NSGW41) when compared 
to normal NSG that were irradiated prior to transplantation15. Strikingly, these NSGW41 had 
higher engraftment of human cells in their peripheral blood when transplanting limiting cell 
numbers and demonstrated better outgrowth of myeloid cells compared to NSG mice. It 
would be interesting to study the addition of human genes for cytokines, as in the MITRG and 
MISTRG mouse strains, in the NSGW41 strain on development of different cell lineages, their 
subsets and functionality.
Checkpoints in human T-cell development
Much of the knowledge on T-cell development stems from murine studies as previously 
human T-cell development could only be studied ex vivo or in vitro. This has changed with 
the development of the different humanized mouse models. However, murine T-cell 
development remains better characterized with the description of markers for many 
subpopulations, especially of the early double negative (DN) compartment in the thymus16. 
Human and murine T-cell development are comparable with respect to the following; the most 
immature populations are in de CD4-CD8- DN compartment, immature single positive (ISP) 
cells develop into CD4+CD8+ double positive (DP), which after selection become either CD4+ 
or CD8+ single positive (SP)17. However, ISP are CD8+CD3- in mice while CD4+CD3- in humans 
and the markers described to characterize the murine DN compartment are not applicable 
to human T-cell progenitors18. This, combined with the fact that the phenotype in transgenic 
mice is not always comparable to the phenotype observed in patients, illustrates that there 
are also many interspecies differences and not all murine data can be extrapolated to human 
T-cell development.
The data described in chapter 3 demonstrates that mutations in genes causative for SCID, such 
as IL7RA and IL2RG, show a phenotype different from their corresponding mouse mutants. 
When HSPCs from either IL7RA- or IL2RG-SCID were transplanted in NSG mice a very early 
block in T-cell development was observed, probably caused by an immediate need of signaling 
through these receptors after thymic entry. Also in normal thymopoiesis a restriction in the 
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CD34+ cells in the NSG mouse model, an arrest in T-cell development was demonstrated at 
the DP stage, which led to a T-cell deficiency in peripheral blood. We hypothesize that the 
identified mutation translates into a dominant negative form of VPS4B protein that might 
affect TCR signaling. However, confirmation by functional experiments is still needed. The 
results described in chapter 4 potentially link a new gene to the development of T-B+NK+-SCID.
Newborn screening
Newborn screening for SCID is implemented in many states in the USA and more countries 
might follow. In the Netherlands, the “Gezondheidsraad” (Health Council) has advised the 
Minister of Health to implement SCID, amongst other diseases, in the newborn screening33. 
This will be performed by TREC analysis on Guthrie card dried blood spots, which will detect T 
cell lymphopenia34. If tested positive, the patient will be referred for testing of the underlying 
defect. There already exists a fraction of SCID patients for whom the underlying genetic defect 
remains unknown, ranging from 7 to 33% of SCID patients35-39, and when included in newborn 
screening the incidence of SCID might increase and thereby also the number of SCID patients 
with unknown cause. Using WES analysis of the SCID patient and both parents new genes can 
be identified. Combined with a gene therapy approach, the patient cells could be transplanted 
in NSG mice to confirm the causative effect of the gene and determine the stage of arrest(s) 
in lymphoid development in mice transplanted with untransduced HSPCs. Other patients that 
are suspected to suffer from SCID from the newborn screening could then also be screened 
for these newly identified genes. Newborn screening will lower the age of diagnosis for more 
SCID patients and this might benefit their outcomes after transplantation as it has been 
demonstrated that the survival after hematopoietic stem cell transplantation (HSCT) before 
the age of 3.5 months is higher40. In France, it has been calculated that transplantation before 
3.5 months of age will be cost-effective41.
T-ALL development in gene therapy trials by insertional mutagenesis
HSCT provides a cure for SCID; however survival is worse when a matched donor is not 
available42. Gene therapy might be an alternative and for many types of SCID, there are studies 
either in a clinical trial43, 44 or in a preclinical phase45-48. Initial clinical trials for X-linked SCID 
(caused by mutations in IL2RG) and ADA-SCID have shown to be successful, but unfortunately 5 
out of 20 IL2RG-SCID patients treated with gene therapy developed T-ALL caused by insertional 
mutagenesis (see chapter 1). Development of T-ALL caused by insertional mutagenesis was 
also found in 6 out of 10 treated patients in a gene therapy trial for Wiskott-Aldrich Syndrome 
(WAS), which is also a primary immunodeficiency, using a same type of vector as the initial 
trials for X-linked SCID and ADA-SCID49. Trials initiated thereafter made use of newly developed 
and safer SIN-lentiviral or SIN-gammaretroviral vectors and up to now no leukemias have been 
observed in treated patients50-52.
depending on the type of mutation. These patients often present with an atypical form of SCID, 
such as Omenn syndrome. Omen syndrome is most often caused by hypomorphic mutations 
in RAG127 or RAG228 but has, for instance, also been described for CORO1A mutations29. It was 
even demonstrated that similar mutations in RAG1 can lead to a diverse clinical presentation 
probably caused by differences in endogenous antigenic challenge and environmental factors30. 
Furthermore, upon transplantation of HSPCs from a RAG2-SCID patient in the described NSG 
mouse model, it was observed that there was indeed a deficiency in both T cells and B cells in 
the peripheral blood as in the patient. However, in the thymus there was development until 
the CD3-CD4+CD8+ double positive (DP) with rearrangement of TRD, TRG and TRB (unpublished 
data). This demonstrates that even the patients that phenotypically present as a null mutant, 
might still have residual activity and therefore not be a molecular null mutant. In chapter 3 it 
was already demonstrated that a hypomorphic IL2RG-SCID indeed is different from the null 
mutant after transplantation in the NSG mouse. Therefore, it would be interesting to study 
patients with different mutations in the same gene in the humanized NSG model to obtain 
more insights into the functional effects of various mutations on T-cell development. 
Identification of new types of SCID
In addition to studying hypomorphic patients, the described NSG model can also be used to 
study patients suspected of SCID with atypical presentation. This will enable the exclusion of 
niche factors and determine whether the presumed defect is intrinsic to the hematopoietic 
cells. Using this approach it was determined that a girl with an atypical presentation of SCID 
indeed suffered from T-B+NK+-SCID and that the arrest in T-cell development was at the DP to 
single positive (SP) transition (see chapter 4). Although disease characteristics of SCID with 
unknown genetic cause can be studied using this murine model, unfortunately, the duration of 
this type of experiments is too long to aid in diagnosis in this type of patients.
Whole exome sequencing (WES) of the patient and both parents was performed to search 
for the underlying genetic defect after exclusion of known SCID-causing genes by Sanger 
sequencing. Previously, WES of a patient and her parents has led to the discovery of a mutation 
in CARD11, which was thereby inactivated, and led to the development of SCID31. Casanova et 
al., have postulated guidelines for studies on genetic causes for primary immunodeficiencies32. 
Primary immunodeficiency is a group of inherited rare diseases and therefore studies on 
disease causing genetic aberrations often rely on single patients. Thereby, it is more difficult to 
determine the affected gene in a single patient as compared to other types of diseases where 
more patients are available. As the analysis is more difficult in these case studies, the candidate 
gene needs to be validated in different assays. This can be done by cellular assays or animal 
models. However, most of the genes that are causative in inborn errors of immunity have 
been discovered in single patients32. Only after publication of the study that identifies the first 
patient, other patients can be screened for the same gene as not often these patients would 
present in the same center. In chapter 4 we have identified a heterozygous de novo mutation in 
VPS4B using WES in a SCID patient with atypical presentation. By transplanting patient derived 
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development for WAS patients. Knowledge on the stage of arrest might provide more insights 
into the mechanisms of ectopic expression of LMO2 on T-ALL development in these patients 
and whether this is comparable to the mechanisms in X-linked SCID.
In a gene therapy trial for X-linked chronic granulomatous disease (X-CGD), using a 
gammaretroviral vector driving expression of the transgene by the LTR, insertional mutagenesis 
in EVI1 resulted in the development of myelodysplasia. X-CGD can be caused by a mutation in 
GP91phox that affects the phagocytic capacity of neutrophils. These cells belong to the myeloid 
lineage and therefore myeloid cells that are transduced with the correct version of GP91phox 
will most probably have a selective advantage over their non-transduced counterparts. In 
WAS, all lineages are affected and in the above described gene therapy trials for WAS patients 
did develop both T-ALL and acute myeloid leukemia (AML) due to insertional mutagenesis. 
Leukemia of B cells and/or NK cells has not been observed in the gene therapy trial for WAS. 
Also in the X-linked SCID trials, in which beside the T cells also the NK cells are affected by IL2RG 
deficiency, leukemia in NK cells was not observed. It could be that the selective advantage 
for B cells and NK cells over untransduced cells is not as great as for T cells and myeloid cells 
whereby they experience less selective pressure leading to lower changes for development of 
clonal outgrowth of B cells and NK cells. 
Assessment of genotoxicity of preclinical viral vectors
As leukemia development by insertional mutagenesis was not observed in preclinical models, 
new screening methods for genotoxicity have been developed. The in vitro immortalization 
(IVIM) assay screens for clonal outgrowth of transduced lineage-negative murine BM cells 
using a limiting dilution assay63. Using this assay, different designs of vectors can be screened 
in a preclinical stage to determine their genotoxicity in a relatively short period. However, it 
is a myeloid skewed assay and thereby it is unknown how accurate the predictions will be 
for development of T-ALL due to the stringent selective pressure during T-cell development, 
which might be different from the limiting dilution used in this assay. A different assay makes 
use of lineage-negative BM cells of tumor-prone Cdkn2a-/- mice that are then transduced with 
different designs of viral vectors and transplanted in wildtype mice64. The advantage of this 
model is the in vivo readout by tumor development, although the selective advantage over 
uncorrected cells, as present in a gene therapy setting, is not there. Both assays make use 
of murine BM-derived cells, but as indicated, differences exist between human and murine 
lymphoid development. In chapter 6 it was demonstrated that the humanized NSG model can 
be used to study the effects of LMO2 overexpression in human cells. The same model might 
be used to study insertional mutagenesis in human cells. Experiments to assess genotoxicity 
of viral vectors in NSG mice have been performed by transplanting CD34+ cells that were 
transduced by an LTR-driven gammaretroviral vector in these mice65. Presence of dominant 
clones was observed in transplanted NSG mice, however, no tumor development was 
observed as was in the Cdkn2a-/- mouse model. It was speculated that longer duration (more 
than 6 months) of experiments would be needed or secondary transplantations to observe 
What remains striking is that ADA-SCID patients did not develop T-ALL after gene therapy while 
similar gammaretroviral vectors have been used as in the other trials in which expression of the 
transgene was driven by the long terminal repeat (LTR)53-56. The T-ALLs that developed in the 
X-linked SCID trials and the WAS trial all had an integration in or nearby LMO2, a gene frequently 
upregulated in T-ALL49, 55, 56. LMO2 is normally highly expressed in HSCs and is downregulated 
early in human T-cell development57. In the ADA-SCID trials these integrations were also 
found in cells from peripheral blood of treated patients but no leukemia development was 
observed58. It remains a question why T-ALL did not develop in the ADA-SCID trials. The most 
likely answer is the difference in disease background44.
SCID disease background
In chapter 3 the stages of arrest in development were studied for different types of SCID 
including X-linked SCID and ADA-SCID. For X-linked SCID, caused by a mutation in IL2RG, a 
very early arrest just after seeding of the thymus was observed. It has been reported by Kohn 
et al. that in these patients there is no aberrancy in prethymic commitment and that effects 
of IL2RG deficiency will most likely be present in the thymus and not in the thymus seeding 
progenitor (TSP)59. For ADA-SCID no phenotype could be observed after transplantation in the 
NSG mouse model, most likely caused by complementation of murine ADA as this enzyme is 
also secreted. Therefore it remains elusive where the arrest in human T-cell development is in 
ADA-SCID patients. Joachims et al. have mimicked this by inhibition of ADA in human cells in 
FTOC and have observed a gradual decrease of populations during development most severely 
affecting the more mature populations60. However, the data obtained from transplantation 
of ADA-SCID derived HSPCs in NSG mice does demonstrate that in a gene therapy setting 
the transduced cells might have a bystander effect of the non-transduced cells thereby 
decreasing the selective pressure. For X-linked SCID the block in development is very early; 
at a normally high proliferative stage. The cells that were transduced with the correct version 
of IL2RG will have a highly selective advantage, as the block is alleviated, and undergo rapid 
expansion. When LMO2 expression is not downregulated due to insertional mutagenesis, this 
will give additional proliferative advantage during T-cell development. It was indeed observed 
in chapter 6 that overexpression of LMO2 in HSPCs, which were transplanted in NSG mice, 
gives rise to accelerated human T-cell development leading to higher frequencies of T cells 
in peripheral lymphoid organs together with an altered CD8/CD4 ratio. In addition, a delay in 
development was observed in some but not all mice confirming previous data obtained from 
in vitro studies57. Together with an accumulation of CD3- DP cells this study indicates three 
different mechanisms by which LMO2 overexpression affects human T-cell development.
WAS patients do have low T-cell numbers in their peripheral blood, which have reduced 
functionality, and it is thought that this decrease is caused by diminished thymic output61. As 
WAS protein (WASP) deficiency affects migrational properties62, it might be that the arrest in 
T-cell development is leaky and caused by the lowered capacity to migrate through the thymus 
during development. It would be of interest to determine the stage of arrest in human T-cell 
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tool for future site-specific gene therapy72. However, to obtain enough cells for transplantation 
into patients after site-specific gene correction, even higher targeting efficiencies or better 
stem cell expansion protocols will be needed.
Future perspectives
Knowledge on human T-cell development lags behind that of murine T-cell development. Using 
humanized mouse models, the role of genes on human T-cell development can now be studied 
in an in vivo setting by transplantation of human null mutants and other patient samples, which 
will provide new insights. As SCID is a rare disease, the availability of human SCID derived 
HSPCs is limited. Potentially, this could be circumvented by exploiting the CRISPR/Cas9 system 
to induce DSBs in genes of interest in cord blood-derived CD34+ cells. Repair of these DSBs 
can occur via non-homologous end-joining (NHEJ), leaving insertion/deletion (indel) mutations 
that can lead to frameshift mutations and premature stopcodons73. Introduction of the 
targeting sequence together with Cas9 and a reporter gene can be performed by lentiviral 
transduction74. In addition, the function of genes that are known to be important in murine 
T-cell development and of which the role in human T-cell development is unknown, such as 
TCF7 deficiency75, could be tested using this system. Screening for knockouts is easy when 
the targeted gene normally results in a protein expressed on the cell surface. These HSPCs 
could then be sorted after transduction and transplanted in immunodeficient mice. The most 
preferable model could be the NSGW41; these mice do not need to be irradiated, which could 
otherwise also affect transplanted HSPCs. As described, without irradiation a better estimation 
of repopulation capacity can be made. When the targeted gene does not result in a surface-
expressed protein, clones would have to be grown to be screened on DNA level. Currently, 
there are no protocols available that would allow for this expansion while maintaining 
repopulating capacity of HSPCs.
Furthermore, the above described NSGW41 will be very useful for better characterization of 
the “true” long-term repopulating (LT)-HSC. The Lin-CD34+CD38-CD90+CD45RA-CD49f+ have a 
LT-HSC frequency of 1 in 10.5 cells8. In mice the expression of c-Kit is used for characterization 
of the HSC compartment. Currently, there is also indication that expression of this receptor 
on human HSC would confer more potent repopulation activity15. Another marker used for 
isolation of more primitive HSPCs is CD133 of which the expression is, in contrast to CD38, 
less influenced during culture76. Sorting of different fractions of the hematopoietic progenitor 
compartment and transplantation into non-irradiated NSGW41 mice might help in the search 
for the “true” LT-HSC and more differentiated progenitors and their developmental potential, 
which might result in a more defined human hematopoietic developmental hierarchy. As 
transplantation of single cells remains challenging, barcoding technology77 (and chapter 
5) could be used to determine whether progenitors give multi-lineage output or are more 
restricted. More insights towards the phenotype of human multipotent progenitors and their 
lineage offspring would be of great interest as also here differences remain between mice 
and man78. As described above, Dick and coworkers have performed many studies on the 
identification of the human LT-HSC and their multipotent offspring. As the T-cell potential was 
not studied in their in vivo experiments, it remains difficult to determine presence of common 
progenitors for different lymphoid lineages and when this potential diverges.
insertional mutagenesis caused leukemias. In conclusion, there is currently no accurate model 
to determine genotoxicity of integrating viral vectors in human cells in a preclinical setting that 
will be predictive for the clinical setting, at least for lymphoid leukemias.
Up to now, insertional mutagenesis in gene therapy trials has only been observed when 
gammaretroviral constructs driving expression of the transgene from the viral LTR were used. 
During preclinical testing in mouse models insertional mutagenesis leading to development 
of T-ALL has not been observed. As described in chapter 1, clinical trials for primary 
immunodeficiencies are currently based on using selfinactivating (SIN) vectors that drive 
expression of the transgene from in internal promoter thereby decreasing enhancer activities 
on nearby genes. Recently, alpharetroviral vectors have been demonstrated to be successful in 
correcting X-linked chronic granulatomous disease (CGD) in preclinical models66. These vectors 
have a more safe integration profile than both gammaretroviral and lentiviral vectors, which 
lowers the chance of insertional mutagenesis67. However, viral vectors need integration in the 
host genome for stable expression and this remains random whereby the chance of insertional 
mutagenesis will always remain.
Targeted strategies for gene correction
Correcting the genetic defect itself instead of expressing a correct version of the affected gene 
would allow for physiological expression and normal regulation of the gene without the need 
for random integration of a viral vector. This strategy is being tested by many different labs using 
different technologies. Genovese et al., have used zinc finger nucleases (ZFNs), which generate 
a site-specific double strand break (DSB) in the DNA together with an integrase-defective 
lentiviral vector (IDLV) encoding a gene targeting construct for IL2RG68. Hereby, they corrected 
the IL2RG mutation in HSCs from an X-linked SCID patient and after transplantation in NSG mice 
there was restored development of both T cells and NK cells. Another approach makes use of 
patient-derived induced pluripotent stem cells (iPSCs) combined with transcription activator-
like effector nucleases (TALENs) to correct the mutation in IL2RG69. In vitro it was shown that 
corrected cells could differentiate into both T cells and NK cells while the uncorrected cells 
could not. The advantage of these types of approaches is the site-specific correction thereby 
circumventing the chance for insertional mutagenesis. However, the number of cells that can 
be specifically targeted by these strategies at this moment remains low as compared to viral 
transduction, which is used currently in gene therapy clinical trials. Another repair approach 
utilizes the CRISPR/Cas9 system in which guide RNAs target the Cas9 endonucleases to the 
gene of interest, which is mutated, to generate DSBs70. When the correct version of the 
gene is introduced as well, this can be used as template to repair the DSB by homologous 
recombination thereby correcting the mutation. This has not been used for SCID yet, but 
proof of principle has been obtained by correcting a mutation in CFTR, which can cause cystic 
fibrosis, in organoid cultures and thereby restoring functionality71. The CRISPR/Cas9 system is 
easier to adapt for different targets, by changing the sequence of the guide RNA, and results in 
comparable or higher targeting efficiencies than ZFNs or TALENs and therefore is a promising 
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A single hematopoietic stem cell (HSC) can make up all the different cells of the immune 
system. Most of the different cell lineages of the immune system develop in the bone marrow. 
T cells, however, develop in the thymus where a specialized environment is present. Within 
the thymus, the T-cell progenitors are selected; T cells that do not recognize antigens and 
autoreactive T cells are deleted. T cells are needed to fight virus infections, provide help to B 
cells during bacterial infections and can also be reactive towards tumors.
A multipotent progenitor migrates from the bone marrow, via the bloodstream, to the thymus. 
After engraftment in the tissue, this progenitor will start to proliferate and develop towards 
more mature cell types. Once committed to the T-cell lineage, it will start to rearrange different 
parts in the DNA, T-cell receptor loci that can form a T-cell receptor. This rearrangement 
provides the great diversity that is present within the T-cell receptors expressed on mature T 
cells to ensure recognition of many different antigens of, for instance, pathogens.
T-cell development follows a defined path during which the thymus seeding cell will proliferate 
and differentiate. Most of the knowledge of this development stems from studies performed 
in mice. The availability of many transgenic mouse strains makes it possible to study the 
influence of signaling pathways on the development of T cells. Knowledge on the development 
of human T cells is mainly derived from descriptive studies in which ex vivo human thymus 
material is studied by cellular phenotyping and gene expression analysis or in vitro assays as 
described in chapter 1.
There are different diseases in which patients suffer from abnormal T-cell development from 
which insights can be gained into the pathways regulating human T-cell development. Such 
diseases include on the one hand Severe Combined Immunodeficiency (SCID), in which there 
is a block in T-cell development leading to absence of functional T cells, and on the other 
hand T-cell acute lymphoblastic leukemia (T-ALL) where patients suffer from an accelerated 
malignant growth of T cells. As it is difficult to study the mechanisms behind both these forms 
of pathological T-cell development, an optimized in vivo model for the study of human T-cell 
development has been developed that is described in chapter 2. As the NOD/Scid-Il2rg-/- (NSG) 
mice are severely immunodeficient, caused by the absence of NK cells, B cells and T cells, they 
allow the engraftment of human cells. A short culture of isolated human hematopoietic stem 
and progenitor cells (HSPCs) allows for possibility of genetically modifying these HSPCs while 
maintaining robust engraftment of human cells and the development of a human immune 
system in this mouse. The B cells and T cells that develop within in these mice are able to 
mount an immune response to an endogenous antigen demonstrating their functionality. The 
HSCs present in the transplant do engraft in the bone marrow of the mouse and are able to 
self-renew as illustrated by the fact that bone marrow from primary recipients can fully engraft 
secondary recipients. In addition, the optimized protocol also leads to good engraftment of 
HSPCs obtained from human bone marrow and development of the different lymphoid cell 
types. Together with the finding that thymi from mice engrafted with human hematopoietic 
cells show comparable human T-cell development to ex vivo analyzed human thymus biopsies 
opened the possibility to study patient material from biobanks.
Chapter 8    English summary
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This idea has been exploited in chapter 3 to study the stages of arrest in human T-cell 
development for different types of SCID. As from most of the SCID patients no thymic biopsies 
are taken, the T-cell developmental blocks have remained elusive. Previously, extrapolations 
have been made from knockout mice. However, it was found that the blocks in human T-cell 
development for different types of SCID reside at earlier stages then anticipated from these 
models illustrating the differences between human and murine T-cell development. From 
the obtained data, a model was proposed that shows and early need for cytokine-driven 
proliferation directly after seeding of the thymus by progenitors. In addition, the point of 
β-selection could be attributed to an earlier stage then previously described as demonstrated 
by the block in development observed for Artemis-SCID. As this study illustrated the power of 
the model in detecting developmental arrests in development of human lymphoid cells, HSPCs 
from a patient with atypical presentation of SCID were transplanted in these immunodeficient 
mice. In chapter 4 the results of this study are described that confirmed that the patient 
indeed suffered from T-B+NK+-SCID. The arrest in development was found to reside in the 
CD4+CD8+ double positive stage. As none of the known SCID-causing genes contained a genetic 
aberration, whole exome sequencing of the patient and both parents was performed leading 
to the detection of a heterozygous de novo mutation in VPS4B in this patient. This gene has not 
been previously associated with SCID.
Chapter 5 described the severe restriction of hematopoietic clones during human T-cell 
development demonstrating two restriction points. Despite the severe hematopoietic clonal 
restriction this limited number of clones can still make up a very diverse polyclonal T-cell receptor 
repertoire, which is needed to fight different pathogens that are encountered on a daily basis.
In contrast to chapter 3 and 4, in which gene deficiencies were studied, the effect of 
overexpression of LMO2, a known oncogene in T-ALL, on human T-cell development was 
studied. LMO2 was overexpressed in human HSPCs isolated from umbilical cord blood and 
these cells were transplanted in the severe immunodeficient NSG mice as described in chapter 
6. In gene therapy trials for immunodeficiencies, T-ALL did develop in several patients due to 
insertional mutagenesis. Often the insertion of the therapeutic vector was in or near LMO2 and 
resulted in overexpression of this gene causing the development of T-ALL in some patients. 
Transgenic mouse models for Lmo2 demonstrated blocks in immature T-cell progenitors and 
the development of leukemia with a long latency. Using the humanized NSG mouse model, 
it was demonstrated that LMO2 overexpression causes aberrant human T-cell development 
by three different mechanisms; the delayed development as also observed in transgenic 
mice and in vitro assays, an accumulation of CD4+CD8+ double positive cells and accelerated 
development leading to a higher frequency of mature T cells.
Altogether, this thesis describes novel insights in human T-cell development by transplanting 
human HSPCs in severe immunodeficient NSG mice. Thereby a model is provided that can 
further aid both in fundamental studies and can be used for optimization of gene therapy 
approaches and stem cell expansion protocols. Furthermore, it illustrates (see chapter 7) the 
need for more in depth understanding of human T-cell development, which could help further 
improve T-cell reconstitution after transplantation in patients and might aid in the diagnosis 
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Een enkele hematopoietische stamcel (HSC) kan door middel van zelfvernieuwing en 
differentiatie zorgen voor alle verschillende celtypen van het afweersysteem. De meeste van 
de verschillende typen afweercellen ontwikkelen zich in het beenmerg. Behalve de T-cellen, 
die hebben een gespecialiseerde omgeving nodig. Deze omgeving vinden zij in de thymus. 
De thymus is beter bekend als de zwezerik, een orgaan boven het hart dat kleiner wordt 
vanaf de puberteit. In dit orgaan worden de voorlopers van volwassen T-cellen opgeleid en 
geselecteerd. Cellen die geen antigenen herkennen of cellen die antigenen van het eigen 
lichaam herkennen worden daar verwijderd. Als dit niet gebeurt, dan zou dit leiden tot een 
sterk verhoogde incidentie van auto-immuunziekten, bijvoorbeeld diabetes. Tijdens ons leven 
hebben we T-cellen nodig om ons te beschermen tegen virusinfecties. Daarnaast helpen ze 
B-cellen om bacteriële infecties te voorkomen én kan hun respons gericht zijn tegen tumoren.
Een multipotente voorlopercel migreert vanuit het beenmerg, via de bloedsomloop, naar de 
thymus. Nadat hij daar aankomt, start de voorlopercel met delen (proliferatie) en ontwikkelt 
hij zich tot een meer volwassen celtype. Daarbij verliest hij geleidelijk zijn multipotentie. 
Door middel van verschillende signaleringen kunnen er verschillende ontwikkelpaden actief 
worden in de cel. Als de cel zich ontwikkelt tot een volwassen T-cel, herschikt hij verschillende 
stukken in het DNA die coderen voor de T-cel receptor. Deze receptor is nodig om antigenen te 
herkennen. Antigenen zijn stukjes eiwit die worden gepresenteerd door andere cellen aan de 
T-cel. Door het DNA dat codeert voor de T-cel receptor te herschikken, kan de grote diversiteit 
worden gegenereerd die nodig is om de vele verschillende antigenen van bijvoorbeeld 
virussen en bacteriën te kunnen herkennen. Dat zorgt dan weer voor een optimaal 
functionerend afweersysteem.
Nadat de multipotente voorlopercel is aangekomen in de thymus, begint hij zich te delen en te 
ontwikkelen (differentiatie) via verschillende stadia. De meeste kennis over deze differentiatie 
is afkomstig uit studies met muismodellen. Doordat er veel verschillende transgene 
muismodellen beschikbaar zijn, is het mogelijk om de rol van verschillende signaleringsroutes 
gedurende de T-cel ontwikkeling te bestuderen. De meerderheid van onze kennis over de 
ontwikkeling van T-cellen bij de mens komt uit beschrijvende studies. Hierbij wordt menselijk 
thymusweefsel bestudeerd. Dat gebeurt aan de hand van analyse van de aanwezigheid van 
verschillende celtypen en ontwikkelingsstadia en de expressie van genen in de verschillende 
celtypen. Deze studies en data afkomstig van proeven met cellen in kweekbakjes, worden 
beschreven in hoofdstuk 1 van dit proefschrift.
Als we ziektes met problemen in de T-cel ontwikkeling bestuderen, zouden we meer inzicht 
kunnen krijgen in de ontwikkeling van deze T-cellen en de signaleringsroutes die een rol in 
spelen gedurende deze ontwikkeling. Dit soort ziektes zijn onder andere Severe Combined 
Immunodeficiency (SCID) en T-cel acute lymfoblastische leukemie (T-ALL). SCID is een 
ernstige aangeboren afwijking waarbij er geen functionele T-cellen aanwezig zijn in het bloed. 
Meestal wordt de diagnose in het eerste levensjaar gesteld. Onder andere doordat een kind 




SCID kunnen veroorzaken. Een mutatie in één van deze genen kan leiden tot een blokkade 
in de ontwikkeling van T-cellen. Wat kan leiden tot een T-cel deficiëntie. T-ALL is een vorm 
van leukemie waarbij er een kwaadaardige wildgroei is van T-cellen. Het is lastig om de 
mechanismes die aan deze twee vormen van pathologische T-cel ontwikkeling ten grondslag 
liggen te onderzoeken bij de mens. Dat komt doordat er geen biopten van de thymus worden 
genomen bij deze patiënten.
In hoofdstuk 2 wordt een geoptimaliseerd gehumaniseerd muismodel beschreven dat gebruikt 
kan worden voor het in vivo bestuderen van T-cel ontwikkeling van menselijke cellen. Daarbij 
wordt gebruik gemaakt van een muis met een sterk verzwakt immuunsysteem: de NOD/Scid-
Il2rg-/- (NSG) muis. Deze muis heeft geen NK-cellen, B-cellen en T-cellen; celtypen die cruciaal 
zijn in een afweerreactie. Daardoor is dit type muis een goede ontvanger van menselijke cellen. 
In een gewone muis worden menselijke cellen afgestoten omdat de muis deze als indringer 
ziet. De NSG-muis doet dat niet omdat hij verschillende typen immuuncellen mist. Hierdoor 
is het mogelijk om de NSG muis te transplanteren met humane hematopoietische stam- en 
progenitorcellen (HSPC) zonder dat deze worden afgestoten. HSPC bestaan uit bloedstamcellen 
- de HSC - en multipotente voorlopercellen. Al deze cellen zijn te herkennen aan de expressie 
van CD34 op het celoppervlak. De HSPC werden geïsoleerd uit navelstrengbloed en werden 
kort gekweekt in het lab. Deze korte kweek maakt genetische modificatie mogelijk. Een 
ander voordeel van een korte kweek is dat de HSPC hun stamceleigenschappen behouden. 
Genetische modificatie is toegepast in hoofdstuk 5 en 6 van dit proefschrift.
De data in hoofdstuk 2 laat zien dat de kort gekweekte HSPC, na transplantatie in de NSG-
muis, migreren naar het beenmerg en kunnen differentiëren in cellen van het menselijk 
immuunsysteem. De humane B- en T-cellen die zich in de muis ontwikkelen, zijn ook functioneel 
aangezien zij een afweerrespons laten zien tegen een lichaamsvreemd antigeen. Eén van de 
eigenschappen van een HSC is zelfvernieuwing. Deze capaciteit kan bepaald worden door het 
beenmerg van de ontvangende muis te isoleren en vervolgens te transplanteren in een andere 
muis. Daar moet zich dan weer een immuunsysteem ontwikkelen. Ook in het geoptimaliseerde 
model was het mogelijk om het beenmerg – dat humane HSC bevat – te transplanteren in 
een tweede muis. Dit toont aan dat de HSC niet verloren gaan of uitgeput raken. Ook was 
het mogelijk om, naast navelstrengbloed, HSPC te isoleren uit humaan beenmerg en te 
transplanteren in de NSG-muis. Daardoor is het mogelijk om patiëntmateriaal uit bio-banken 
in dit model te bestuderen. Dat kan omdat de thymus uit NSG-muizen getransplanteerd met 
humane cellen er erg vergelijkbaar uit ziet met humaan thymusmateriaal. En omdat het met 
het geoptimaliseerde protocol mogelijk is om HSPC uit menselijk beenmerg te transplanteren.
Patiëntmateriaal afkomstig uit een bio-bank is gebruikt in hoofdstuk 3 om de blokkades 
in T-celontwikkeling voor verschillende typen SCID te onderzoeken. Bij de meeste SCID-
patiënten worden geen biopten van de thymus genomen. Daardoor is niet bekend waar de 
blokkades in T-celontwikkeling precies liggen. Door muizen te bestuderen die hetzelfde gen 
missen, weten we in welk stadium de blokkades liggen in deze muizen. Maar het is lastig 
deze data te extrapoleren naar de mens. De data in hoofdstuk 3 laat zien dat de blokkades 
in een vroeger stadium liggen dan voorspeld vanuit de muismodellen. Dit laat duidelijk de 
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verschillen in T-celontwikkeling zien tussen de muis en de mens. Met de verkregen data is 
een model opgesteld voor humane T-celontwikkeling. Dit model laat zien dat direct nadat een 
multipotente voorloper cel aankomt in de thymus deze gaat prolifereren onder invloed van 
cytokines (groeifactoren). Ook laat het model zien dat het punt van β-selectie – een belangrijk 
selectiepunt in T-cel ontwikkeling – in een eerder stadium plaats vindt dan eerder beschreven. 
Dit kon worden afgeleid uit het stadium waarin T-cel ontwikkeling blokkeert bij Artemis-SCID.
De hierboven beschreven studie laat duidelijk de kracht van het geoptimaliseerde 
gehumaniseerde muismodel zien bij het ontdekken van blokkades in T-cel ontwikkeling. In 
hoofdstuk 4 wordt een patiënt beschreven met een atypische klinische presentatie van SCID. 
Door HSPC van deze patiënt in het muismodel te transplanteren, kon worden bevestigd dat 
deze patiënt inderdaad een T-B+NK+-SCID patiënt was. De blokkade in de T-celontwikkeling lag 
in het CD4+CD8+ dubbel positieve stadium; het stadium waarin de T-cel selectie ondergaat via 
de T-cel receptor. Omdat in geen van de genen die geassocieerd zijn met SCID een mutatie kon 
worden ontdekt, is de genetische code van de exonen van alle genen van zowel de patiënt als 
beide ouders bepaald. Exonen zijn stukken DNA die coderen voor eiwitten en daarom zou een 
mutatie in deze gebieden kunnen leiden tot een eiwitverandering. Deze analyse leidde tot de 
detectie van een nieuwe mutatie in VPS4B in deze patiënt. Dit gen werd voorheen nog niet 
geassocieerd met SCID.
Hoofdstuk 5 beschrijft de beperking van het aantal hematopoietische klonen gedurende 
humane     T-cel ontwikkeling. Door introductie van een unieke barcode in HSPC en transplantatie 
in NSG-muizen, kan het aantal klonen per ontwikkelingsstadium worden bestudeerd. Ondanks 
de sterke afname van het aantal hematopoietische klonen, ontstaat er wel een polyklonaal 
repertoire van verschillende T-cel receptoren. Dit laat zien dat een enkele hematopoietische 
kloon kan uitgroeien in meerdere T-cel klonen. Een grote verscheidenheid aan T-cel klonen is 
nodig om een goede afweerrespons te kunnen maken tegen de verschillende ziekteverwekkers 
die wij dagelijks tegenkomen.
In tegenstelling tot hoofdstuk 3 en 4, waarin gendeficiënties zijn onderzocht, is in hoofdstuk 
6 het effect van een te hoge expressie van het LMO2-gen onderzocht op humane T-cel 
ontwikkeling. LMO2 is een oncogen dat vaak tot verhoogde expressie komt in T-ALL. Ook in 
klinische trials voor gentherapie voor immuundeficiënties ontwikkelden een aantal patiënten 
T-ALL als gevolg van insertionele mutagenese. Vaak was de insertie van de therapeutische 
vector in het DNA in de buurt van het LMO2-gen. Dat kwam daardoor tot verhoogde expressie 
en dat kan leiden tot T-ALL. Transgene muismodellen voor Lmo2 laten een blokkade in 
T-celontwikkeling zien in een vroeg stadium. Verder laten deze muismodellen zien dat de 
muizen leukemie ontwikkelen als zij ongeveer één jaar oud zijn. Het effect van LMO2 op humane 
T-celontwikkeling werd onderzocht door LMO2 tot overexpressie te brengen in humane HSPC. 
Deze HSPC waren geïsoleerd uit navelstrengbloed en vervolgens getransplanteerd in het 
gehumaniseerde muismodel. Deze transplantatie toonde aan dat LMO2 via drie verschillende 
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ontwikkeling zoals ook geobserveerd in transgene muizen en in kweekbakjes, een accumulatie 
van CD4+CD8+ dubbel positieve cellen en een versnelde ontwikkeling die resulteerde in een 
verhoogde frequentie van T-cellen in het bloed.
Kort samengevat beschrijft dit proefschrift nieuwe inzichten in humane T-cel ontwikkeling door 
middel van transplantatie van humane HSPC in muizen met een sterk verzwakt immuunsysteem. 
Het geoptimaliseerde gehumaniseerde muismodel kan verder worden gebruikt in 
fundamentele studies naar de ontwikkeling van T-cellen en voor optimalisatie van strategieën 
voor gentherapie en stamcelexpansie protocollen. Verder illustreert het (zie hoofdstuk 7) de 
noodzaak voor een beter begrip van en meer inzicht in humane T-cel ontwikkeling. Dit kan 
helpen om de uitgroei van T-cellen na stamceltransplantatie te verbeteren. Daarnaast kan het 
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